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General introduction and outline
SCOPE OF THIS THESIS 
The work described in this thesis focuses on the development of  a therapeutic 
vaccine against hepatitis C virus (HCV) infection. Approximately 150 million people 
worldwide are chronic carriers of  HCV1. Currently, there is no prophylactic or 
therapeutic vaccine available. Several novel antiviral protease inhibitors have been 
approved in the last few years. These are used either alone or in combination with 
pegylated interferon-α and ribavirin, and have improved the cure rates considerably. 
However, these novel treatment modalities are very expensive, unavailable for 
underdeveloped countries and also sometimes associated with serious side effects. A 
therapeutic vaccine, which activates the immune response of  patients, could be used 
either as a single treatment modality or be combined with antiviral drugs. 
The vaccines used in this PhD study are based on an alphavirus, a recombinant 
alphavirus vector system derived from Semliki Forest virus (rSFV). We developed, 
characterized and studied the efficacy of  three HCV vaccine modalities. To enhance 
the immunogenicity of  rSFV-based vaccines, we included endoplasmic reticulum- 
(ER) targeting and universal helper epitopes within the vaccines. These modifications 
were analyzed both in the candidate HCV vaccines and in an rSFV-based therapeutic 
vaccine against human papillomavirus (HPV). 
In this first chapter, we introduce viral- and tumor immunology and the basic 
concepts underlying immunotherapy. Subsequently, HCV and HPV are introduced 
and finally, we present an overview of  the thesis.
VIRAL AND TUMOR IMMUNOLOGY 
The function of  the immune system is to protect against invading pathogens and 
derailed cells. The immune system therefore needs to recognize pathogens and 
distinguish pathogen-infected cells as well as cancer cells from healthy cells. Next, 
responses that lead to destruction of  pathogens, infected cells or cancer cells are 
needed that do not damage healthy cells or tissues. Effective immune responses 
against infection and cancer thus depend on a critical balance between clearance of  
“foreign antigen” and maintenance of  the host’s integrity.
Recognition of ‘foreign’ by the immune system
Foreign antigens can be derived from pathogens or tumor cells. When e.g., viruses 
enter their host, surface antigens on these viruses can already be recognized by 
the immune system. Viruses subsequently infect their target cells and start their 
reproduction cycle. Infected cells make themselves visible to immune cells by 
presenting pieces of  degraded viral proteins (peptides) on their surface in the context 
of  major histocompatibility complex (MHC) molecules. Peptide-MHC complexes 
are recognized by the T cell receptor of  T cells, which represent important players of  
the immune system. 
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Although tumor cells originate from host cells that are ignored by the immune 
system under normal conditions, tumor cells often express tumor-associated antigens 
(TAAs) either as naïve proteins or as peptides complexed to MHC molecule that 
can be recognized by the immune system. Malignant transformation can result from 
heterogeneous genetic changes leading to uncontrolled cell proliferation2. Thus, 
TAAs can be derived from tissue-specific differentiation antigen, over-expressed self-
antigens or mutated antigens3-5. And since also approximately 20% of  cancers are 
caused by persistent infection with cancer-associated pathogens such as Helicobacter 
pylori, HPV and HCV6, various tumors also specifically express pathogen-derived 
TAA.
A battle of the immune system against intruders, focusing on viruses and 
tumors
The immune system includes innate immunity and adaptive immunity. Innate 
immunity is the first line of  defense against incoming pathogens. Members of  the 
innate immunity, such as macrophages, neutrophils and natural killer cells, can 
quickly identify a virus by recognizing the pathogen-associated molecules on the 
viral surface. Although this reaction is non-specific, the fast response of  the innate 
immunity allows an immediate attack of  the invading virus7.
Adaptive immunity, which is triggered by the innate immune system, requires 
recognition of  the viral components and subsequently develops antigen-specific 
effector and memory responses. Depending on the type of  response, adaptive 
immunity is divided into humoral and cellular immune responses. The humoral 
(fluid) immune response involves antibodies secreted by activated antigen-specific 
B cells. Antibodies recognize native antigen on the surface of  the virus and lead to 
neutralization and clearance of  circulating free viruses. Antibodies also recognize 
antigen on the surface of  virus-infected cells or tumor cells and kill these target 
cells through activation of  the complement system. In contrast, cellular immunity 
is mediated by T cells that recognize the processed antigens (peptides) presented in 
the context of  MHC molecules on the surface of  virus-infected cells or tumor cells. 
Activation of  the adaptive cellular immune response involves (i) antigens expressed 
by virus-infected or tumor cells, (ii) uptake, processing and presentation of  these 
antigens by antigen presenting cells (APCs), (iii) priming and activation of  immune 
cells (APCs, CD4+ and CD8+ T cells) in lymphoid organs, (iv) trafficking of  activated 
T cells towards the affected site, (v) infiltration of  the diseased site by activated T 
cells, (vi) recognition of  virus-infected or tumor cells by T cells and (vii) killing of  
target cells mainly by cytotoxic T lymphocytes (CTL). Killing of  target cells leads to 
release of  antigen resulting in further activation of  the immune system (step 1 of  the 
cycle)8.
Viral infections can be prevented by an effective humoral immune response 
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as the neutralizing antibodies block the entry of  virus into its target cells. However, 
once viruses have entered cells or tumors have developed, both humoral and cellular 
immune responses are required for effective killing of  the affected cells. Taken 
together, activation of  adaptive immunity should lead to eradication of  virus-infected 
cells or tumor cells and development of  antigen-specific memory response. However, 
this does not always happen as viruses and tumors can escape immune responses by 
mechanisms described below. 
Regulation of the immune response 
Tumor progression and persistence of  viral infections requires coevolution and 
coexistence of  the “foreign” and the host. As a consequence viruses and tumors 
develop strategies to reduce their immunogenicity and to allow the escape from 
immune surveillance. These strategies involve hiding from immune recognition and 
suppression of  the immune system. 
Viruses and tumors avoid immune recognition for example by (i) persisting in 
an immune-tolerant environment such as the liver, (ii) developing escape mutants and 
(iii) down-regulating antigen production, processing and presentation (reviewed in 
ref. 9-11). These mechanisms of  evasion lead to non-responsiveness of  the immune 
system or induction of  adaptive immune tolerance12. Adaptive immune tolerance is 
characterized by the development of  anergic T cells (both CD4+ and CD8+ T cells) 
that are not able to attack virus-infected and tumor cells13.
Virus-infected and tumor cells suppress the function of  T cells and other 
immune cells e.g., APCs and nature killer cells by (i) expressing inhibitory 
molecules such as programmed death receptor ligand-1 (PD-L1), (ii) secretion of  
immunosuppressive molecules such as transforming growth factor (TGF)-β and 
indoleamine 2,3-dioxygenase (IDO), or (iii) by recruitment of  suppressive immune 
cells such as regulatory T cells, myeloid derived suppressive cells (MDSCs) and tumor-
promoting tumor-associated macrophages to the affected area14,15. Thus, suppression 
of  immune system may result in persistence of  viruses and tumors15-17. 
As escape immune surveillance is observed in both viral diseases and cancer, 
activating the immune system could possibly support the combat against these 
diseases. 
TREATMENT AGAINST CHRONIC VIRAL INFECTIONS AND 
TUMORS 
Current standard treatment modalities against virus infections and cancer in general 
directly target viruses, virus-infected cells or tumor cells. And although some of  these 
standard treatments may indirectly or as a consequence of  cell death also augment 
immune responses, antiviral and cytostatic drugs are not primarily designed for this. 
Yet, with our emerging knowledge and activation methods of  immune responses, 
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immunotherapy will likely in the near future develop as a novel treatment modality 
for infections and cancers. In fact, improvement in cancer immunotherapy was 
selected by Science as the “breakthrough of  the year 2013”18.
Immunotherapeutic strategies
Immunotherapy includes treatments that induce or boost specific immune responses. 
To boost existing immune responses, immune modulators so-called check-point 
blocking antibodies such as anti-cytotoxic T lymphocyte antigen (CTLA)-4 and 
anti-PD-L1 antibodies are being used to activate T cells and restore the function 
of  resident anergic/exhausted T cells, respectively19,20. These promising immune 
modulators lead to prolonged survival of  cancer patients21. Ways to induce and/or 
boost immune responses involves for example adoptive transfer of  specific T cells22 or 
APCs and delivery of  therapeutic vaccines. 
Therapeutic vaccines 
Induction of  immune response can be achieved with different vaccine platforms 
that are based on proteins, synthetic peptides, DNA plasmids, virus-like particles 
or bacterial and viral vectors. Each platform has its pros and cons with respect to 
production, costs, efficacy and safety23. We focused on the Semliki Forest virus 
(SFV) system to deliver our antigen of  interest. Viral vectors generally induce robust 
innate and adaptive immune responses and therefore are potent tools for therapeutic 
vaccine development. The most commonly used viral vector vaccines are based on 
adenoviruses or vaccinia viruses. Both vector systems can induce strong immune 
responses. However, pre-existing vector-specific neutralizing antibodies in patients 
developed by natural infection and/or repeated vaccination, may hamper the efficacy 
of  these vaccines24. Vaccines based on Alphaviruses, such as Venezuelan Equine 
Encephalitis virus (VEE), Sindbis virus (SIN) or SFV, are highly promising. Pre-
existing immunity against these viruses is rare in human. Moreover, it has been shown 
in mice that pre-existing antibodies against SFV do not hamper immune responses25.
The recombinant Semliki Forest virus (rSFV) system
Semliki Forest virus belongs to the Alphavirus genus of  the Togaviridae family26. 
The Togaviridae are a family of  viruses with a linear, single-stranded, positive sense 
RNA genome. The SFV vector system is based on the self-replicating (“replicon”) 
properties of  the positive-strand RNA genome of  SFV. In rSFV replicon particles, 
the recombinant RNA genome encodes the viral RNA replicase and the gene(s) for 
the antigen(s) of  interest, but lacks the genes for the structural proteins of  the virus. 
Thus, in a single round of  infection, the virus penetrates targets cells producing large 
amounts of  the antigen(s) involved without generating new progeny virions. The 
rSFV replicon particles are thus replication-incompetent27. rSFV replicon particles 
15
1
General introduction and outline
can infect a wide variety of  cells, activate both innate and adaptive immunity28-31 
and induce high expression of  the antigen of  interest32,33. Within 48-72 hours after 
infection, rSFV-infected cells undergo programmed cell death34,35. This results 
in release of  a large amount of  antigen and the subsequent initiation of  a robust 
adaptive immune response. 
In preclinical studies, rSFV-based vaccines have been shown to induce strong 
and protective immune responses against foreign proteins such as antigens from 
viruses, bacteria and tumors36. Because of  the high level of  transgene expression, 
rSFV can also be used for temporary delivery of  immune modulators such as anti-
tumoral cytokines, IL-12 (ref. 37). There is no clinical study on rSFV yet. However, 
recombinant VEE-based vaccines, which are constructed in a similar way as rSFV, 
are now being studied in phase I/II clinical trails. These include prophylactic 
vaccines against human immunodeficiency virus (HIV), influenza A virus and 
cytomegalovirus (CMV) and a cancer vaccine against colorectal cancer and breast 
cancer38. 
TUMOR-ASSOCIATED VIRUSES 
As described earlier, some tumors arise as a consequence of  infection with a virus. In 
1910, Peyton Rous described that a spindle cell sarcoma of  a hen is transmissible with 
tumor filtrates39. The virus in the tumor filtrates was identified and named as Rous 
sarcoma virus and it was the first identified tumor-associated virus in mammals40. 
Nowadays, six human viruses are recognized as tumor-associated viruses and 
contribute to 10-15% of  global cancer6. Tumor formation is caused by inflammation 
due to chronic infection with hepatitis B virus, HCV or by persistent expression of  
oncoproteins by Epstein-Barr virus, HPV, human T-cell lymphotropic virus and 
Kaposi’s associated sarcoma herpesvirus (KSHV)41. Since this thesis includes studies 
of  rSFV-based HCV and HPV vaccines, a general introduction of  these viruses is 
given below.
Hepatitis C virus
Hepatitis C virus (HCV) is a small, enveloped, positive-sense single-stranded 
RNA virus belonging to the Hepacivirus genus of  the family Flaviviridae. The viral 
RNA genome (9.6 kb) is consists of  a 5’ and 3’ UTR and one open reading frame 
encoding a viral polyprotein. This polyprotein is post-translationally cleaved into 
three structural proteins (core, envelope 1 and 2), a small membrane polypeptide p7 
and six nonstructural proteins (nsPs) (NS2, NS3, NS4A, NS4B, NS5A and NS5B). 
The function of  these proteins is described in detail by Lindenbach and Rice42. Until 
now, 7 genotypes and more than 50 subtypes of  HCV have been identified. HCV 
quasispecies are escape mutants evolved in patients as a result of  the high mutation 
rate as well as the host’s immune pressure43,44. HCV is transmitted by blood and mainly 
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infects hepatocytes. Spontaneous resolution occurs in 10 to 15% of  HCV-infected 
patients who do not receive any treatment. The majority of  HCV-infected patients 
acquire a persistent infection correlating with the development of  liver cirrhosis, liver 
failure and hepatocellular carcinoma. Current treatment includes a combination of  
pan-antiviral drugs and HCV-specific protease inhibitors (direct acting antivirals, 
DAAs) that primarily target the replication of  the virus45. 
A broad and robust T-cell response against HCV nsPs is key to resolve acute 
HCV infection17,46-48. Viral-neutralizing antibodies have been identified in patients49,50. 
However, the role of  humoral immunity against HCV is still controversial, as 
antibody-deficient patients have been shown to recover from acute HCV infection51. 
HCV evades the host immune response through direct or indirect action of  viral 
proteins52-54. Moreover, patients with a chronic HCV infection have reduced diversity 
of  HCV-specific T cell with exhausted phenotypes55,56. Therefore, besides antiviral 
treatment, induction and augmentation of  T-cell responses against HCV antigen is 
required for effective clearance of  the infection. 
Various therapeutic approaches using protein, plasmid DNA and viral vectors 
are being developed. Viral vectors so far induce the most robust cellular immune 
response in preclinical studies57. For example, it has been shown that rSFV expressing 
the NS3 and NS4A proteins of  HCV is able to induce robust NS3-specific responses 
in mice58. In order to broaden the spectrum of  the T-cell response, we generated rSFV 
expressing all HCV nsPs and studied its vaccine potency (Chapter 3).
Human papillomavirus
Human papillomavirus (HPV) is a small non-enveloped double-stranded DNA virus 
(8 kb) belonging to the Papillomavirus genus of  the family Papovaviridae. The DNA 
genome consists of  six early (E1, E2, E4, E5, E6 and E7) and two late genes (L1 
and L5)59. Over 190 HPV genotypes have been identified of  which 40 genotypes 
are classified as sexually transmissible HPV60. Fifteen HPV types are considered to 
have oncogenic potential and are therefore classified as high-risk HPV types61. The 
high-risk HPV types 16 and 18 are associated with 54.6% and 15.8%, respectively, 
of  cervical cancer62. Treatment depends on the stage of  disease, generally involving 
surgery and/or radiotherapy and chemotherapy. Combined treatment achieves a 
curative rate of  approximately 90%, however, it may also come with side effects such 
as infertility63.
HPV infection initially occurs at the basal layer of  the cervical squamous 
epithelia that is exposed by micro-abrasions. Although the majority of  people 
infected with a high-risk HPV type clear the infection, persistent infections may lead 
to (pre)malignancy. Persistent/latent HPV infection is characterized by the presence 
of  episomal HPV DNA in the nucleus of  infected epithelial cells followed by the 
integration of  HPV DNA genome into the chromosome of  the infected epithelial 
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cells. This results in uncontrolled expression of  HPV viral proteins64. Development of  
HPV-associated lesions is mainly attributed to the expression of  HPV oncogenic early 
proteins E6 and E7 (ref. 65). Furthermore, HPV is capable to escape from the host 
immune surveillance enabling persistent infection and cervical cancer progression66.
Immunotherapy against HPV aims to induce cellular responses against cells 
expressing the oncogenic proteins E6 and E7 (ref. 67-69). For most vaccine strategies 
such as peptide and protein vaccinations, a robust cellular response is achieved by 
inclusion of  immune modulators that act as an adjuvant to boost the overall immune 
response70. For DNA vaccines, carrier proteins are extensively used in order to directly 
or indirectly augment the HPV-specific cellular responses71. Our group demonstrated 
that rSFV expressing HPV E6 and E7 induced protective cellular immune response 
that outperformed other vaccination strategies such as protein, DNA and adenoviral 
vectors72,73. Since carrier proteins used in DNA vaccines highly up-regulate the 
vaccine immunogenicity, we investigated the possible roles of  immunogenic carrier 
proteins in rSFV vectors (Chapter 4, 5). 
OUTLINE OF THIS THESIS 
Chapter 2 reviews literature on HCV therapeutic vaccines (until 2012) in both 
preclinical and clinical studies.
Chapter 3 describes the production and characterization of  rSFV replicons particles 
expressing all or a part of  the nsPs of  HCV in order to induce a robust and broad-
spectrum immune response. Inclusion of  all HCV nsPs induced a strong and long-
lasting HCV-specific CD8+ T-cell response in mice. Furthermore, immunization 
with rSFV expressing all nsPs of  HCV significantly reduced the outgrowth of  HCV-
expressing tumors.
Chapter 4 describes strategies to augment rSFV vaccine immunogenicity with 
inclusion of  various immunogenic carrier proteins. Since carrier proteins used in 
DNA vaccines highly up-regulate the vaccine immunogenicity, we investigated the 
possible roles of  immunogenic carrier proteins in the rSFV system. We generated, 
characterized and evaluated the efficacy of  rSFV vectors expressing HPV E6 and/
or E7 proteins fused to a protein expressing helper T cell (Th) epitopes, tetanus toxin 
fragment C (TTFC) or a series of  Th epitopes and an endoplasmic reticulum targeting 
signal (sigHELP-KDEL). Inclusion of  the sigHELP-KDEL strongly increased the 
frequency of  E7-specific T cell and protected mice from tumor formation even with 
very low immunization doses of  rSFV. 
Chapter 5 presents a preliminary study on the effect of  the inclusion of  the 
immunogenic carrier protein described in Chapter 4, sig-HELP-KDEL, into 
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the HCV-nsPs-expressing rSFV replicon. Immunization with sigHELP-KDEL-
expressing rSFVeNS3/4A (rSFVe-sHELP-NS3/4A) induced similar high levels of  
functional NS3-specific T cells as compared to immunization with rSFVeNS3/4A. 
Further investigations have to be performed to clarify the effect of  the inclusion of  
sigHELP-KDEL on HCV-expressing tumor growth.
Chapter 6 describes an in silico approach to identify HCV T cell epitopes which can 
be used for the rational design of  a tailor-made therapeutic HCV vaccine. An in 
silico approach which includes both the prediction of  CTL and Th epitopes as well 
as proteasomal cleavage sites with multiple mathematic algorithms is presented. 
Furthermore, the binding affinity and immunogenicity of  the identified CTL epitopes 
were validated in vitro and in vivo. 
Chapter 7 presents a summarizing discussion of  the studies in this thesis and a future 
perspective on the development and application of  a therapeutic HCV vaccine. 
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Therapeutic Vaccination Against Chronic Hepatitis C Virus 
Infection 
ABSTRACT
Approximately 170 million people worldwide are chronic carriers of  Hepatitis C 
virus (HCV). To date, there is no prophylactic vaccine available against HCV. The 
standard-of-care therapy for HCV infection involves a combination of  pegylated 
interferon-α and ribavirin. This therapy, which is commonly associated with side 
effects, has a curative rate varying from 43% (HCV genotype 1) to 80% (HCV 
genotype 2). In 2011, two direct-acting antiviral agents, telaprevir and boceprevir, 
were approved by the US Food and drug Administration and are now being used in 
combination with standard-of-care therapy in selected patients infected with HCV 
genotype 1. Although both drugs are promising, resulting in a shortening of  therapy, 
these drugs also induce additional side effects and have reduced efficacy in patients 
who did not respond to standard-of-care previously.
An alternative approach would be to treat HCV by stimulating the immune 
system with a therapeutic vaccine ideally aimed at (i) the eradication of  HCV-infected 
cells and (ii) neutralization of  infectious HCV particles. The challenge is to develop 
therapeutic vaccination strategies that are either at least as effective as antiviral drugs 
but with lower side effects, or vaccines that, when combined with antiviral drugs, can 
circumvent long-term use of  these drugs thereby reducing their side effects.
In this review, we summarize and discuss recent preclinical developments 
in the area of  therapeutic vaccination against chronic HCV infection. Although 
neutralizing antibodies have been described to exert protective immunity, clinical 
studies on the induction of  neutralizing antibodies in therapeutic settings are limited. 
Therefore, we will primarily discuss therapeutic vaccines which aim to induce 





The World Health Organization (WHO) has estimated that about 3% of  the world 
population is infected with hepatitis C virus (HCV) and approximately 170 million 
individuals are chronic carriers of  HCV. In this group of  chronic carriers, 5-10% are 
at risk of  developing liver cirrhosis and liver cancer1. Each year, 3-4 million people are 
newly infected with HCV and 350,000 patients die from HCV-related disease. HCV 
infection is distributed worldwide (Figure 1) with high rates of  chronic infection in 
Egypt (22%)2, Pakistan (4.8%)3 and China (3.2%)4. The standard-of-care treatment for 
patients infected with HCV is a combination of  pegylated interferon-α and ribavirin. 
This treatment is generally associated with side effects and is effective in 43% and 
80% of  the patients with genotype 1 and genotype 2 infections, respectively5-7. A 
prophylactic or therapeutic vaccine against HCV is not yet available. Yet, it is known 
that immune responses against HCV do play a significant role in viral clearance. 
While patients recovering from an acute HCV infection mount an effective cellular 
and humoral immune response against HCV; in individuals with a chronic infection, 
T-cell responses are often deficient and production of  neutralizing antibodies is 
delayed. 
An ideal therapeutic vaccine to treat patients with a chronic infection aims at 
the induction of  both cellular and humoral immune responses. HCV-specific cellular 
immune response to effectively clear HCV infected cells and humoral response to 
reduce the amount of  circulating HCV particles. And, humoral immune responses 
against HCV have been shown to also play a role in clearance of  infected cells by 
antibody-dependent cellular cytotoxicity in vitro8. 
Several approaches are currently being studied to develop vaccines that 
induce or reactivate a robust T-cell response. Yet, so far studies on the induction 
of  neutralizing antibodies in therapeutic settings are limited. In this review, we will 
therefore summarize different preclinical vaccine candidates, vaccine formulations, 
approaches and clinical studies which aim to induce HCV-specific cellular immune 
responses in patients with a chronic HCV infection (see Table 1). However before 
reviewing these vaccination strategies we will, in Section 2, briefly describe the 
virology and pathology of  HCV and the standard-of-care treatment for HCV patients. 
Next, in Section 3, we will address immune mechanisms in acute HCV-infected 
patients that either result in clearance of  the virus or result in chronic disease. In 
Section 3 we will also address the problems and challenges associated with the 
development of  prophylactic and therapeutic HCV vaccines.
2. HEPATITIS C: VIROLOGY, PATHOGENESIS AND CURRENT 
THERAPY 
2.1. Virology















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Prevalence of hepatitis C virus infection. Sources: The US Centers for Disease Control and 
Prevention, Hepatitis C virus database project.
Figure 2. Hepatitis C virus proteins. The HCV polyprotein is processed by cellular proteases (diamonds) 
or viral proteases (circles) into 10 viral proteins. The basic function of  each protein is indicated and 
extensively discussed in reference 19.
in 1989 (ref. 9). HCV is a small enveloped, positive-sense single-stranded RNA virus 
belonging to the family Flaviviridae in the genus Hepacivirus. The 9.6 kb viral RNA 
genome is composed of  one open reading frame encoding a polyprotein of  3000 
amino acid residues, and a 5’ and 3’ UTR. HCV enters cells through receptor-mediated 
endocytosis. Several cellular receptor proteins for HCV have been identified. Among 
them are tight-junction proteins occludin and claudin-1, scavenger receptor class B 
type I, and the tetraspanin CD81 (ref. 10-13). Since HCV particles are associated with 
lipoproteins such as LDL and VLDL14,15, binding of  viral particles may be initiated by 
interaction of  the lipoprotein on the viral particles and their corresponding receptors 
expressed on host cells16, followed by recognition through other cellular receptors. 
Recently, Sainz and coworkers demonstrated that, besides the scavenger receptor B 
type I and the LDL receptor, also the Niemann-Pick C1-like cholesterol adsorption 
structural Nonstructural 




















receptor is involved in HCV entry17. Upon entry into the cytoplasm, the viral RNA 
genome is translated to a polyprotein that is post-translationally cleaved by viral 
and cellular proteases into three major structural viral proteins, a small membrane 
polypeptide p7 and six non-structural proteins (nsPs). The structural proteins are 
core (C), envelope (E) 1 and 2, and the nsPs are NS2, NS3, NS4A, NS4B, NS5A and 
NS5B (Figure 2). HCV encodes a small protein, F (or ARFP, for “alternative reading 
frame protein”), which is produced by a ribosomal frame shift within the core gene18. 
The function of  each of  the viral proteins is discussed in ref.19. 
To date, at least seven genotypes and 50 subtypes of  HCV have been isolated 
worldwide and the presence of  HCV quasispecies can be detected in HCV-infected 
individuals. HCV has a high production rate of  1012 particles per day with a half-life 
of  2.5 hours. With the high error rate of  the viral RNA-dependent RNA polymerase, 
the mutation rate of  the HCV genome has been estimated to be 1.92 Í 10-3 base 
substitutions per site per year20. This mutation rate is higher than that of  human 
immunodeficiency virus (HIV) type 1 which is 3.4 Í 10-5 base substitutions per site 
per year21. These frequent mutations result in production of  viral variants which may 
not only improve replication fitness but also hampers the host immune system to 
recognize and clear the virus22.
2.2. Pathogenesis
HCV represents a major cause of  liver disease in humans and chronic HCV infection 
is also the primary cause for liver transplantation in the Western world. HCV 
is transmitted mainly by blood transfusion, re-use of  medical devices and shared 
needles among injection-drug users. Both innate and adaptive immune responses are 
required for viral clearance and will be discussed in detail below. Inefficient immune 
responses and chronic HCV infection induce liver damage and inflammation which 
may lead to liver cirrhosis, liver failure and ultimately hepatocellular carcinoma. 
Hepatocarcinogenesis is caused by the interaction of  several indirect mechanisms 
including chronic inflammation, steatosis, fibrosis and oxidative stress23.
2.3. Standard-of-care therapy and novel drugs 
The standard-of-care therapy of  patients with chronic HCV infection consists of  
weekly injections of  pegylated interferon-α and a twice-daily intake of  ribavirin for 
24-48 weeks. A sustained virological response defined as the absence of  HCV RNA 
in serum for 6 months or longer after therapy, is achieved in about half  of  the treated 
patients. This treatment in most patients leads to side effects such as influenza-like 
symptoms and depression and about 20% of  treated patients develop anemia7. Two 
new direct-acting antiviral (DAAs) drugs, INCIVEKTM/ INCIVO® (telaprevir) and 
VICTRELISTM (boceprevir), which both specifically inhibit the activity of  the HCV 




to be used in combination with the standard-of-care therapy for patients infected 
with HCV genotype 1 (ref. 24, 25). New treatment schedule with either telaprevir 
or boceprevir is promising. In treatment-naïve populations response-guided therapy 
can be shortened to 24 weeks in approx. 55% of  patients treated with the telaprevir-
based regime and to 28 weeks in approx. 45% of  patients treated with the boceprevir-
based regime26. Side effects such as rash and anemia occur in around 40% of  the 
treated patients24,25. In two large phase 3 studies, the SPRINT-2 study (boceprevir in 
combination with pegylated interferon-α and ribavirin) and the HCV RESPOND-2 
study (Retreatment with HCV Serine Protease Inhibitor boceprevir and PegIntron/
Rebetol 2), more than 40% of  patients developed anemia and required erythropoietin 
administration for up to 150 days25,27. Presently, many other drugs inhibiting HCV 
viral proteins or host proteins essential for viral replication such as cyclophilin A 
inhibitors, including alisporivir, are under investigation. However, due to the error-
prone replication of  HCV, combinations of  antiviral drugs as a cocktail treatment 
will be required to prevent development of  drug resistance. On the other hand, 
combination therapy may lead to side effects induced by drug-drug interaction of  
these new DAAs. Alternatively, therapeutic vaccines may, in combination with 
DAAs, not only reduce the duration of  the standard-of-care therapy, but may also 
cure patients that do not respond to the standard-of-care therapy.
3. IMMUNE RESPONSE AND VACCINATION AGAINST HCV 
INFECTION 
3.1. Immune responses in acute HCV-infected patients
Based on the level of  viral load and alanine aminotransferase (ALT) in serum, HCV 
infection is divided into three stages, which are the incubation, the acute and the 
chronic phase. During the incubation phase, HCV is actively proliferating in the liver 
with a high level of  HCV RNA detected in serum. However, this period is mostly 
asymptomatic and therefore difficult to be diagnosed. Upon infection, the viral 
dsRNA replication intermediates of  the HCV RNA activate host innate immunity 
through Toll-like receptor 3 (TLR3) and the polyuridine motif  at 3’ UTR activates the 
retinoic acid-inducible gene I (RIG-I) signaling in a viral 5’ triphosphate-dependent 
manner28. This results in production of  IFN-β by infected hepatocytes which is a first 
line of  defense to control further infection by inducing antiviral IFN-α production 
in neighboring uninfected hepatocytes as described by Rehermann29. Furthermore, 
HCV NS3/4A protein also reduces the production of  IFN-α by infected hepatocytes 
by inhibiting TLR3 and RIG-I signaling through the cleavage of  the adapter 
molecule TRIF (Toll-IL1 receptor domain-containing adaptor inducing IFN-β) and 
IPS1 (IFN-β promoter stimulator protein 1), respectively30,31. The incubation phase 
with the activation of  innate response lasts for 8-12 weeks and HCV infection can 
be diagnosed only when the levels of  ALT and HCV-specific T cells increase which 
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characterize the acute phase of  the disease29. 
During the acute phase of  the disease, the level of  HCV RNA fluctuates 
coincidentally with the level of  ALT. HCV-specific T cells and HCV-specific antibodies 
are detectable at 5-9 and 8-20 weeks after primary HCV infection, respectively32-34. 
HCV-specific adaptive immune responses are mild and delayed, which may be due to 
poor antigen presentation in the immune-tolerant environment of  the liver35 and to 
direct inhibitory effects of  HCV proteins. A protective role of  anti-HCV antibodies 
is still controversial as it has been shown that antibody-deficient patients can recover 
from acute infection of  HCV in the absence of  anti-HCV antibodies36. Other studies 
demonstrate that neutralizing antibodies, induced in the early phase of  disease, 
positively correlate with control of  virus replication37 and resolution38, reducing the 
chance to develop a chronic infection. Because of  lack of  an appropriate animal 
model for HCV infection, the potency of  neutralizing antibodies was studied in a 
human liver-chimeric mouse model (Alb-uPA/SCID). These mice lack an adaptive 
immune system and are susceptible to HCV infection. Alb-uPA/SCID mice injected 
with neutralizing antibodies derived from patients with chronic HCV infection were 
protected from homologous HCV39,40 or heterologous HCV challenges41. 
Cellular immune responses have been shown to play a crucial role in clearance 
of  HCV as proliferation of  HCV-specific T cells and increased levels of  IFN-γ 
coincide with the first decline of  HCV RNA level in blood. Virus clearance depends 
on the diversity and effector function of  pathogen-specific CD8+ T cells. HCV-
specific CD8+ T cells isolated from patients at early onset of  the disease (1 week) 
exhibit a broad antigen specificity. Yet these cells often seem to have impaired effector 
functions, including proliferative capacity, IFN-γ production and cytotoxicity42,43. 
The effector functions of  HCV-specific CD8+ T cells in patients who later recover 
from the acute disease improve over time. In patients who develop a chronic HCV 
disease this change does not occur43. HCV-specific CD4+ T cells, perform differently 
between patients. Robust proliferation of  HCV-specific CD4+ T cells is detectable 
in patients who later recover from acute disease, but not in patients who progress to 
chronic infection. Only a minority of  patients recovers from acute infection without 
treatment. However, these patients in general develop protective immunity against 
re-infection44-46. Protective immunity against re-infection, which has been shown to 
be T cell-dependent47, is characterized by a reduced duration of  viremia and a lower 
amount of  viral RNA in the serum of  homologous or heterologous HCV re-infected 
patients46.
3.2. Failure of immune responses in chronic HCV-infected patients 
A majority of  primary HCV-infected patients (60-80% of  those infected with HCV 
genotype 1) develop chronic infection characterized by stable HCV serum RNA levels 




during the acute phase. The induction of  virus-neutralizing antibodies is delayed but 
detectable during the entire period of  chronic infection. Most importantly, HCV-
specific CD8+ T cells isolated from chronic patients are functionally exhausted which 
ultimately leads to a reduced breadth of  the response48,49. T cell exhaustion in general 
and also in chronic HCV infection is caused by a number of  factors including: 
•	 long-term antigen stimulation in the presence of  a persisting substantial 
(HCV) viral load; 
•	 upregulation of  anti-inflammatory cytokines such as IL-10 and transforming 
growth factor (TGF-β) and downregulation of  pro-inflammatory cytokines 
such as IFN-γ, IL-2 and IL-21;
•	 reduced help from antigen-specific CD4+ T cells; 
•	 expression of  inhibitory receptors including programmed cell death 1 
(PD1), lymphocyte activation gene-3 (LAG3), CD244 (2B4), CD160, T 
cell immunoglobulin and mucin domain-containing molecule (TIM3) and 
CTL4 on the surface of  antigen-specific T cells50; 
•	 presence of  immune suppressor cell populations such as regulatory T cells 
(Treg)51. 
For instance, several groups reported on the presence of  high frequencies of  
both Treg and HCV-specific CD8+ T cells expressing PD1, CTLA4 and TIM3 in the 
periphery and liver of  patients with chronic HCV infection52-54. Exhaustion occurs 
for both CD4+ and CD8+ T cells. Exhaustion of  CD8+ T cells is characterized by a 
gradual progression of  dysfunction. It begins with a reduced, and later a complete 
lack of, production of  tumor necrosis factor α (TNF-α) and IL-2, followed by a 
reduced production of  IFN-γ and loss of  cytolytic function. At later time points, 
expression of  inhibitory receptors such as PD1 and TIM3 is induced and apoptosis 
begins51. Exhaustion of  CD4+ T cells is not fully understood but it has been shown 
that HCV-specific CD4+ T cells isolated from patients with chronic disease have a 
reduced production of  IL-2 and IFN-γ55. Since dysfunction of  HCV-specific CD4+ 
T cells is not observed in patients who clear the infection, this may provide clues 
as to how to treat patients with a chronic infection. If  the function of  exhausted 
HCV-specific T cells can be restored and the diversity of  HCV-specific T cells will be 
broadened, patients with a chronic infection may regain the ability to clear the virus. 
Fortunately, exhaustion of  T cells is reversible; for example, it has been shown that 
HCV-specific cytotoxic T lymphocyte (CTL) activity can be restored by blockade of  
either PD1/CTLA4 or TIM3 (ref. 56, 57). The function of  exhausted T cells can also 
be restored by elimination of  the original causes of  dysfunction. For example, such 
as to increase help from CD4+ T cells, to provide adequate amount of  IFN-γ, IL-2 
and IL-21 and to inhibit the function of  Treg. All these strategies should be taken 
into account in the design of  therapeutic vaccines against HCV infection in order to 
restore exhausted T cells and to increase the diversity of  HCV-specific T cells.
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Viral mutants or quasispecies, appearing under immune pressure58 may not 
be recognized by an intact immune system despite the fact that patients develop a 
spectrum of  functionally active HCV-specific T cells22. Mutations can be found in 
various regions of  the viral genome including T cell epitopes, B cell epitopes or other 
regions. For example, viral mutants which have mutations within neutralizing epitopes 
have been described to infect hepatocytes more efficiently than their consensus virus 
in the transplanted liver of  patients with chronic HCV infection59. Mutations within 
T cell epitopes are positively correlated to the development of  chronic disease in both 
chimpanzees60 and humans61. Recent studies show mutations in protective HLA-
B27-restricted epitopes in patients who developed chronic disease but not in those 
who recovered from acute infection62,63. Of  note, the rate of  mutation in CD8 T cell 
epitopes is comparable to the hypervariable region 1 (HVR-1) of  the E2 gylcoprotein, 
the most variable region in the HCV genome22. The lack of  immune recognition of  
these mutants was demonstrated in studies which showed that HCV-specific T cells 
isolated from patients can be stimulated by consensus but not by mutated CD8 T 
cells epitopes22,64. Immune escape mutations may occur on the costs of  viral fitness 
as the antiviral effect of  T cells forces the virus to adopt a relatively unfavorable 
sequence58,65. In fact, half  of  the detectable CD8 T-cell responses observed in patients 
with chronic disease were found associated with viral mutations64. Chronic HCV 
infection therefore results from the selection of  immune escape mutants and the 
existence of  functionally exhausted T cells. 
3.3. Vaccination against HCV 
3.3.1. Prophylactic vaccination
Conventional prophylactic vaccines against viral infections generally aim at induction 
of  a humoral immune response resulting in the production of  virus-neutralizing 
antibodies that eventually block receptor binding and cell entry of  the viral pathogen 
involved. Although the neutralizing function of  antibodies against the HCV envelope 
glycoproteins E1 and E2 in humans is still controversial66,67, vaccination strategies 
which induce production of  neutralizing antibodies against E1 and E2 do protect 
HCV-naïve chimpanzees from virus challenge68,69. Several studies have now shown 
that polyclonal antibodies against HCV may prevent the attachment to and entry 
of  virions into hepatocytes70-74. Although E1 gylcoprotein-specific antibodies can be 
identified in patients with chronic HCV infection74, the major antigenic determinants 
on the viral surface are located in the HVR-1 of  the E2 glycoprotein75 and this 
variability occurs not only between patients but also within a single patient making 
the design of  prophylactic vaccines difficult. One possible solution is to delete the 
HVR-1 region from E2 glycoprotein allowing the presentation of  other epitopes 
that may induce protective virus-neutralizing antibody responses. A recent study 




glycoprotein can indeed clear HCV in chimpanzees in a T-cell-dependent manner76. 
Furthermore, a study in macaques has shown that antibodies against E1 and E2 
glycoproteins possess neutralizing ability against both homologous and heterologous 
virus77. Clarification of  the immunogenicity of  E1 and E2 glycoproteins and the 
protective effect of  neutralizing antibodies is essential for a more precise formulation 
of  prophylactic and therapeutic HCV vaccines. To date, more neutralizing epitopes 
have been identified in patients, which may facilitate the development of  prophylactic 
vaccines. Recently, in a phase I clinical study in healthy humans, E1- and E2-specific 
antibodies with in vitro virus-neutralizing activity were induced by vaccination with 
recombinant E1 and E2 protein and MF59 adjuvant78.
3.3.2. Therapeutic vaccination
Therapeutic vaccines preferably activate both humoral and cellular immune responses, 
thereby generating antibodies and virus-specific CD8+ cytotoxic T lymphocytes (CTL) 
that neutralize the circulating virus and eliminate virus-infected cells, respectively. 
The majority of  the viral epitopes recognized by CTLs and CD4+ T cells in patients 
with HCV infection are located in the NS3 region32,79-86. Therefore, NS3 is considered 
to be a good cellular target candidate for a therapeutic vaccine. Yet as also CTL 
and CD4+ T cells recognizing epitopes from other conserved HCV proteins such 
as core and NS5A/B, have been identified in self-limited HCV patients87, vaccines 
containing these epitope regions are currently being studied (Section 4).
The development of  therapeutic vaccines against HCV is challenging, not only 
because such vaccines have to tackle the broad range of  HCV types, but also because 
there is a lack of  appropriate animal models and, most importantly, vaccination 
strategies have to deal with the ineffective host immune response against HCV, as 
discussed above. The high viral production rate and the presence of  multiple HCV 
quasispecies impede the design of  an effective universal therapeutic vaccine. The lack 
of  immunocompetent small-animal models for HCV infection stands in the way of  
evaluation of  the efficacy of  vaccine candidates. Yet, recently an immunocompetent 
transgenic mouse has been generated expressing human CD81 and occludin thereby 
facilitating HCV cell entry88. This transgenic mouse could represent a crucial step in 
the development of  an HCV-susceptible immunocompetent mouse model in the near 
future. And, as discussed in Section 3.2, co-administration of  a therapeutic vaccine 
with immune-modulators and/or blockers of  inhibitory molecules may potentially 
restore ineffective immune response. 
4. SPECIFIC APPROACHES IN THE DEVELOPMENT OF A 
THERAPEUTIC VACCINE AGAINST HCV INFECTION 
4.1. Peptide- or protein-based vaccines
Vaccines composed of  viral peptides or recombinant viral proteins can be generated 
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relatively easily and are being developed for infectious diseases and cancer. As 
peptide/protein vaccines in general are not very immunogenic, these vaccines are 
often combined with adjuvants. And to avoid the risk of  immune escape, these 
vaccines often contain multiple epitopes for the induction of  broad CTL and Th 
responses.
4.1.1. Preclinical studies 
To induce an HCV-specific cellular immune response, already in 1999 Hiranuma et 
al. reported on a study on the vaccination with HCV peptides containing CTL and 
CD4+ helper T (Th) epitopes89. To demonstrate the important role of  Th epitopes in 
activation and maturation of  CTL, mice were immunized with either CTL peptides 
only, a mixture of  Th and CTL peptides or conjugated Th-CTL peptides. Th-mediated 
enhancement of  HCV-specific CTL responses were only observed in the last group 
demonstrating the indispensable role of  conjugated Th peptides for priming of  a 
CD8+ T-cell response89. 
Vaccination with recombinant HCV viral proteins has been reported to induce 
a Th2-biased response, which favors the production of  IL-4 and antibodies rather 
than a Th1-biased response which favors the production of  IFN-γ and activation 
of  CTLs90. To induce a balanced immune response, Th1 adjuvants and/or immune 
modulators have been included in experimental vaccine formulations. Adjuvants 
such as Montanide ISA 720 or TLR agonists (TLR3, TLR9 or TLR4) shift the HCV-
specific immune response in vaccinated mice from a Th2 to a Th1 phenotype90-92. 
Currently, studies on the design of  vaccines based on proteins, peptides, DNA and 
dendritic cells (DC) strongly focus on the selection and/or development of  proper 
adjuvants and/or immune modulators.
4.1.2. Clinical studies
Peptide-based vaccination in clinical trials may either be predesigned93,94 or 
personalized95,96. Predesigned peptides, which contain immunodominant regions 
of  HCV in specific HLA genotypes, stimulate naïve and resting T cells in healthy 
individuals and HCV-infected patients. Personalized peptides are tailor-made and 
stimulate memory T cells and activated T cells that are already present in the patient. 
To identify effective peptides, peripheral blood mononuclear cells (PBMC) are isolated 
from the patient and cultured in the presence of  different predicted HLA-restricted 
immunodominant peptides. Only peptides that can activate CTLs are administrated 
to the patients. 
The efficacy of  a personalized peptide vaccine derived from the HCV E1, E2, 
NS3 and NS5A regions has been evaluated in a phase I clinical study95. HLA-A24+ 
patients with a chronic HCV infection, who did not respond to the standard-of-care 




peptide vaccine in Montanide ISA 51 VG. The treatments were well-tolerated and 
there was no severe toxicity. These personalized vaccines stimulated peptide-specific 
IFN-γ production by CTLs in 50% of  the vaccinees. However, a decrease of  HCV 
RNA in serum was observed in only 3 out of  12 patients. 
In a recent phase I clinical study with personalized peptides, HCV-infected 
patients were vaccinated with a peptide derived from the HCV core protein 
supplemented with Montanide ISA 51 VG96. This peptide was tested in patients 
with different HLA genotypes as it contains a CTL epitope79,80 which is conserved in 
various HCV genotypes and has binding activity to several HLA class I-A molecules 
(HLA-A2, HLA-A24, HLA-A26, HLA-A31 and HLA-A33). Peptide-specific CTL 
responses were enhanced after six vaccinations in 15 out of  25 patients and there 
was a > 1 log decline of  HCV serum RNA level in two patients. The amount of  
peptide-specific IgG was significantly increased in more than 50% of  the vaccinees 
in both studies using personalized peptides. This augmentation has been described to 
positively correlate with increased survival of  advanced cancer patients97-99. Of  note, 
vaccination with personalized peptides activates responses against specific epitopes 
but this strategy is relatively time-consuming and not applicable for all patients.
Klade and colleagues93 reported on a phase I clinical trial with a pre-designed 
peptide vaccine, IC41, containing five synthetic peptides derived from core, NS3 
and NS4 of  HCV with poly-
L
-arginine as an adjuvant. The peptides encompassed 
four HLA-A*0201-restricted CTL epitopes and three CD4 Th epitopes82. The study 
indicates that both healthy volunteers and patients with a chronic HCV infection 
respond to IC41 vaccination. However, patients with a chronic HCV infection showed 
a lower induction of  epitope-specific CTL activity, proliferation of  CD4+ Th cells and 
production of  IFN-γ by epitope-specific CD4+ and CD8+ T cells compared to the 
healthy volunteers93. Because of  this suboptimal immune response, which is most 
likely the result of  the low immunogenicity of  synthetic peptides, the authors suggest 
to optimize T-cell responses by including more antigenic peptides or by combining 
IC41 treatment with the standard-of-care in the future. 
An effective therapeutic vaccine also aims at maturation of  memory CD8+ T 
cells which are classified as either effector memory T cells (T
EM
) or central memory 
T cells (T
CM
) based on their location, functions and different expression of  surface 
molecules100. T
EM
 cells have been described to stably produce perforin and granzyme 
B, molecules required to lyse virus-infected cells101. Of  note, HCV-specific T
EM
 
cells dominate in patients with an acute HCV infection, while T
CM
 cells dominate 
in patients with a chronic HCV infection. Further analysis of  the phenotypes of  





 cells after IC41 vaccination94. However, the T-cell responses were too 
weak to induce reduction of  HCV RNA in the serum of  most of  the patients, which 
may be due to the low immunogenicity of  the peptides93. Recently, to optimize 
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immunogenicity, different vaccination routes and dosages of  IC41 have been 
investigated in healthy subjects. Intradermal (i.d.) administration of  IC41 induced 
more robust peptide-specific immune responses than s.c. administration. Although 
intradermal vaccination with IC41 proved to be safe, efficacy needs to be enhanced 
in order to obtain sufficient protective cellular immune responses in patients with 
chronic HCV infection102. 
Vaccinations with peptides together with adjuvant in general are well-
tolerated, even after repeated injections. And although most of  the HCV peptide/
protein vaccines clinically evaluated so far do induce cellular immune responses, 
these responses do not seem strong enough or do not encompass the appropriate 
phenotype of  cells that would be required to induce viral clearance in patients with a 
chronic HCV infection. 
4.2. DNA vaccines
In the early 1990s, it was shown that plasmid DNA can directly transfect mouse 
muscle cells in vivo103. Upon intramuscular (i.m.) administration to mice, plasmid 
DNA expressing the influenza A virus nucleoprotein (NP) elicited both antigen-
specific antibodies and CTLs104. These studies initiated the development of  DNA 
vaccines against infectious diseases and tumors105. 
4.2.1. Preclinical studies
Plasmid DNA encoding antigenic HCV protein(s) or peptide epitope(s) of  varying 
sizes can induce both humoral and cellular immune responses in vivo. Antigen-specific 
memory responses have also been described in animal studies106,107. Yet, plasmid DNA 
injected i.m. or s.c. is poorly immunogenic and several studies have demonstrated 
that immune induction is lower in non-human primates than in mice108-110. In order 
to stimulate the in vivo transfection rate, different immunization approaches such as 
the usage of  a gene gun111, micro-needles112, gene-electrotransfer113 and in vivo local 
electroporation114,115 have been developed and tested in experimental animal models. 
All these approaches enhance both humoral and cellular immune responses against 
expressed HCV viral proteins when compared with conventional i.m. or s.c. injection. 
Host immune responses against HCV viral proteins in experimental mice 
models can also be skewed and enhanced by co-administration of  adjuvants such as 
CpG116,117, QuilA117 and/or immune modulators such as Flt3-L and GM-CSF118, IL-2 
(ref. 107) or IFN-α119. Mice vaccinated with these adjuvants or immune modulators 
have increased HCV-specific humoral and cellular immunity. Interestingly, inclusion 
of  sequences of  the core protein of  Hepatitis B virus, thus creating a priming 
environment by recruiting “healthy” heterologous T cells and by activating innate 
signaling, resulted in a restoration of  HCV-specific responses in mice tolerant for 




of  Flt-3L and GM-CSF with HCV DNA vaccines have been shown to protect 
mice from development of  HCV-antigen-expressing tumors. Long-term memory 
responses are induced in mice vaccinated with HCV DNA vaccine together with a 
plasmid expressing IL-2 (ref. 107). Some HCV viral proteins are known to directly 
suppress the host immune system121. Modification of  these proteins without removal 
of  the antigenic epitopes could also enhance the immune responses against these 
antigens. Modification of  antigens expressed by DNA vaccines, such as truncated 
core proteins115, truncated or secreted forms of  the E2 protein122, and codon-
optimized NS3/4A proteins111 has been shown to improve the immunogenicity of  
these proteins when compared with that of  native viral proteins. The main advantage 
of  the use of  DNA vaccines is the high flexibility of  the approach thereby allowing 
combinations of  strategies as mentioned above, to further improve the overall 
efficacy of  DNA vaccines.
4.2.2. Clinical studies
The first therapeutic HCV vaccine based on plasmid DNA evaluated in a phase 
I clinical study was CIGB-230. This vaccine is composed of  a combination of  
recombinant HCV core protein and a plasmid DNA expressing HCV core, E1 and 
E2. The trial was performed in patients with a chronic HCV infection who did not 
respond to standard-of-care therapy123,124. Participants were immunized six times 
with CIGB-230 by i.m. injections with 4-week intervals. Moderate adverse effects 
such as headache were observed and no autoimmune responses, which could be 
possibly induced by DNA immunization125-127, such as anti-mitochondrial or anti-
nuclear antibodies were generated. Almost half  of  the tested subjects had increased 
proliferation of  CD4+ and CD8+ T cells upon in vitro antigen stimulation of  PBMCs 
and increased titers of  antibodies against E1 and E2 proteins in the serum. Although 
only 1 out of  15 vaccinated patients had a reduced level of  serum HCV RNA, more 
than 40% of  them had improved liver histology. The phase I trial showed CIGB-230 
to be safe for humans. However further studies with optimized vaccination dose 
schedules and methods of  vaccine delivery are required. 
ChronVac-C® (ChronTech Pharma AB), which contains a plasmid expressing 
the NS3/4A proteins of  HCV genotype 1 has passed a phase I clinical trial and is 
now under investigation in a phase II clinical trial. In the phase I clinical study, 
patients with a chronic HCV infection without previous treatment were immunized 
i.m. twice with a 4-week interval with ChronVac-C® in combination with in vivo 
electroporation using Inovio’s Medpulser® DNA Delivery System. Standard-of-care 
therapy was given to all participants after the second administration of  ChronVac-C®. 
Results showed that 83% of  the participants (5 of  6 patients) achieved a sustained 
virological response. Standard-of-care normally results in a sustained virological 
response of  40-50% in this patient group. Yet, as the number of  patients included 
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in this ChronVac-C® trial was limited to six, no firm conclusions can be drawn so 
far. A phase II clinical trial with an increased number of  patients is now underway 
to evaluate the safety, tolerability and efficacy of  ChronVac-C® (ClinicalTrials.gov 
Identifier: NCT01335711).
4.3. Viral vector vaccines
Similar to DNA vaccines, viral vector vaccines encode target proteins or peptides. The 
major advantage being that in general viral vector vaccines are more immunogenic 
than DNA-based vaccines. The major disadvantage is that as these vaccines are 
derived from viruses, they require extensive evaluation by regulatory authorities, 
which may delay or even obstruct the progress of  clinical application. The mostly 
tested viral vector vaccines against HCV are based on replication-defective adenovirus 
and modified non-replicative vaccinia virus Ankara (MVA). 
4.3.1. Adenovirus vectors 
Among the serotypes of  Adenovirus (Ad) vectors investigated, Ad5 induces the 
strongest and longest lasting humoral and cellular immune response in mice128. 
However, a significant proportion of  the world population has pre-existing humoral 
and cellular immunity against Ad5, with up to 50% in the United States and 88% 
in South Africa129-131. To overcome pre-existing immunity, viral vectors based on 
low prevalence Ad serotypes such as Ad6 (ref. 132), Ad24 or Ad35 (ref. 133) or on 
adenovirus strains from chimpanzees (ChAd)132 with a prevalence of  12%134 are being 
developed. Ad6 induces strong humoral responses in Rhesus monkeys, although the 
effects on cellular immune responses are unknown135. 
Apart from pre-existing Ad immunity, the efficacy of  Ad-based vaccines 
and MVA-based vaccines, which will be discussed in the next subsection, is 
also diminished in homologous prime-boost immunization protocols due to the 
induction of  neutralizing antibodies against the viral vector initiated by the prime 
immunization. Heterologous prime-boost immunizations may solve this problem as 
has been shown by combinations of  different serotypes of  Ad vectors133, plasmid 
DNA and Ad vector136-138, peptides and Ad vector139, liposomes and Ad vector140 or 
other viral vectors including Semliki Forest virus (SFV)138, ovine atadenovirus141, 
MVA142 and Ad vector. 
Although an adjuvant is normally not required in viral vector-based vaccines, 
the polarity and breadth of  the immune response can be further improved by giving 
different immune modulators before, during and/or after the immunization. Studies 
combining an Ad vector expressing HCV proteins and MHC class II chaperone 
protein invariant chain143, IL-12 (ref. 136, 140), anti-CD137 antibodies144 or P60 
(inhibitor of  Foxp3)145 have shown dramatic increases in both humoral and cellular 




is not yet known. 
Recently, Barnes et al. developed an HCV vaccine in which Ad6 and ChAd3 
vectors were being used to induce a broad HCV-specific T-cells response132. A phase 
I study was performed in healthy human volunteers. Robust production of  IFN-γ 
was induced 2 weeks after the prime immunization with an average of  > 1000 IFN-γ-
producing cells per 1 million PBMCs at the optimal dose of  recombinant virus. This 
vigorous production of  IFN-γ by HCV-specific T cells has never been observed in 
other clinical trials in which on average 100-500 IFN-γ-producing cells per 1 million 
PBMCs have been observed. This HCV-specific T-cell response is shown to be long 
lasting (at least 1 year) with wide diversity. Most importantly, the HCV-specific T cells 
have a mixed effector/central memory phenotype and have strong effector functions 
such as degranulation and production of  IFN-γ, TNF-α. Of  note, the vaccinations 
induced the production of  neutralizing antibodies against the Ad vector which might 
affect the overall response of  HCV-specific T cells. Robust HCV-specific immune 
responses can be induced in healthy volunteers but the efficacy of  these vaccines is 
not known in patients with persistent HCV infection. Further studies on patients with 
chronic HCV infection are now underway aiming at the restoration of  dysfunctional 
T cells and, at the same time, broadening of  the HCV-specific T-cell response132. 
4.3.2. Modified vaccinia virus Ankara vectors
Similar to Ad vectors, vaccines based on modified vaccinia virus Ankara (MVA) 
are safe in humans. However, pre-existing immunity and neutralizing antibodies 
against the vector backbone also reduces the efficiency of  MVA-based vaccines.  The 
levels of  pre-existing immunity against vaccinia virus, as seen in persons previously 
vaccinated against smallpox virus, seem to be lower than those against Ad5 (ref. 
146, 147). And obviously this vaccine-induced pre-existing immunity will disappear 
as the population that received this vaccine grows older. Several preclinical studies 
have been performed and showed that MVA-based HCV therapeutic vaccines can 
induce HCV-specific cellular immune responses and protect mice from for example, 
NS3-expressing recombinant murine gammaherpesvirus 68 (ref. 142) or recombinant 
Listeria monocytogenes challenge148.
TG4040 (Transgene) is a viral vector-based therapeutic HCV vaccine that 
entered phase I and phase II clinical trials. The vaccine is based on MVA expressing 
NS3, NS4 and NS5B of  HCV. Administration of  TG4040 to patients with a chronic 
HCV infection induced no severe adverse effects in a phase I clinical study. Eight out 
of  15 patients had a reduction in HCV serum RNA and 4 out of  the 8 responders 
had an increased number of  HCV-specific IFN-γ-producing cells149. A randomized 
phase II study (HCVac study) involved 153 patients in three treatment groups: (A) 
standard-of-care alone, (B) combination of  the standard-of-care treatment with 
TG4040 in the same treatment schedule or (C) pre-vaccination with TG4040 before 
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the standard-of-care. Preliminary data, published on the website of  Transgene shown 
that a reduction of  viral load in treatment group C can be detected one week after 
the start of  treatment which is faster than in both other groups (ClinicalTrials.gov 
Identifier: NCT01055821).
4.3.3. Alphavirus vectors
To overcome problems related to pre-existing immunity against Ad and MVA in 
humans, other viral vector vaccines such as alphaviruses including SFV, Venezuelan 
equine encephalitis virus and Sindbis virus, are currently being evaluated for the 
induction of  HCV-specific immunity139,150-152. In general, the immune and anti-
tumor responses induced by alphavirus-based vaccines seem more robust than those 
induced by DNA-, peptide-, recombinant protein-, or adenovirus-based vaccines in 
animal studies150,153,154. This can be ascribed to the high-level antigen expression by 
these vector systems and the low anti-vector responses induced by the viral vectors 
themselves155,156 and, possibly most importantly, the activation of  multiple innate 
signaling pathways157. An additional advantage of  alphavirus-based vaccines relates 
to the lack of  pre-existing immunity in most humans against the native viruses. 
4.4. Recombinant yeast-based vaccines
Recombinant Saccharomyces cerevisiae is one of  the candidates for vaccine development 
because of  its nonpathogenicity in humans and since this yeast can easily be engineered 
to express multiple proteins of  varying size. Furthermore, recombinant yeast cells are 
able to activate both innate and adaptive immune responses by activating dendritic 
cells through direct yeast cells-dendritic cells interaction. Interaction of  yeast cells 
with dendritic cells leads to increase antigen presentation and production of  pro-
inflammatory cytokines such as TNF-α, IFN-g, GM-CSF, IL-2, IL-6 and IL-12 
(ref. 158). Haller and colleagues showed that heat-inactivated S. cerevisiae yeast cells 
expressing HCV NS3 and core protein (GI-5005) induces effective NS3 and core-
specific cellular immune responses in both C57BL/6 and BALB/c mice. Activation 
of  cellular immune responses including induction of  CTLs and helper T cells 
protected mice against a challenge with an HCV-expressing tumor159. 
GI-5005 (GlobeImmune) entered a phase I clinical trial in 2007 and results 
showed that it is well-tolerated and is able to induce significant HCV-specific immune 
response in patients with a chronic HCV infection (ClinicalTrials.gov Identifier: 
NCT00124215). The induction of  HCV-specific cellular immune responses positively 
correlated to the reduction of  serum viral RNA in vaccinated patients. A phase II 
trial aiming to investigate the treatment effect of  combining GI-5005 and standard-
of-care treatment is ongoing. Although not statistically significant, the preliminary 
results showed that 63% of  the patients with combined treatment achieved sustained 




treatment alone. Additional patients were recruited in this trial in order to further 
evaluate the efficacy of  GI-5005 in combination with standard-of-care (ClinicalTrials.
gov Identifier: NCT00606086). 
4.5. Vaccines based on dendritic cells 
Vaccines composed of  isolated DC, which are modified ex vivo to express foreign 
proteins, are considered very promising160,161. As natural antigen-presenting cells, 
DCs take up antigens and present these to both T cells and B cells. The phenotypes 
and immunological functions of  antigen-loaded DCs can be extensively characterized 
before administration of  the vaccine to the patient. However, tailor-made treatment is 
expensive and time-consuming. In addition, the availability of  functional DCs from 
patients depends on the severity of  the disease, treatment history of  the patients and/
or other unknown factors162-164. 
4.5.1. Preclinical studies
Bone marrow-derived dendritic cells (BM-DC) from mice have been loaded with 
HCV antigen by transfection with either plasmid DNA or mRNA encoding HCV 
nsPs165,166, infection with Ad vector expressing HCV nsPs167-171, uptake of  either HCV 
peptides168, HCV lipopeptides172 or HCV nsPs-coated magnetic microbeads173,174. 
Transfection of  NS5A mRNA by electroporation into BM-DC resulted in the 
strongest immune response when compared with BM-DC loaded with plasmid DNA 
encoding NS5A or recombinant NS5A protein165. A comparative study between BM-
DC loaded with Ad vector encoding HCV NS3 DNA (AdNS3), NS3 peptides or 
recombinant NS3 protein showed that infection with AdNS3 resulted in the highest 
level of  antigen loading and expression165,168,170. The infection rate of  Ad vector 
could be further enhanced by co-administration of  AdNS3 and an adaptor molecule 
CFm40L containing the Coxsackie adenovirus receptor and CD40L, the ligand for 
CD40 on the surface of  DC, thus targeting AdNS3 directly to BM-DC in vitro167. 
To stimulate maturation and cytokine production of  DC, BM-DC have been 
treated in vitro with immune modulators such as TLR2 antagonist, Pam
2
Cys172 or 
IL-10-inhibiting peptides resulting in an increased production of  IL-12 (ref. 168). 
Enhancement of  immune responses could also be achieved by repeated injection 
of  antigen-loaded and unloaded BM-DC. Alternatively, splenocytes loaded with 
antigen-coated magnetic microbeads selected by magnetic field were used for in vitro 
immunization174. 
The ratio of  subpopulations of  DC is one of  the main concerns in the 
development of  cell immunotherapy. CD8α+ DC have the highest antigen-presenting 
ability175. However, the expression of  CD8α could not be increased by the ex vivo 
cultivation of  BM-DC with GM-CSF, IL-4 and/or IL-10, which do increase the 
expression of  CD11c175. In order to obtain balanced subpopulations of  DC for in vitro 
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loading of  antigen, naïve mice were injected with plasmid DNA encoding Flt3-L 
to expand the populations of  DC in vivo176. DCs pretreated with Flt3-L have a low 
maturation level and retain their phagocytic properties that enable the in vitro uptake 
of  antigen. These antigen-loaded DCs were able to induce robust CD8+ and CD4+ T 
cells and prevented tumor formation in mice173,174,177.
4.5.2. Clinical studies
The application of  DC therapy for patients with a chronic HCV infection progresses 
slowly due to contradictory results on the functionality of  monocyte-derived dendritic 
cells (MoDC) from patients with a chronic HCV infection. Results from earlier studies 
have shown that MoDC from patients have an immature phenotype and deviating 
cytokine profile compared with those from healthy donors162. However, two studies 
have shown that the maturation status and cytokine-secreting ability of  MoDC from 
patients with a chronic HCV infection are similar to those of  MoDC from healthy 
donors163,164. These contradictory results could be explained by differences in the stage 
of  disease and the pretreatment that the patients experienced. For example, ribavirin 
can suppress the functions of  DC in vivo178. MoDC obtained from patients who did 
not respond to the standard-of-care therapy showed reduced maturation markers 
and cytokine production162, while cells from patients with a chronic HCV infection 
with mild disease without the standard-of-care therapy have similar phenotypes and 
activity as those from healthy donors. Thus, treatment with DC can, at present, not be 
applied in all patients with a chronic HCV infection, since the disease stage and prior 
treatment affect DC function. Nonetheless, recently, Jirmo and colleagues showed 
that human monocytes, of  which the functions are not affected by HCV infection, 
can be infected with a lentivirus vector resulting in the activation of  both human 
CD4+ and CD8+ T cells in vitro179. This study suggests that the use of  monocytes as 
cell therapy warrants further investigation.
Recently, results of  a clinical trial with DC treatment among patients with 
a chronic HCV infection were reported180. MoDC from patients were loaded ex 
vivo with six lipopeptides comprising HLA-A2.1 CTL epitopes (3 core, 1 NS3 and 
2 NS4B) individually linked to one conventional Th epitope and a lipid moiety, 
Pam
2
Cys. These antigen-loaded MoDCs were injected once i.d. and sequentially 
intravenously into patients. Patients had no severe adverse effects throughout the 
study. Furthermore, patients developed IFN-γ responses against the loaded epitopes 
but also against novel epitopes which were not present in the lipopeptides suggesting 
that killing of  infected hepatocytes and cross presentation of  HCV antigen occurred 
after vaccination. However, no significant changes in serum viral load, anti-core 
antibodies, level of  cytokines and alanine transaminase were observed. Although the 
magnitude of  the immune response was not robust, it can possibly be improved by 




5. CONCLUSIONS AND FUTURE PERSPECTIVES
Despite all efforts to develop a therapeutic vaccine against HCV over the last decades, 
no therapeutic vaccine has yet reached a phase III clinical trial. Most clinical trials so 
far demonstrate some decline of  HCV serum RNA level and antigen-specific immune 
responses, yet major therapeutic responses have not been observed. Peptide/protein-
based vaccines, which are relatively easy to manufacture, require better adjuvants 
that enhance appropriate responses and at the same time do not elicit too severe 
adverse effects. DNA-based vaccines require better delivery methods and viral-vector 
based vaccines face problems associated with anti-vector responses. Similar problems 
are observed in the development of  therapeutic cancer vaccines. In this research 
field more and more studies are now being conducted in which cancer vaccines are 
combined with other therapies. With an increasing number of  HCV-specific antiviral 
drugs under investigation181, a combination of  a therapeutic HCV vaccine and novel 
antiviral drugs may also become the trend of  treatment in the future. Since outcome of  
any treatment is often affected by both viral and host factors, such as, HCV genotype, 
presence of  quasispecies and HLA type of  the patients, it would be worthwhile to 
study correlations between the effects of  any treatment with both viral and host factor 
which may identify the most optimal therapy for each patient. 
To enhance the efficacy of  vaccination strategies, vaccines could possibly be 
combined with methods to direct HCV-specific immune effector cells to the liver 
and at the same time alleviate the immunosuppressive liver environment. Yet, it will 
be essential that therapeutic vaccines also restore the exhausted immune function 
of  HCV-specific T cells and broaden their epitope-specific diversity, while, also in a 
therapeutic setting, vaccines should induce neutralizing antibodies.
From preclinical studies in animal models, it appears that the choice of  
the antigen is an important factor affecting the quality of  therapeutic vaccination 
against HCV. However, the results from these preclinical studies, performed in HCV 
non-susceptible animal models, are difficult to extrapolate to humans. Therefore, a 
prediction of  the most effective approach and/or target antigens for humans based on 
these studies cannot be made. An immunocompetent small animal model, susceptible 
to HCV infection, would be very instrumental to evaluate therapeutic HCV vaccine 
candidates before their introduction into clinic. Such models will accelerate the 
development of  therapeutic vaccines for HCV infection.
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Alphavirus-based Vaccines Encoding Nonstructural 
Proteins of Hepatitis C Virus Induce Robust and 
Protective T-cell Responses 
ABSTRACT
An absolute prerequisite for a therapeutic vaccine against hepatitis C virus (HCV) 
infection is the potency to induce HCV-specific vigorous and broad-spectrum T-cell 
responses. Here, we generated three HCV vaccines based on a Semliki Forest virus 
(rSFV) vector expressing all- or a part of  the conserved nonstructural proteins (nsPs) 
of  HCV. We demonstrated that an rSFV vector was able to encode a transgene as large 
as 6.1 kb without affecting its vaccine immunogenicity. Prime-boost immunizations 
of  mice with rSFV expressing all nsPs induced strong and long-lasting NS3-
specific CD8+ T-cell responses. The strength and functional heterogeneity of  the 
T-cell response was similar to that induced with rSFV expressing only NS3/4A. 
Furthermore this leads to a significant growth delay and negative selection of  HCV-
expressing EL4 tumors in an in vivo mouse model. In general, as broad-spectrum 
T-cell responses are only seen in patients with resolved HCV infection, this rSFV-
based vector, which expresses all nsPs, inducing robust T-cell activity has a potential 
for the treatment of  HCV infections. 
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INTRODUCTION
Hepatitis C virus (HCV) infection is a major cause of  liver disease and the primary 
cause for liver transplantation in the western world. The World Health Organization 
estimated that approximately 150 million people worldwide, i.e., around 2.5% of  
the world population, are chronically infected with HCV. Sixty to 70% of  these 
patients develop chronic liver disease such as liver fibrosis and cirrhosis and 1-5% 
of  these patients develop liver cancer within 10-40 years after infection1. The former 
standard of  care treatment, a combination of  antiviral agents, pegylated interferon-α 
and ribavirin, achieved sustained viral response in less than 50% of  the patients with 
chronic HCV (CHC) infected with HCV genotype 1 (ref. 2). Currently, in some 
countries, this standard of  care treatment is being combined with the novel HCV 
protease inhibitors boceprevir and telaprevir, resulting in a sustained viral response 
of  ~70% in patients infected with HCV genotype 1 (ref. 3, 4). Yet these drugs are not 
widely available, the drugs are not always tolerated and not all genotypes respond 
equally to interferon and the antiviral drugs. In contrast to vaccines against hepatitis 
A and B virus, there is no prophylactic HCV vaccine available, amongst other 
reasons due to the high variability of  the structural proteins of  the virus. Therapeutic 
vaccines, aimed at inducing T-cell responses against the more conserved proteins of  
the virus are therefore urgently needed. These vaccines can possibly be used as single 
treatment modalities or can be combined with standard antiviral treatments.
HCV-specific adaptive cellular immunity plays an essential role to control 
HCV infection, particularly in the induction of  functional HCV-specific T cells5 as 
also exemplified by the following observations. The presence of  NS3/4A-specific 
CD8+ T cells is positively correlated with a sustained viral response6-8. Patients who 
develop CHC have a narrow-spectrum and low number of  HCV-specific T cells in 
both circulating blood and liver5. A low ratio of  the HCV-specific CD8+ T cells to 
the non-specific CD8+ T cells in infected liver leads to an ineffective clearance of  
virus and a nonspecific inflammation9. Next, dysfunctional HCV-specific T cells with 
reduced IL-2 secretion and cytotoxic activities are being observed in patients with 
CHC10,11, and surprisingly, also in patients who recovered from chronic HCV infection 
by IFN/ribavirin treatment12. Moreover, the longer the duration of  the exposure of  
HCV antigen, the deeper the level of  T-cell exhaustion12. Thus, immunotherapeutic 
approaches against HCV, should not only induce de novo HCV-specific T-cells 
production but also restore T-cell function.
Several immunotherapeutic approaches are being developed to induce HCV-
specific immune responses13. Among those approaches, viral vectors induce the 
most robust immune response in both preclinical and clinical settings. In this study, 
recombinant Semliki Forest virus (rSFV) vector, which induces strong and long-
lasting antigen-specific response14, was used to develop a therapeutic vaccine against 
HCV. The nonstructural proteins (nsPs) of  HCV have been identified as promising 
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vaccine targets due to the fact that they are genetically conserved, essential for viral 
replication and most importantly, immunogenic. In an effort to improve immune 
responses against the nsPs of  HCV, we generated three rSFV constructs encoding 
either the entire nsPs of  HCV (1. NS2’-5B’) or parts of  these proteins of  HCV (2. 
NS3/4A and 3. NS5A/B’). The in vivo efficacy of  these rSFV-based vaccines was 
determined in naïve and tumor-bearing mice.
RESULTS
Characterization of rSFV encoding the entire or the part of HCV nsPs
Aiming to induce immune responses against the entire or part of  the HCV nsPs, 
three rSFV expressing (i) NS2’-5B’, (ii) NS3/4A and (iii) NS5A/B’ proteins of  HCV, 
were designed and produced (Figure 1a). Production and stability of  the HCV nsPs 
synthesized by rSFV infected BHK-21 cells were determined by 35S-methionine 
pulse labeling (Figure 1b). Incubation with rSFVeNS3/4A induced production of  
the NS3/4A fusion protein (75.9 kDa) and the NS3 protein (70 kDa) by BHK-21 
cells. On the other hand, cells incubated with rSFVeNS2’-5B’ synthetized five distinct 
proteins, corresponding to the NS2/3/4A fusion protein (86.9 kDa), the NS2/3 
fusion protein (81 kDa), the NS5B’ protein (60.8 kDa), the NS5A protein (49 kDa) 
and the NS4B protein (28.7 kDa). Cells incubated with rSFVeNS5A/B’ produced 
one NS5A/B’ fusion protein (109.8 kDa). Cells incubated with control rSFVe or 
buffer were negative controls. Proteins expression was also determined by western 
blotting stained with anti-NS3 and anti-NS5A antibodies (data not shown). The 
newly constructed rSFVs induced abundant expression of  HCV nsPs which were 
stably expressed till 22 hours after incubation with rSFVs.
Frequencies and phenotypes of NS3-specific T cells induced by rSFV 
immunizations
Next, to verify the immunogenicity of  these newly constructed rSFV vaccines in vivo, 
mice were intramuscularly primed and boosted with 5 × 106 purified rSFV or buffer 
(phosphate-buffered saline (PBS)) with a 2-week interval and the in vivo induction of  
NS3-specific T-cell response was evaluated. Ten days after the last immunizations, 
NS3-specific CD8+ cells were identified by GAVQNEVTL-dextramer and the 
phenotype of  these cells was studied. The peptide GAVQNEVTL is derived from 
HCV NS3 and has been identified as a potent cytotoxic T lymphocyte (CTL) epitope 
presented by the major histocompatibility complex (MHC) class I molecule H-2Db of  
C57BL/6 mice15. Both rSFVeNS2’-5B’ and rSFVeNS3/4A immunizations induced 
potent NS3-specific CD8+ T-cell responses, yet mice immunized with rSFV encoding 
only NS3/4A had higher frequencies than mice immunized with rSFV encoding the 
entire HCV nsPs (rSFVeNS2’-5B’: 2.2% ± 0.4% vs. rSFVeNS3/4A: 5.5% ± 0.4%, 
P < 0.05) (Figure 2a). The NS3-specific CD8+ T cells were classified into three 
61
3
Alphavirus-based HCV therapeutic vaccines
subsets, corresponding (i) central memory T cells (T
CM
, CD44+CD62L+CD127+), 
(ii) effector memory T cells (T
EM
, CD44+CD62L-CD127+) and (iii) effector T cells 
(T
eff
, CD44+CD62L-CD127-). The total number of  each T-cell subset in the spleen is 
shown (Figure 2b). The increased number of  the total NS3-specific CD8+ T cells in 
mice immunized with rSFVeNS3/4A (Figure 2a) was mainly due to the increase in 
the number of  T
EM
 cells and T
eff
 cells (P < 0.05). Immunization with rSFV encoding 
either the entire or the part of  HCV nsPs induced NS3-specific responses with similar 
frequencies of  T
CM
 cells.
Effector function of HCV-specific CD8+ cells
In order to investigate the spectrum of  the HCV-specific response, spleen cells from 
rSFV-immunized mice were stimulated with stimulants containing the entire or 
part of  the HCV nsPs and the effector functions of  HCV-specific CD8+ T cells were 
determined. The stimulants were Hepa1-6V cells, Hepa1-6V-NS2’-5B’ cells, or the 
HCV synthetic peptides, GAVQNEVTL or ILDSFDPL. Hepa1-6V-NS2’-5B’ cells 
are murine hepatoma cells expressing HCV NS2’-5B’ protein as well as a yellow 
fluorescence reporter protein, VENUS (abbreviated to V) and Hepa1-6V cells are 
mock transduced cells expressing VENUS protein only (Supplementary Figure 
S1). The peptide ILDSFDPL has been recently identified as a HCV NS5A CTL 
a
b
Figure 1. Stable expression of hepatitis C virus (HCV) nsPs in vitro. (a) Size of  plasmid Semliki Forest 
virus (SFV), number is the nucleotide position in the plasmid DNA containing full genome of  HCV 1a 
(H/FL). (b) BHK-21 cells were incubated with rSFVeNS2’-5B’, rSFVeNS3/4A, rSFVeNS5A/B’ or rSFVe. 
“No rSFV” was negative control cultured in medium only. Cells were pulsed with 35S-methionine for 
1 hour at 6 hours after addition of  rSFV and were further cultured for 1, 6 or 18 hours. Radioactively 
labeled proteins were revealed by autoradiography after 12% SDS-PAGE. The molecular weight of  each 
nonstructural protein is as following: NS2’: 11 kDa, NS3: 70 kDa, NS4A: 5.9 kDa, NS4B: 28.7 kDa, 
NS5A: 49 kDa, NS5B’: 60.8 kDa. Vertical lines on the left image show where separate lanes from the same 
gel were juxtaposed for better comparison with the image on the right. Data represent two independent 
experiments.
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Figure 2. Induction of polyfunctional hepatitis C virus (HCV)-specific CD8+ cells by recombinant 
Semliki Forest virus (rSFV) immunizations. Mice were primed and boosted intramuscularly with 5 × 
106 rSFV or phosphate-buffered saline (PBS) with a 2-week interval. Ten days after the last immunization, 
mice were sacrificed and splenocytes were isolated for phenotypic analysis using flow cytometry. (a) NS3-
specific CD8+ cells are shown as a percentage of  total CD8+ cell population. Data represent two independent 






 (CD44+CD62L-CD127-) cells of  the total NS3-specific CD8+CD44+ cell 
population in the spleen. (c) Splenocytes were stimulated with Hepa1-6V-NS2’-5B’ cells, GAVQNEVTL 
or ILDSFDPL peptides for 4 hours and subjected to surface and intracellular cytokines staining. The 
frequencies of  each T-cell subset in the CD8+ cell population are shown. Background (PBS immunized) 
subtraction was applied. (d) Pie charts present the mean frequencies of  T-cell subsets. (c, d) 1, single 
producers; 2, double producers; 3, triple producers; 4, quadruple producers. Data represent the (a, b, d) 
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epitope presented by the MHC class I molecule, H-2Kb of  C57BL/6 mice16. The 
binding affinities of  both synthetic peptides were confirmed on RMA-S cells. The 
GAVQNEVTL peptide bound to H-2Db at as low as 0.3 μmol/l, while the ILDSFDPL 
peptide bound to H-2Kb at higher concentration (> 30 μmol/l) (Supplementary Figure 
S2). In vitro stimulation with the Hepa1-6V-NS2’-5B’ cells or GAVQNEVTL peptide 
induced degranulation (CD107a/b+) and secretion of  multiple cytokines by CD8+ 
cells from mice immunized with rSFVeNS2’-5B’ and rSFVeNS3/4A (Figure 2c, 2d). 
However, very weak response was detected in mice immunized with rSFVeNS5A/B’. 
Stimulation with neither Hepa1-6V cells (Supplementary Figure S3) nor ILDSFDPL 
induced multifunctional CD8+ T cells (Figure 2c, 2d). Of  note, immunization with 
rSFVeNS2’-5B’ and rSFVeNS3/4A increased the frequencies of  polyfunctional 
CD8+ T cell subsets that produced more than 1 cytokine (e.g., CD107a/b+IFN-
g+TNF-α+ and CD107a/b+IFN-g+TNF-α+IL-2+ populations) to similar level upon 
specific stimulations (Figure 2d). Lower numbers of  NS3-specific CD8+ cells were 
detected in mice immunized with rSFV encoding the entire HCV nsPs, the effector 
functions of  these HCV-specific CD8+ cells were similar to mice immunized with 
rSFV expressing NS3/4A only.
Induction of HCV-specific CTL with rSFV immunizations
The most important criterion for functional effector T cells is the ability to lyze 
their target cells, which, in this study, are the HCV-infected cells. Therefore, the 
cytolytic activity of  HCV-specific CTLs was investigated in vitro (Figure 3b-d) and in 
vivo (Figure 3e). CTL activity was determined 10 days after the last immunization. 
To detect cytotoxicity in vitro, spleen cells isolated from immunized mice were re-
stimulated with the Hepa1-6V-NS2’-5B’ cells for 7 days. The number of  NS3-specific 
CD8+ T cells induced after 7-day re-stimulation was higher in mice immunized with 
rSFVeNS3/4A (58.2% ± 15.8%) than in mice immunized with rSFVeNS2’-5B’ (27.6% 
± 7.0%) (P < 0.05) (Figure 3a). This correlated with the higher number of  precursor 
cells in mice immunized with rSFVeNS3/4A (Figure 2a). Restimulated CTLs from 
mice immunized with rSFVeNS2’-5B’ or rSFVeNS3/4A lysed Hepa1-6V-NS2’-5B’ 
cells (Figure 3b) and GAVQNEVTL–pulsed EL4 cells (Figure 3c) to a similar extent. 
In general, there was a higher cytotoxic activity against the GAVQNEVTL-pulsed 
EL4 cells than the Hepa1-6V-NS2’-5B’ cells. The ILDSFDPL-pulsed EL4 cells were 
not lysed in all groups of  mice (Figure 3d). Since the cytotoxic effect on Hepa1-6V-
NS2’-5B’ cells revealed activity against unidentified HCV nsPs epitopes, this may 
mimic the real situation during HCV infection when infected liver cells present multi-
epitopes. To determine CTL activities in vivo, rSFV prime-boost immunized mice 
were adoptive-transferred with autologous splenocytes pulsed with HCV peptides 
and irrelevant peptides 10 days after the boost immunizations. The GAVQNEVTL-








Figure 3. Induction of hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTL) with 
recombinant Semliki Forest virus (rSFV) immunizations. Mice were primed and boosted intramuscularly 
with 5 × 106 rSFV or phosphate-buffered saline (PBS) with a 2-week interval. Ten days after the last 
immunization, mice were sacrificed and splenocytes were isolated for in vitro bulk CTL assay. Splenocytes 
were cultured with irradiated Hepa1-6V-NS2’-5B’ cells at a ratio of  25:1. After a 7-day culture, splenocytes 
were subjected to (a) NS3-dextramer staining and (b-d) bulk CTL assay. Bulk CTL assay was performed by 
coculturing effector cells, splenocytes, with 51Chromium pulsed target cells at the indicated E:T ratios for 
4 hours. Various target cells, (b) Hepa1-6V-NS2’-5B’ cells, EL4 cells pulsed with either (c) GAVQNEVTL 
or (d) ILDSFDPL peptides, were cocultured with restimulated splenocytes. (e) For in vivo CTL assay, 
mice were immunized with the same protocol and were intravenously transferred with peptides-pulsed 
fluorochromes-labeled autologous splenocytes on day 10 after the last immunization. Each mouse received 
a mixture of  autologous splenocytes containing SIINFEKL-pulsed CFSElo-labeled, GAVQNEVTL-
pulsed CFSEhi-labeled and ILDSFDPL-pulsed TRITIC-labeled splenocytes at a 1:1:1 ratio. Mice were 
sacrificed at 14 hours after adaptive transferred. Splenocytes were isolated and the presences of  transferred 
splenocytes were analyzed using flow cytometry. Data represent (a) mean and (b-e) mean ± SD of  two to 
three independent experiments with n = 2-4. *P < 0.05.
65
3
Alphavirus-based HCV therapeutic vaccines
5B’ (90.5% ± 6.7%) or rSFVeNS3/4 (97.9% ± 2.2%) (Figure 3e). No cytotoxic effect 
on the ILDSFDPL-pulsed autologous splenocytes was detected in all groups of  mice. 
Of  note, cytotoxic activity was more potent in vivo though no extra re-stimulation of  
HCV-specific cells was performed. The cytotoxic effector on peptide-pulsed EL4 cells 
or splenocytes and Hepa1-6 cells expressing all HCV nsPs indicated the potency of  
these rSFV vaccines inducing functional HCV nsPs-specific CTL in vivo.
Therapeutic effect of the rSFV immunizations against EL4 tumor cells
Next, we tested the potencies of  these rSFV vaccines to eradicate established HCV 
nsPs-expressing tumor. Mice subcutaneously inoculated with EL4V-NS3/4A cells, 
expressing only HCV NS3 and NS4A, were immunized three times with rSFVeNS2’-
5B’, rSFVeNS3/4A or PBS on days 2, 9 and 16 after tumor inoculation. Mice 
inoculated with EL4V-NS5A/B’ cells, expressing only HCV NS5A and NS5B, 
were treated with either rSFVeNS2’-5B’, rSFVeNS5A/B’ or PBS with the same 
immunization schedule. These EL4 tumor cells express diverse levels of  HCV nsPs 
and VENUS protein mimicking the expression of  nsPs by naturally HCV-infected 
hepatocytes (Supplementary Figure S4). With this immunization schedule, the 
expansion phase of  effector T cells after the third immunizations will take place 
during the exponential growth of  tumor cells (days 15-20 after tumor inoculation) 
as observed in PBS-treated mice. Immunizations with both rSFVeNS2’-5B’ and 
rSFVeNS3/4A induced delay in growth of  EL4V-NS3/4A cells (P < 0.001) (Figure 
4a). Of  note, immunizations with rSFVeNS3/4A synchronized the rate of  tumor 
growth that was not observed in PBS-treated mice (Supplementary Figure S5a). 
An immunization effect on EL4V-NS5A/B’ cells was undetectable (Figure 4a and 
Supplementary Figure S5b). 
The effect of  immunizations on EL4 tumor cells was further analyzed by 
analyzing the expression of  VENUS protein, being co-expressed with the HCV 
nsPs. EL4 tumor cells were isolated at different time points when the tumor volume 
reached ~1 cm3. VENUS+ cells frequencies were reduced in EL4V-NS3/4A tumor 
cells in rSFV-immunized mice but not in PBS control (P < 0.01) (Figure 4b). VENUS 
expression levels within the VENUS+ cell population (Supplementary Figure S5c) 
and total EL4V-NS3/4A cell population (Supplementary Figure S5d) was also 
reduced. This effect was not time-dependent as expression differences between 
groups of  mice were detected in mice that were sacrificed on the same day. There was 
no reduction of  the number of  VENUS+ cells (Figure 4b) and the expression level 
of  VENUS in VENUS+ cells (Supplementary Figure S5c) and total EL4V-NS5A/B’ 
tumor cells (Supplementary Figure S5d) remained the same in all groups of  mice. 
Immunizations with rSFVeNS2’-5B’ or rSFVeNS3/4A delayed tumor growth by 




To investigate the effect of  T cells during the early formation of  tumor, the 
first rSFV immunization was performed before tumor inoculation. Mice were 
immunized with 5 × 106 rSFV particles on day -5, followed with EL4V-NS3/4A 
cells inoculation on day 0. Mice were then boosted with rSFV particles twice on day 
2 and day 9 after tumor inoculation. The effect on the growth of  tumor was mild 
(Figure 5a). Nevertheless, immunizations with rSFVeNS2’-5B’ and rSFVeNS3/4A 
induced reduction on the number of  VENUS+ cells (Figure 5b) and expression of  
VENUS in the VENUS+ cell (Supplementary Figure S6b) and total EL4V-NS3/4A 
cell (Supplementary Figure S6c). The immunization effect on EL4V-NS5A/B’ was 
not determined. In both late and early immunization setups, both rSFVeNS2’-5B’ 
and rSFVeNS3/4A particles reduced the expression of  VENUS and the frequencies 
of  VENUS+ EL4 cells demonstrating the activity of  HCV-specific CD8+ cells in vivo. 
a
b
Figure 4. Therapeutic effects of recombinant Semliki Forest virus (rSFV) immunizations against EL4 
tumor cells. Naïve mice were subcutaneously inoculated with 5 × 105 of  EL4V-NS3/4A or EL4V-NS5A/B’ 
cells. Mice were then immunized intramuscularly with 5 × 106 rSFV on days 2, 9 and 16 after tumor 
inoculation. (a) Survival curve is determined when tumor volume equals to 1 cm3. (b) Mice were sacrificed 
when the volume of  tumor exceeded 1 cm3. Tumor cells were isolated to analyze the frequency of  VENUS+ 
cells in the EL4V-NS3/4A and EL4V-NS5A/B’ cell population using flow cytometry. Cumulative results of  
two independent experiments with n = 5-7 are presented. ***P < 0.001, **P < 0.01.
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DISCUSSION
Therapeutic vaccination against HCV infection aims to induce robust cellular 
immunity against conserved HCV proteins leading to eradication of  HCV-infected 
liver cells. Here, we demonstrated that an rSFV-based viral vector vaccine encoding 
HCV NS3/4A as well as an rSFV vaccine encoding all HCV nsPs induced strong T-cell 
response against an epitope within the HCV NS3 protein. This NS3-specific T-cell 
population consisted of  both effector and memory cells. Furthermore, these induced 
NS3-specific T cells were polyfunctional, secreting multiple pro-inflammatory Th1 
cytokines and possessed cytolytic activity against HCV nsPs-expressing cells in vitro 
and in vivo. Immunizations partially protected mice from HCV NS3/4A-expressing 
tumor formation. Vaccine-induced immune pressure on the tumors lead to selection 
of  tumor cells, resulting in decreased frequencies of  HCV NS3/4A-expressing EL4 
cells and reduced expression levels of  the transgene (NS3/4A-VENUS).
To our knowledge, this is the first time showing that an rSFV vector retains its 
immunogenicity when expressing a foreign transgene as large as 6.1 kb. Previously, it 
has been showed that rSFV expressing a smaller transgene, HCV NS3/4A, induced 
NS3-specific CTLs17. Due to the limitation of  the cellular protein synthesis machinery, 
increasing the size of  the transgene will lower the expression of  each protein. As a 
result, vaccine immunogenicity may be reduced or even lost. We demonstrated that 
an rSFV vector could be packed with all HCV nsPs, expressing all intact HCV nsPs, 
and induced a HCV NS3-specific response, although this response was lower than the 
response induced by rSFV expressing HCV NS3/4A only. Thus the immunogenicity 
of  rSFV vector is maintained even when a large transgene is inserted. Increasing the 
size of  foreign transgenes allows broadening of  the spectrum of  T-cell responses 
a b
Figure 5. Effect of early immunizations with rSFVeNS2’-5B’ and rSFVeNS3/4A against EL4V-NS3/4A 
tumor cells. Mice were intramuscularly immunized thrice with 5 × 106 recombinant Semliki Forest virus 
(rSFV) on days -5, 2 and 9. On day 0, immunized mice were subcutaneously inoculated with 5 × 105 of  
EL4V-NS3/4A cells. (a) Survival curve is determined when tumor volume equals 1 cm3. (b) Mice were 
sacrificed when the volume of  tumor exceeded 1 cm3. Tumor cells were isolated and the frequencies of  
VENUS+ cells in the EL4V-NS3/4A cell population were analyzed using flow cytometry. Data represent 
results from one independent experiments with n = 7. 
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which is considered essential for the induction of  protective HCV immunity18-20. 
T-cell responses against HCV
2252-2259 
ILDSFDPL, an epitope recently identified 
by Holmstrom, F and colleagues16, was not detectable in this study. It should 
however be noted that the ILDSFDPL-specific T-cell responses were identified in 
mice immunized with DNA plasmid expressing NS5A only. Expressing more than 
one protein may lead to increase competition between epitopes resulting in reduced 
responses against subdominant epitopes21. Yet to allow a non-HLA restricted 
application of  HCV vaccines expression of  as many relevant proteins as possible 
is desirable. Other T cell epitopes in HCV nsPs were predicted with mathematic 
algorithms including SYFPEITHI22, NetMHCpan 2.8 (ref. 23) and Immune Epitope 
Database and Analysis Resource (IEDB)24. The MHC affinity of  the identified 
peptides was determined and the peptides were used to re-stimulate splenocytes 







 were observed in both groups of  mice 
(manuscript in preparation). Nevertheless, rSFV-based vaccines encoding all possible 
T-cell epitopes allow induction of  a unique spectrum of  immune response depending 
on the patient’s HLA alleles.
The magnitude of  a T-cell response is positively correlated with the dominance 
of  its cognate epitope25. Activation of  T cells against a protective but not pathogenic 
immunodominant epitope results in control of  virus-induced diseases26. We observed 
induction of  CD8+ T-cell responses against an immunodominant epitope located in 
the HCV NS3 protein in mice immunized with rSFV expressing either NS3/4A or all 
HCV nsPs. In the latter group however, lower frequencies were observed. Since the 
anti-tumor effect of  both rSFV vectors was similar, this suggests that T-cell responses 
against this immunodominant T-cell epitope are protective when a threshold 
frequency is reached27.
On the other hand, activation of  T cells against one immunodominant 
epitope facilitates selection of  viral escape mutants28,29. Furthermore, enhanced 
responses against immunodominant epitopes will reduce or even abrogate response 
against subdominant T cell epitopes narrowing the T-cell repertoire26,30. Therefore, 
T-cell responses against subdominant epitopes are desirable31,32. Interestingly, we 
observed a decreased response against the immunodominant epitope (HCV
1629-1637 
GAVQNEVTL) in mice immunized with rSFV expressing all HCV nsPs as lower 
frequencies of  GAVQNEVTL-specific T cells were detected which may indeed allow 
enhanced responses against other subdominant epitopes33.
The functionality of  de novo induced antigen-specific CD8+ cells is also a 
reliable indicator for effective immunizations34. A hallmark of  an effective antiviral T 
cell is the secretion of  multiple Th1 cytokines including IFN-γ, TNF-α and IL-2 (ref. 
34). IFN-γ and TNF-α mediate control of  intracellular infections synergistically35 
while IL-2 strongly enhances the expansion of  both CD4+ and CD8+ T cells and 
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the development of  memory cells36. Furthermore, it has been shown that IFN-γ 
reduces the expressing of  HCV nsPs in vitro37. In a recent study, heterologous prime-
boost immunizations with a DNA and a MVA vaccine successfully enhanced the 
number of  multifunctional T cells38. In our study, with homologous prime-boost 
rSFV immunizations, function-active HCV-specific T cells secreting IL-2, IFN-γ and 
TNF-α were induced. In addition, we showed that the HCV-specific T-cell population 





cells). Central memory T cells have a high proliferation 
rate and are high producers of  IL-2, whereas effector memory cells are potent 
producers of  IFN-γ and cytotoxic granules39. Phenotype and cytokine secretion of  
HCV-specific T cells reflect the potency of  rSFV-based vaccines. It would be highly 
interesting to study the immunogenicity of  rSFV vectors in mice or other animal 
models with exhausted T cells as patients with CHC have dysfunctional T cells10,11. 
Small animal models susceptible for HCV infection are not available yet, 
and still under development40. To investigate the immunogenicity of  our rSFV-
based HCV vaccines, we therefore produced a polyclonal EL4 tumor cells line 
by transducing EL4 with HCV nsPs-expressing lentivirus. These tumor cells are 
heterogeneous, expressing variable levels of  HCV nsPs as indicated by the expression 
level of  the cotransduced reporter gene VENUS. Also, in natural HCV infections, 
this heterogeneity in expression level occurs because of  the HCV genetic diversity 
within a host41-43. Eradication of  these heterogenic tumors involved negative selection 
and lysis of  the VENUShi tumor cells by tumor-specific CD8+ T cells. Furthermore, 
the kinetics of  effector CD8+ T-cell responses plays a crucial role on the developing 
tumor. In this EL4 model, tumor developed exponentially from day 15 to 25 after 
tumor inoculation. To investigate the therapeutic efficacy of  the rSFV-based HCV 
vaccines, immunizations were scheduled such that the peak of  CD8+ T-cell responses 
overlapped with the exponential growth of  the EL4 tumor. Since immunizations 
were given after tumor inoculation, time for negative selection of  VENUShi EL4 
cells was short (approximately from day 6 to day 15). As a result, eradication of  
tumor cells occurred during the expansion and plateau phases of  T-cell response but 
the reduction of  VENUS expression was moderate. In other immunization setups 
when immunization was given before tumor inoculation, tumor cells were exposed 
to activated T cells for longer time (from day 0 to day 15) allowing more selection 
pressure on VENUShi cells resulting in a significant reduction of  the expression 
of  VENUS. However, selection alone was not enough for eradication of  this fast-
growing tumor as the VENUSlo cells escaped from the immune responses and started 
to grow exponentially during the contraction phase of  T-cell responses. Therefore, 
rSFV-based HCV immunizations induced immune pressure on HCV nsPs-expressing 
cells resulting in lower expression of  HCV nsPs. Furthermore, the development of  




To conclude, rSFV encoding the entire HCV nsPs is a potent vaccine inducing 
robust and effective HCV-specific immunity. Immune pressure was exerted on HCV 
nsPs-expressing tumor cells reducing the expression and frequencies of  HCV nsPs-
expressing tumor cells. The next step will be to study combinations of  therapeutic 
vaccines with other immune interventions and/or direct acting antiviral drugs. For 
example, PD1/CTLA-4 blockage44,45 and anti-TIM3 treatment46 have been shown to 
restore HCV-specific dysfunctional T cells in vitro, while direct acting antiviral drugs 
aimed to reduce viral load result in reduced production of  viral mutants as well as a 
decreased T-cell exhaustion47. Combined treatment of  a potent HCV-specific vaccine 
with immune-interventions and/or direct acting antiviral drugs will hopefully result 
in de novo HCV-specific T cells and restoration of  existing dysfunctional T cells 
resulting in a better prognosis in patients at various stages of  HCV infection.
 
MATERIALS AND METHODS
Cell culture. Baby hamster kidney cells (BHK-21, ATCC #CCL-10) were obtained from the 
American Type Culture Collection and were maintained in RPMI1640 (Life technologies, 
Bleiswijk, The Netherlands) supplemented with 10% fetal bovine serum (FBS) (Lonza, Basel, 
Switzerland). EL4 lymphoma cells and RMA-S cells were kindly provided by Cornelis JM 
Melief  (Leiden University Medical Center, The Netherlands) and were maintained in IMDM 
(Life technologies) supplemented with 10% FBS. Hepa1-6 cells (provided by Jurgen Seppen, 
Academic Medical Center, Amsterdam, The Netherlands) and Human embryonic kidney 
(HEK) 293T cells were maintained in DMEM (Life technologies) supplemented with 10% 
FBS. All cells were cultured with 100 U/ml penicillin and 100 μg/ml streptomycin (Life 
technologies) at 37°C with 5% CO
2 
otherwise indicated.
Construction of rSFV replicon vectors. pSFV-helper 2 and pSFV4.2 (pSFV), were provided 
by P Liljestrom (Karolinska Institute, Stockholm, Sweden). The plasmid DNA containing the 
full-length cDNA of  HCV H77 genotype 1a consensus sequence (H/FL) was kindly provided 
by Charles M Rice via Apath, LLC (AIDS Research and Reference Reagent Program, 
Division of  AIDS, NIAID, NIH: p90HCVconsensuslongpU)48. pUC57-enh which contains 
the translational enhancer, foot-and-mouth disease virus 2A auto-protease fragment, was 
synthesized by Eurogentec (Maastricht, the Netherlands). pSFVe (10764 bps) was generated 
by subcloning the translational enhancer from pUC57-enh into pSFV between the BamHI and 
BssHII sites. pSFVeNS2’-5B’ (16838 bps) was generated by subcloning NS2’-5B’ from H/FL 
into pSFVe between the BssHII and NotI sites. pSFVeNS3/4A (12839 bps) was constructed 
by cloning the BssHII-NS3/4A-SpeI fragment, which was amplified by PCR using H/FL as 
a template DNA, into pSFVe between the BssHII and SpeI sites. pSFVeNS5A/B’ (13700 bps) 
was constructed by cloning the BssHII-NS5A/B’-NotI fragment, which was amplified by PCR 
using H/FL as a template DNA, into pSFVe between the BssHII and NotI sites. All restriction 
enzymes were purchased from Thermo Fisher scientific (Landsmeer, The Netherlands). DNA 
sequences were verified by sequence analysis.
Production, purification and titer determination of rSFV. rSFVe, rSFVeNS2’-5B’, 
rSFVeNS3/4A and rSFVeNS5A/B’ were produced as previously described49. In brief, the 
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plasmid DNA was in vitro transcribed into RNA using SP6 RNA polymerase (GE Healthcare, 
Diegem, Belgium). RNA of  pSFV encoding various parts of  HCV nsPs and pSFV-helper2 were 
co-transfected at a molar ratio of  1:1 into BHK-21 cells. Likely due to the size of  rSFVeNS2’-
5B’, lower production of  rSFVeNS2’-5B’ was observed. Therefore, transfected BHK-21 cells 
were cultured at 30°C with 5% CO
2
 for 78 hours instead of  37°C for 36 hours as described 
previously. The supernatant containing the viral particles was collected and tittered with BHK-
21 cells. Titer of  unpurified rSFVeNS2’-5B’ was ~2 × 107 particles/ml and titers of  other rSFV 
particles were ~1 × 108 particles/ml. rSFV particles were further purified on a discontinuous 
sucrose density gradient and titrated with BHK-21 cells. 
Production of HCV nsPs-expressing lentivirus and HCV nsPs-expressing cell lines. 
Packaging construct (pCMV 8.91), Glycoprotein envelop plasmid (pMD2.G) and lentiviral 
vector expressing VENUS (442 New pRRL.PPT.SF.IRES-VENUSSnucmer pre or pLenti) 
were kindly provided by Jan Jacob Schuringa (University of  Groningen, The Netherlands). 
pLenti-NS2’-5B’-VENUS was generated by subcloning the BglII-NS2’-5B’-BglII fragment 
from pSFVeNS2’-5B’ into the BamHI site of  pLenti vector. pLenti-NS3/4A-VENUS was 
generated by removing the AgeI-NS5A/B’-Eco81I fragment from pLenti-NS2’-5B’-VENUS. 
The sticky ends of  AgeI and Eco81I were then filled by Klenow fragment and self-ligated. 
pLenti-NS5A/B’-VENUS was generated by removing Bst1107I-NS2’-4A-Eco81I from pLenti-
NS2’-5B’-VENUS. The sticky ends produced by Eco81I were filled in by Klenow fragment and 
ligated to the blunt ends produced by Bst1107I. To confirm the expression of  HCV nsPs, HEK 
293T cells were transfected with each plasmid DNA and the expressed nsPs were determined 
by western blot analysis (data not shown).
Production of  lentivirus and transduction of  target cells was performed as previously 
described for other lentiviruses and cells50. In brief, HEK 293T cells were transiently transfected 
using FUGENE HD (Promega, Leiden, The Netherlands) with pCMV 8.91, pMD2.G and 
pLenti DNA (pLenti-NS2’-5B’-VENUS, pLenti-NS3/4A-VENUS, pLenti-NS5A/B’-VENUS 
or pLenti-VENUS) at a molar ratio of  3:0.7:3. HEK 293T culture medium was replaced by 
complete medium of  EL4 cells or Hepa1-6 cells 24 hours after transfection. The supernatant 
containing lentiviral particles were harvested, passed through a 0.45 μm filter and stored at 
-80°C. 
Hepa1-6V (V represents VENUS), Hepa1-6V-NS2’-5B’, EL4V-NS3/4A, EL4V-NS5A/B’ 
cells were generated by transducing Hepa1-6 or EL4 cells with corresponding lentivirus 
particles. Two cycles of  transduction were performed with a 6-hour interval. Forty-eight hours 
after the second transduction, cells were harvested and the VENUS+ population was isolated 
by cell sorting using MoFlo Astrios (Beckman coulter, Woerden, The Netherlands). Cell 
sorting was performed thrice with a 1-week interval to produce stable cell lines. Expression of  
VENUS was verified using FACSCalibur cytometer (BD Bioscience, Breda, The Netherlands). 
Fluorescence activated cell sorting (FACS) data were analyzed using FlowJo analysis software 
(Tree Star, Ashland, OR) otherwise indicated. More than 95% of  the sorted cells had stable 
expression of  VENUS after 1 month of  culture (Supplementary Figure S1 and S4). VENUS 
expression of  each transduced cells was verified before every experiment.
Protein expression by pulse labeling. BHK-21 cells (5 × 105 cells in a well of  a six-well 
plate) were incubated with 5 × 106 rSFVe, rSFVeNS2’-5B’, rSFVeNS3/4A or rSFVeNS5A/B’. 
After 6 hours, supernatant was removed and the cells were washed with PBS 3 times. The cells 
were then further cultured in methionine-free DMEM for 30 min followed by labelling with 
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[35S]-methionine (0.37 Mbq/well) (PerkinElmer, Groningen, The Netherlands) for 1 hour. 
After 1, 6 or 18 hours of  [35S]-methionine labeling, cells were washed with cold PBS and 
then lysed with TENT lysis buffer (50 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, and 0.5% 
Triton-X-100, pH7.5) containing 0.2 mM phenyl-methane-sulphonyl-fluoride. Cell lysate was 
analyzed by SDS/PAGE and autoradiography.
Synthetic peptides. The synthetic peptides HCV
1629-1637
 GAVQNEVTL (H-2Db), HCV
2252-
2259
 ILDSFDPL (H-2Kb), OVA
257-264
 SIINFEKL (H-2Kb) and human papillomavirus-16-E7
49-57
 
RAHYNIVTF (H-2Db) were manufactured by the department of  Immunohematology, Leiden 
University Medical Center, The Netherlands. The purities of  the synthetic peptide were 
analyzed with HPLC. All synthetic peptides have a purity of  > 90%.
Peptides stabilization assay. RMA-S cells were cultured at 26°C with 5% CO
2
 for 48 hours 
to induce expression of  MHC class I. Cells were then incubated with various concentrations 
of  synthetic peptides at 26°C for 4 hours, followed by cultured at 37°C for 1 hour. Cells were 
harvested, washed once with 0.5% bovine serum albumin/PBS and stained with APC-anti-H-
2Kb Ab (clone: AF6-88.5.5.3) and FITC-anti-H-2Db Ab (clone: 28-14-8) (eBioscience, Vienna, 
Austria) at 4°C for 20 min. The surface expression of  MHC class I molecules were analyzed 
by FACSCalibur cytometer (BD Bioscience). 
Mice. Specific pathogen-free female inbred C57BL/6JOlaHsd (H-2b) mice were obtained from 
a commercial vendor (Harlan CPB, Zeist, The Netherlands) and were kept under the institute 
guidelines of  the University of  Groningen, The Netherlands. All mice were 8 to 10 weeks of  
age at the start of  all experiments. All animal experiments (DEC number: 5946) were approved 
by the local Animal Experimentation Ethical Committee (the Institutional Animal Care and 
Use Committee of  the University Medical Center of  Groningen).
Prime-boost immunizations. Mice were intramuscularly primed and boosted immunized 
with a 2-week interval with 5 × 106 rSFV (rSFVe, rSFVeNS2’-5B’, rSFVeNS3/4A or 
rSFVeNS5A/B’) in 50 μl (25 μl/thigh muscle) under anesthesia (isoflurane/O
2
). For negative 
controls, the same volume of  PBS was injected intramuscularly.
Phenotypic analysis of NS3-specific cells. Splenocytes and blood cells were stained with 
PE-GAVQNEVTL-dextramers (Immudex, Copenhagen, Denmark) in 5% FBS/PBS for 10 
min at room temperature. Followed by staining with PE-Cy7-anti-CD8a Ab (clone: 53-6.7), 
PerCP-Cyanine5.5-anti-CD44 Ab (clone: IM7), APC-anti-CD62L Ab (clone: MEL-14) and 
eFluor 450-anti-CD127 Ab (clone: A7R34) for 20 min at 4°C. All antibodies were purchased 
from eBioscience. Death cells were excluded with 4’-6’-diamidino-2-phenylindole staining. 
FACS analysis was conducted with LSR-II flow cytometer (BD Bioscience).
Identification of multifunctional HCV-specific cells. Splenocytes isolated from 
immunized mice were cultured with the 100 Gy-irradiated Hepa1-6 cells (Hepa1-6V-NS2’-5B’ 
cells or Hepa1-6V cells) at a ratio of  25:1 or with 10 μg/ml of  synthetic peptides. The Hepa1-
6 cells were cultured in the presence of  50 U/ml of  recombinant mouse IFN-g (Peprotech, 
London, UK) for 48 hours before coculturing with splenocytes. Splenocytes were cultured in 
the presence of  anti-CD28 Ab (clone: PV-1, Bioceros B.V., Utrecht, The Netherlands), eFluor 
660-anti-CD107a Ab (clone: eBio1D4B) and eFluor 660-anti-CD107b Ab (clone: eBioABL-93) 
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in a 96-well plate at 37°C with 5% CO
2
. One hour after culture, brefeldin A (1 mg/ml) was 
added and the cultures were further incubated for 4 hours. Cells were then harvested, washed 
and stained with LIVE/DEAD fixable violet dead cell stain kit (Life technologies) according 
to manufacturer’s manuals. Followed by surface staining with PE-Cy7-anti-CD8a Ab at 4°C 
for 20 min and intracellular staining with PerCP-Cyanine5.5-anti-IFN-g Ab (clone: XMG1.2), 
FITC-anti-TNF-α Ab (clone: MP6-XT22) and APC-Cy7-IL-2 Ab (clone: JES6-5H4) at 4°C for 
30 min. eFluor 660-anti-CD107a, eFluor 660-anti-CD107b and PerCP-Cyanine5.5-anti-IFN-g 
antibodies were purchased from eBioscience; FITC-anti-TNF-α and APC-Cy7-IL-2 antibodies 
were purchased from BD Biosciences. FACS analysis was conducted with LSR-II flow 
cytometer, and data were analyzed using FCOM tool of  WinList software (Verity Software 
House, Topsham, ME) and presented as pie charts using SPICE version 5.3 (NIAI freeware).
Bulk CTL assay. The stimulator cells, Hepa1-6V-NS2’-5B’ cells, were cultured in the presence 
of  50 U/ml recombinant murine IFN-g for 48 hours. Hepa1-6V-NS2’-5B’ cells were then 
irradiated (100 Gy) and co-cultured with effector cells, splenocytes, at a ratio of  1:25 in a T25 
flask at 37°C with 5% CO
2
. Recombinant human IL-2 (5 U/ml) (Peprotech) was added on day 
3 and day 5 of  the culture. After 7 days culture, splenocytes were harvested and co-cultured 
with 51Chromium (51Cr)-labeled target cells (Hepa1-6V-NS2’-5B’ cells, EL4 pulsed with 
GAVQNEVTL or EL4 pulsed with ILDSFDPL). Target cells were cultured in the presence 
of  recombinant murine IFN-g (50 U/ml) 48 hours before co-culture with effector cells. Target 
cells were labeled with 51Cr (100 μCi/2 × 106 cells) (PerkinElmer) in the presence or absence 
of  synthetic peptides (10 μg/ml) for 1 hour at 37°C. Co-culture of  effector cells and target 
cells were performed in 96 well plate at 4 E:T ratios in triplicates at 37°C with 5% CO
2
. After 
4 hours of  culture, supernatants were harvested and analyzed with a RiaStar manual gamma 
counter (Packard, Meriden, CT). The percentage of  cytotoxicity was calculated according to 
the formula: % specific release = ((experimental release – spontaneous release) / (maximal 
release – spontaneous release)) count per minute (c.p.m).
In vivo CTL assay. Splenocytes were isolated from naïve syngeneic mice and were pulsed with 
synthetic peptides at 10 μg/ml in IMDM supplemented with 10% FBS, 100 U/ml penicillin 
and 100 μg/ml streptomycin for 2 hours at 37°C with 5% CO
2
. The peptide-pulsed splenocytes 
were then washed and re-suspended in PBS. GAVQNEVTL-pulsed and SIINFEKL-pulsed 
splenocytes were labeled with 5 μmol/l of  CFSE (Life technologies) and 0.1 μmol/l of  CFSE 
for 20 min at 37°C, respectively. ILDSFDPL-pulsed splenocytes were labeled with 30 μg/ml 
of  tetramethylrhodamine-6-isothiocyanate (TRITC) (Life technologies) for 10 min at 37°C. 
Differentially labeled cells were washed, re-suspended in PBS and combined at a 1:1:1 ratio 
for intravenous adoptive transfer. Each mouse received 2 × 106 cells of  each population. After 
14 hours, splenocytes were isolated and analyzed using LSR-II flow cytometer. The percentage 
of  cytotoxicity was calculated with the formula: % cytotoxicity = 1 - (% of  relevant peptides-
pulsed target (GAVQNEVTL or ILDSFDPL) in rSFV immunized mice/ % of  irrelevant 
peptides-pulsed target (SIINFEKL) in immunized mice)/ (% of  relevant peptides-pulsed target 
in PBS-treated mice/ % of  irrelevant peptides-pulsed target in PBS-treated mice).
Tumor inoculation. Mice were inoculated subcutaneously in their right flank with 5 × 105 
EL4V-NS3/4A or EL4V-NS5A/B’ cells suspended in 0.2 ml PBS. The volume of  tumor was 
measured by caliper. Cylinder tumor is calculated with the formula 0.7854 × width2 × length 
(cm3). Round tumor is calculated with the formula 0.5236 × diameter3 (cm3). Mice were 
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euthanized when the tumor volume reached 1 cm3.
Tumor cells isolation. Tumor excised from mice was cut into small pieces and suspended in 5 
ml of  William’s E + Glutamax medium (Life technologies) containing 1 mg/ml of  collagenase 
A (Roche applied science, Almere, The Netherlands). Tumor suspension was transferred 
into a gentleMACS C-tube and homogenized with the program “m_impTUMOR4” with a 
gentleMACSTM dissociator (Miltenyi Biotec, Leiden, The Netherlands) followed by 30 min 
incubation at 37°C. Homogenization and incubation were performed twice. After the second 
incubation, cell suspension was passed through a 70-μm strainer (BD Bioscience), washed 
once with 0.5% BSA/PBS and analyzed with FACSCalibur cytometer. 
Statistical analysis. Differences between two groups were determined with the Mann-
Whitney U test. Differences between two survival curves were calculated using the log-rank 
(Mantel-Cox) test. All data were analyzed with GraphPad Prism software (La Jolla, CA). P < 
0.05 was considered statistically significant.
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Figure S1. VENUS expression of HCV nsPs-expressing Hepa1-6 cell lines. Hepa1-6 cells were trans-
duced with lentivirus encoding VENUS (represented by V) or NS2’-5B’-VENUS DNA to produce Hepa1-
6V and Hepa1-6V-NS2’-5B’ stable cell lines, respectively. VENUS+ cell population of  each cell line was 
FACS-sorted thrice resulting stable cell lines containing > 95% of  VENUS+ cells.
Hepa1-6 Hepa1-6V Hepa1-6V-NS2’-5B’
a
Figure S2. Stabilization of MHC class I molecules on RMA-S cells through binding of HCV peptides. 
Before incubation with peptides, RMA-S cells were cultured at 26°C with 5% CO
2
 for 48 hours to induce 
MHC class I expression. Cells were then incubated with HCV peptides (GAVQNEVTL, ILDSFDPL) at 
the indicated concentrations at 26°C for 4 hours, followed by cultured at 37°C for 1 hour. Positive controls, 
SIINFEKL and RAHYNIVTF are peptides recognizing MHC class I H-2Kb and H-2Db, respectively. The 
expression level of  the surface MHC class I molecules, (a) H-2Kb and (b) H-2Db, were analyzed using flow 
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Figure S3. No induction of polyfunctional HCV-specific T cells upon stimulation with Hepa1-6V cells. 
Mice were primed and boosted intramuscularly with 5 × 106 rSFV or PBS with a 2-weeks interval. Mice 
were sacrificed on day 10 after the last immunization. Splenocytes were stimulated with the control cells, 
Hepa1-6V cells, for 4 hours and subjected to surface and intracellular cytokines staining. The frequencies of  
T-cell subsets in the CD8+ cell population are shown. Background (PBS immunized) subtraction was ap-
plied. 1, single producers; 2, double producers; 3, triple producers; 4, quadruple producers. Data represent 




Figure S4. VENUS expression of HCV nsPs-expressing EL4 cell lines. EL4 cells were transduced with 
lentivirus encoding VENUS, NS3/4A-VENUS or NS5A/B’-VENUS DNA to produce EL4V, EL4V-
NS3/4A and EL4V-NS5A/B’ cell lines, respectively. VENUS+ cell population of  each cell line was FACS-







Figure S5. Therapeutic effect of rSFV immunizations against HCV nsPs-expressing EL4 cells. Naïve 
mice were subcutaneously inoculated with 5 × 105 of  EL4V-NS3/4A or EL4V-NS5A/B’ cells. Mice were 
then immunized intramuscularly with 5 × 106 rSFV on days 2, 9 and 16 after tumor inoculation. Tumor 
growth curves of  each mouse are shown (a: EL4V-NS3/4A cells, b: EL4V-NS5A/B’ cells). Mice were 
sacrificed when the volume of  tumor exceeded 1 cm3. Tumor cells were isolated to analyze the median 
fluorescence intensity (MFI) of  the VENUS+ cells (c) and the total EL4V-NS3/4A and EL4V-NS5A/B’ cell 
population (d) using flow cytometry. Cumulative results of  two independent experiments with n = 5-7 are 
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Figure S6. Effect of early immunization with rSFVeNS2’-5B’ and rSFVeNS3/4A against EL4V-
NS3/4A cells. Mice were intramuscularly immunized thrice with 5 × 106 rSFV on days -5, 2 and 9. On 
day 0, immunized mice were subcutaneously inoculated with 5 × 105 of  EL4V-NS3/4A cells. (a) Tumor 
growth curves of  each mouse are shown. Mice were sacrificed when the volume of  tumor exceeded 1 cm3. 
Tumor cells were isolated and the MFI of  the VENUS+ cells (b) and the total EL4V-NS3/4A cell popula-
tion (c) were analyzed using flow cytometry. Data represent results from one independent experiments 
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Antigen Design Enhances the Immunogenicity of 
Semliki Forest Virus-based Therapeutic Human 
Papillomavirus Vaccines
ABSTRACT
Cellular immunity against cancer can be achieved with viral vector- and DNA-
based immunizations. In preclinical studies cancer vaccines are very potent, but 
in clinical trials these potencies are not achieved yet. Thus a rational approach to 
improve cancer vaccines is warranted. We previously demonstrated that the relatively 
low intrinsic immunogenicity of  DNA vaccines could be enhanced by inclusion 
of  endoplasmic reticulum (ER) targeting and universal helper epitopes within the 
vaccine. We now evaluated whether an optimal antigen format, as defined in DNA 
vaccines can further enhance the effectiveness of  recombinant Semliki Forest virus 
(rSFV) vaccines. To this purpose, we generated, characterized and evaluated the 
efficacy of  rSFV replicon particles expressing human papillomavirus E6 and/or E7 
proteins fused to several helper T cell epitopes and an ER targeting signal. Here we 
show that inclusion of  a helper cassette and an ER targeting signal enhanced protein 
stability and markedly augmented the frequencies of  HPV-specific T cells. Even at 
an immunization dose of  as low as 105 replicon particles this novel vaccine achieved 
tumor regression and protection. Thus, even highly effective viral vector vaccines can 
benefit from an improved antigen format, based on the inclusion of  defined helper 
epitopes and ER targeting.
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INTRODUCTION
Persistent infection with high-risk human papillomavirus (HPV) may result in 
(pre)malignant cervical intraepithelial lesions that can develop into cervical 
cancer, the second most common cancer in women worldwide. HPV infection 
also results in external genital cancers, next to cancer of  anus and cancer of  
mouth and oro-pharynx in both males and females1. HPV-induced malignant cells 
contain the HPV genome in an episomal state and/or a part of  the HPV genome 
integrated into the host chromosome2-5. As a result, HPV-transformed malignant 
cells constitutively express the HPV E6 and E7 oncoproteins, which function 
cooperatively to facilitate malignant progression6. Prophylactic vaccines against 
high-risk HPV induce protective humoral immunity against the capsid protein 
L1 (ref. 7, 8). These prophylactic vaccines do not cure patients with persistent 
HPV infection9 whereby cellular immunity against E6 and E7 oncoproteins plays 
a crucial role to eradicate HPV-infected/transformed cells10-12.
Previously, we demonstrated that a recombinant Semliki Forest virus 
(rSFV)-based HPV vaccine (rSFVeE6,7) has therapeutic anti-tumor effect in 
tumor-bearing mice13,14 and outperformed an adenoviral vaccine encoding HPV 
antigens15. Importantly, in contrast to a protein or DNA-based vaccine, this 
rSFVeE6,7 vaccine is even immunogenic in HPV16 E6 E7 transgenic mice16.
Considering the observation that the outcomes of  clinical trials with 
cancer vaccines do not meet the high expectations based on preclinical studies, 
optimization of  vaccine design might further increase robust long-term immune 
responses, while not increasing or inducing toxicity.
In an effort to improve vaccine potency, carrier proteins have been included 
in vaccines composed of  for example synthetic peptides, recombinant proteins and 
plasmid DNA17. Inclusion of  carrier proteins such as FMS-like tyrosine kinase-3 
(Flt3) ligands18, heat shock protein 70 (ref. 19), and tetanus toxin fragment C 
domain 1 (TTFC)20 successfully improved the efficacy of  HPV DNA vaccines in 
pre-clinical studies. The mechanism of  enhancement has been thought to depend 
on the biological function of  the carrier protein involved21. However, in most 
cases, direct evidence that the biological function of  the carrier protein under 
investigation is responsible for enhanced immunogenicity is limited. In prior work 
we demonstrated that two vaccine formats containing T-helper (Th) epitopes 
which can boost the activation of  antigen presenting cells (APCs) and thereby 
enhance CD8+ T-cell responses22, enhanced E6- or E7-specific T-cell responses 
in HPV DNA vaccines20,23. The two vaccine formats studied included either (i) 
Tetanus Toxin Fragment C (TTFC), or (ii) the combination of  a universal “helper-
cassette” and ER targeting signal (HELPER). In the latter vaccine format, a series 
of  Th epitopes, including the TTFC P30 pan DP epitope, PADRE pan DR epitope 
and HIV NEF pan DQ epitope, is contained23, and localization and retention of  
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the antigen within the endoplasmic reticulum (ER) is achieved by inclusion of  the 
human growth hormone signal peptide24 and a KDEL sequence25,26. As compared to 
vaccination with parental HPV antigen encoding DNA vaccines, immunogenicity 
of  in particular HELPER HPV DNA vaccines was markedly enhanced23.
Immunizations with DNA vaccines encoding Th epitopes and ER 
localization/retention signals induced up to 22% E7-specific T cells within the 
CD8 population23. And remarkably, while rSFVeE6,7 immunizations induced 
lower percentages of  E7-specific T cells (1-4% of  CD8+ T cells)15, the in vivo anti-
tumor responses were higher (Survival rate at 3 months after tumor inoculation: 
rSFVeE6,7: 100%; sigHELP-E7SH-KDEL: 50%). Although these in vivo results 
were derived from independent studies in two institutes, this comparison would 
suggest that the number of  E7-specific CD8+ T cells is not the only factor affecting 
the efficacy of  a vaccine27.
In order to further enhance the potency of  rSFV vaccines, we here evaluate 
the potential added value of  the antigen format strategies that proved successful 
in DNA vaccines. To this end, Th epitopes and ER localization/retention signals-
expressing rSFV vaccines were synthesized and characterized, and their ability 
to induce HPV-specific immune reactivity was investigated in naïve and tumor-
bearing mice.
RESULTS
Construction and characterization of rSFV encoding universal T-helper 
epitopes
To evaluate the effect of  external Th epitopes and ER location/retention signals 
within rSFV, vectors were constructed and characterized in vitro. These vectors 
either expressed an E6,7 fusion protein or a shuffled E7 (E7SH) protein. The HPV 
E6,7 fusion protein-expressing rSFV (E6,7) induced superior E7-specific response 
compared to rSFV expressing individual E6 and E7 proteins which could be ascribed 
to an enhanced stability of  the fusion protein13. E7SH protein, primarily designed 
for DNA vaccines, was constructed by removing the retinoblastoma protein (pRb) 
binding site on E7 by gene shuffling, leading to eradiation of  the transforming 
property of  E7 protein28. Next to our standard HPV-expressing rSFV construct (1) 
rSFVeE6,7 (E6,7), the following constructs were generated: (2) rSFVe-E7SH (E7SH), 
(3) rSFVe-TTFC-E6,7 (TTFC-E6,7), (4) rSFVe-TTFC-E7SH (TTFC-E7SH), (5) 
rSFVe-sigHELP-E6,7-KDEL (sHELP-E6,7) and (6) rSFVe-sigHELP-E7SH-KDEL 
(sHELP-E7SH) (Figure 1a). The abbreviations in brackets will be used throughout 
this paper.
Before testing the efficacy of  the rSFV replicons in vivo, the expression and 
stability of  the transgene-encoded proteins was characterized upon infection of  
BHK-21 cells. Protein expression was determined in the lysate of  BHK-21 cells 
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24 hours after incubation. All rSFV replicons induced expression of  E7 or E7SH 
protein with the expected molecular weight (Figure 1b). As also observed previously, 
bands of  various molecular weights representing high order protein complexes 
were detected13. Inclusion of  the helper epitopes, both TTFC and sigHELP-KDEL, 
enhanced the amount of  transgene-encoded product 24 hours after rSFV infection 
(Figure 1b, relative density).
Pulse-chase experiments showed that the E6,7 fusion protein was more stable 
than the E7SH protein (Figure 1c). Furthermore, consistent with the detection 
of  increased amounts of  transgene-encoded product, fusion of  both TTFC and 
sigHELP-KDEL to E6,7 or E7SH strongly enhanced the stabilities of  the proteins. 
Even 42 hours after [35S]-methionine labeling, heavily labeled bands were visible 
(Figure 1c). 
Figure 1. Expression of HPV E7 protein in vitro. (a) Schematic representation of  the rSFV replicons and 
the size of  the fusion proteins. (b) BHK-21 cells were incubated with (1) E6,7, (2) E7SH, (3) TTFC-E6,7, (4) 
TTFC-E7SH, (5) sHELP-E6,7 (6) sHELP-E7SH or (7) without rSFV replicons. After 24 hours incubation, 
cell lysates were collected and analyzed by SDS-PAGE and immunoblotting. A mouse anti-HPV 16 E7 
antibody was used to detect HPV E7 protein. Density of  all specific bands were analyzed and the numbers 
below the western blot indicate the relative density compared to controls (E6,7 or E7SH). (c) Proteins were 
labeled with [35S]-methionine for 1 hour after incubation with rSFV replicons for 6 hours. Cell lysates were 
collected at 1, 6, 18, 24 and 42 hours post [35S]-methionine labeling for SDS/PAGE and autoradiography. 






rSFV immunizations induce E7-specific CD8+ cells 
To determine the immunogenicity of  the different rSFV replicons, naïve mice were 
immunized twice with 5 Í 106 rSFV replicons with a 2-week interval. The frequency 
of  E7-specific CD8+ cells in peripheral blood was measured using E7
49-57
 MHC class 
I tetramers at different time points. E7-specific CD8+ cells were detected at day 7 
after first immunization and boosted by a second injection (Figure 2) with a equal 
induction kinetics in all groups of  rSFV-immunized mice. The frequencies of  E7-
specific cells in total CD8+ cells 7 days after the boost immunization with E6,7 and 
E7SH were equal. At this time point, genetic fusion of  E7SH with TTFC slightly 
enhanced the frequencies of  E7-specific CD8+ cells compared to E7SH alone but no 
difference was observed in TTFC-E6,7 compared to E6,7 (Figure 2a). An increased 
frequency of  E7-specific cells in total CD8+ cells was detected in mice immunized 
with sHELP-E6,7 compared to E6,7 not only 7 days after the boost immunization 
(E6,7: 2.8% ± 1.2% versus sHELP-E6,7: 5.6% ± 0.8%, P = 0.057) but also at early 
time points (days 7 , 10, 18 after first immunization, P < 0.05). An even stronger 
effect was observed in mice immunized with sHELP-E7SH compared to E7SH on 7 
days after the boost immunization (E7SH: 3.1% ± 0.7% versus sHELP-E7SH: 11.4% 
± 5.6%, P = 0.029) and also at most of  the other time points (days 7, 10 and 25 after 
first immunization, P < 0.05) (Figure 2b). Thus while both E6,7 and E7SH induced 
similar responses, addition of  sigHELP and KDEL to E7SH resulted in a stronger 
augmentation of  the E7-specific CD8+ response, i.e., 3.6-fold increase compared to 
matched control, than when added to E6,7, i.e., 2-fold increase. Nevertheless, even 
though the magnitude of  enhancement differed, inclusion of  sigHELP and ER 
localization/retention signals led to the induction of  enhanced CD8+ T-cell responses 
against both E6,7 and E7SH.
Figure 2. Kinetics of circulating blood E7-specific CD8+ cells upon rSFV immunizations. Mice 
were primed and boosted intramuscularly (i.m.) with 5 Í 106 rSFV with a 2-week interval. (a) TTFC-
expressing rSFV and their matched controls. (b) sigHELP-KDEL-expressing rSFV and their matched 
controls. Blood samples were collected at indicated time points. Percentages of  E7-specific cells in CD8+ 
blood cells are shown. Data represent mean + SEM of  each group (n=4) from 2 independent experiments. 
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Functional capacity of vaccine-induced E7-specific CD8+ cell populations
Since both the quantity and quality of  HPV-specific cells are crucial parameters for 
the effectiveness of  an HPV vaccine, we determined phenotype, IFN-g production 
capacity and degranulation capacity of  vaccine-induced E7-specific CD8+ cells 
in spleen. Mice were immunized twice with 5 Í 106 rSFV with a 2-week interval 
and were sacrificed 10 days after the last immunization. At this time-point, a trend 
toward an increased frequency of  E7-specific CD8+ spleen cells was observed in mice 
immunized with sHELP-E7SH to their matched controls (Supplementary Figure 
S1a). While sHELP-E6,7 immunization did not change the central memory T cells 
(T
CM
) to effector memory (T
EM
) ratio as compared to E6,7 immunization, sHELP-




 ratio (Supplementary Figure S1b). Yet, 
also the number of  T
CM
 cells did increase upon sHELP-E7SH immunizations relative 
to E7SH immunizations. The E7-specific CD8+ cells induced with all vaccines, 
possessed effector cell capacities, as assessed by antigen-induced production of  IFN-g 
and degranulation (Supplementary Figure S1c).
E7-specific CD8+ cells expand and possess cytolytic function after in vitro 
re-stimulation
To further investigate the intrinsic activities of  HPV-specific CD8+ cells induced by 
the different vaccine formats, we re-stimulated splenocytes of  vaccinated mice with 
irradiated TC-1 cells for 7 days and determined the expansion and cytotoxic activity 
of  the resulting HPV-specific cells. In mice immunized with TTFC- or sigHELP-
KDEL-expressing rSFVs, there was a trend towards increased E7-specific T cells 
expansion, as compared to their matched controls (Supplementary Figure S1d). 
The higher cell number may be due to the higher number of  precursor E7-specific 
CD8+ cells in mice immunized with sHELP-E6,7 or sHELP-E7SH before 7-days re-
stimulation (Supplementary Figure S1a). 
Cytotoxic activity of  the HPV-specific cells was determined in vitro by standard 
51Cr release assay using C3 cells expressing the whole genome of  HPV 16 as target 
cells. At higher effector to target (E:T) ratios (30:1 and 10:1), cytolytic activity in all 
groups of  rSFV-immunized mice was similar (Figure 3). Only at the lower E:T ratios 
(3:1 and 1:1), a slightly higher cytolytic activity was detected by splenocytes isolated 
from sHELP-E7SH-immunized mice compared to their controls (Figure 3b). Taken 
together, these results from both expansion and cytolytic analysis of  the E7-specific 
CD8+ cells suggest that the intrinsic activity of  HPV-specific cells induced by all rSFV 
immunizations remained similar. 
Improved therapeutic effect of rSFV vaccines with inclusion of sigHELP-KDEL
Next, we determined the therapeutic effect of  rSFV replicon vaccination in mice 
inoculated with TC-1 tumor cells. Since we did not observe major differences in 
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the frequency of  E7-specific CD8+ cells between rSFVs without carrier proteins 
and rSFVs expressing TTFC (E6,7 versus TTFC-E6,7 and E7SH versus TTFC-
E7SH), the latter vaccines were left out of  this analysis. We previously showed 
that immunizations with 5 Í 106 rSFV particles on days 7, 14 and 21 post TC-1 
inoculation leads to 100% survival for more than 3 months after tumor inoculation. 
In order to reveal a possible effect of  the carrier proteins, we therefore chose to 
immunize mice with a suboptimal dose of  rSFV (1 Í 105 particles) on days 7, 14 and 
21 after TC-1 tumor cells inoculation (Figure 4). Control mice developed palpable 
tumors approximately 14 days post tumor inoculation. After that time-point, tumors 
grew exponentially, reaching a volume of  approximately 1 cm3 between day 20 to 
25 (Figure 4a). Reduced tumor growth rate was observed in mice immunized with a 
suboptimal dose of  all tested rSFV replicons compared to control mice (P < 0.0001). 
Immunization with sHELP-E6,7 not only reduced tumor growth rate but also delayed 
the formation of  tumor (E6,7 versus sHELP-E6,7, P = 0.0036). E7SH and sHELP-
E7SH immunizations both reduced tumor growth rate and had a similar survival 
rate. Suboptimal immunizations with sHELP-E6,7, E7SH and sHELP-E7SH shortly 
after tumor inoculation induced effector T cells and efficiently delayed the growth 
of  tumor to a similar extent (% tumor free mice at 19 weeks post tumor inoculation: 
E6,7: 0%; sHELP-E6,7: 29%; E7SH: 14%; sHELP-E7SH: 29%) (Figure 4b).
rSFV immunizations induce memory response and protect mice from tumor 
formation
Induction of  HPV-specific memory responses is the key to combat HPV re-infection 
and HPV-associated tumor formation. To investigate the quality of  memory T cell 
responses induced by rSFV immunizations, mice were first immunized twice with 
a suboptimal dose of  rSFV (1 Í 105 particles) with a 1-week interval. Next, when 
the frequency of  the E7-specific CD8+ cells in blood had declined, i.e., almost 3 
weeks after the last immunizations (day 26 after first immunization), tumor cells 
a b
Figure 3. Cytotoxic activity of E7-specific CD8+ spleen cells. Mice were primed and boosted i.m. 
with 5 Í106 recombinant Semliki Forest virus particles with a 2-week interval. Ten days after the last 
immunization, mice were sacrificed and splenocytes were re-stimulated with irradiated TC-1 cells for 7 
days. Bulk CTL assay was performed by co-culturing re-stimulated splenocytes (effector cells, E), with 
51-Chromium pulsed C3 cells (target cells, T) at indicated E:T ratios at 37°C for 4 hours. (a) TTFC-
expressing rSFV and their matched controls. (b) sigHELP-KDEL-expressing rSFV and their matched 
controls. Data represent mean ± SEM of  each group (n = 3-4). *P < 0.05 (E7SH versus sHELP-E7SH).
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were inoculated. After this time-point the frequency of  the E7-specific CD8+ cells 
in blood remained constant till day 84 after the first immunization in all groups of  
mice (Figure 5a, 5b). Consistent with two immunizations at optimal dose given 
in a 2-week interval (Figure 2b), sigHELP-KDEL inclusion also increased the 
response of  two immunizations with a 1-week interval with suboptimal doses of  
E7SH or E6,7 at all time points studied. The responses with suboptimal dose, as to 
be expected, were lower than with the optimal doses (Figure 5b). The E7-specific 
CD8+ cell population in mice immunized with sigHELP-KDEL-expressing rSFV 




 cells in blood irrespective of  the target 
antigens expressed by the rSFV (E6,7 or E7SH) (Figure 5c). Mice were monitored 
till week 12 post tumor inoculation. All immunizations delayed tumor growth (P 
< 0.001) (Figure 5d and Supplementary Figure S2) and all mice immunized with 
rSFV containing sigHELP-KDEL remained tumor free (Percentage of  tumor free 
mice: E6,7: 57%; sHELP-E6,7: 100%; E7SH: 71%; sHELP-E7SH: 100%) (Figure 
5d). Thus, immunization with rSFV induces potent memory T-cell response that 












Days after tumor inoculation
Figure 4. Therapeutic effects of rSFV 
immunizations. Mice (n=7) were inoculated s.c. 
with 2 Í 104 TC-1 cells on day 0 and immunized 
i.m. with 1 Í 105 rSFV particles on days 7, 14 and 
21 post tumor inoculation. Growth of  TC-1 tumor 
cells was monitored for 19 weeks post inoculation. 
(a) Individual tumor growth curves. (b) Survival 




In this study we determined whether the inclusion of  specific CD4 helper epitopes 
and ER localization/retention signals in an rSFV vector further enhances the 
immunogenicity of  rSFV-based vaccines. Inclusion of  sigHELP-KDEL enhanced 
vaccine efficacy regardless of  the antigenic nature of  the HPV-target proteins (E6,7 





Figure 5. Memory response induced by rSFV immunizations. Mice (n=7) were immunized i.m. with 
1 Í 105 rSFV particles on days 0 and 7. Three week after the last immunization, mice were inoculated 
s.c. with 2 Í 104 TC-1 cells. (a, b) Kinetics of  the frequency of  E7-specific cells in the total CD8+ blood 
cells and (c) the T cell phenotypes on days 16, 26 and 84 after first immunizations (Days 9, 19 and 
77 after last immunizations; Days -12, -2, 56 of  TC-1 tumor cells inoculation). Percentages represent 
frequencies of  each cell subset in E7-specific CD44+CD8+ cells. Mice were followed for 12 weeks after 
tumor inoculation. (d) Survival curves. *P < 0.05, **P < 0.01, ***P < 0.001.
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enhanced antitumor response achieved by the inclusion of  sigHELP-KDEL within 
the rSFV vectors is most likely due to the induction of  increased numbers of  antigen-
specific CD8+ effector cells with multiple effector functions. Vaccine-induced antigen-
specific CD8+ cells expressed both effector and memory markers and immunization 
with the modified sigHELP-KDEL vaccines resulted in therapeutic and prophylactic 
antitumor responses even at a remarkably low dose of  replicon particles, i.e., 105 
replicon particles per immunization.
Strong cellular immunity against both E7, E6 proteins is correlated with a better 
prognosis of  HPV-induced malignancies10-12,29. We synthesized rSFVs expressing 
carrier proteins fused with functional HPV E6 and E7 proteins. Apart from including 
the carrier proteins, we also generated and characterized rSFV vectors encoding a 
shuffled E7 protein with and without carrier proteins. Differences in immunogenicity 
of  E6,7 and E7SH were not observed at high doses of  rSFV immunizations (Figure 
2). Interestingly, when mice were immunized with a 50-fold lower dose of  rSFVs, 
a significant higher frequency of  E7-specific CD8+ T cells was induced in mice 
immunized with E7SH after the booster immunization (Figure 5a, 5b). This increase 
in E7-specific CD8+ T cell frequency led to better protection against tumor challenge 
(Figure 5d). 
Activation of  Th cells is crucial for the induction and maintenance of  
CTL responses against antigens, certainly in case of  low-immunogenicity30. Also 
in patients with cervical cancer, supportive Th immunity, as characterized by the 
secretion of  Th1/Th2 cytokines such as IFN-g, IL-2 and IL-5 has been shown to 
be protective11,31. Moreover, in patients with high-grade cervical intraepithelial 
neoplasia and carcinoma, the cytokine balance is more Th2-prone11. Fusion of  Th 
epitopes and target antigens allows the simultaneous activation of  both Th cells 
and CTLs. Bystander activated Th cells can license APCs through CD40L-CD40 
interaction, resulting in efficient antigen-processing, up-regulation of  both MHC and 
co-stimulatory molecules and to prime naïve CTLs32. Activated Th cells can as well 
directly influence expansion of  activated CD8+ T cells, through the secretion of  pro-
inflammatory cytokines such as IL-2 (ref. 33). Combined, these effects enlarge the 
pool of  antigen-specific CD8+ T cells by both enhancing clonal expansion of  CTLs, 
reducing CD8+ T cell death and memory T cell formation30,34. 
Within the rSFV vaccines tested here, only sigHELP-KDEL, but not TTFC, 
strongly enhanced the frequency of  E7-specific CTLs relative to the standard rSFV 
vector. In contrast, when using HPV E7SH DNA vaccines, inclusion of  TTFC also 
significantly increased immunogenicity relative to the parental vaccine23. We speculate 
that rSFV vectors already provide a certain level of  T cell help, to which addition of  
the TTFC helper epitope adds little. The higher immunogenicity of  sigHELP-KDEL 
may then be explained by the high level of  protein expression by sigHELP-KDEL 
expressing rSFV (Figure 1b, 1c), potentially because of  ER localization, resulting in 
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prolonged antigen expression in rSFV-infected cells35,36. In addition, increased ER-
stress related apoptosis may also lead to increased exposure of  antigen to APCs, 
thereby increasing vaccine immunogenicity37. And the universal helper epitope 
cassette present within this vaccine is likely to also increase the magnitude of  the 
vaccine-induced T helper response. 
With both the therapeutic and prophylactic rSFV treatment schedules, 
we observed a marked improvement of  anti-tumor responses with sHELP-E6,7 
immunizations compared to E6,7 immunizations. In the therapeutic immunization 
schedules (Figure 4) differences in antitumor responses between sHELP-E7SH 
and E7SH immunizations were not revealed, yet in the prophylactic schedules, 
sHELP-E7SH resulted in better antitumor responses than E7SH (Figure 5d and 
Supplementary Figure S2). Furthermore, the differences in ability to control tumor 
growth were positively correlated with the frequency of  circulating E7-specific CD8+ 
effector T cells. The functional characteristics of  the HPV-specific T-cell responses 
induced by the different rSFV vaccines, as assessed by IFN-g secretion, release of  
toxin granules and cytotoxic capacity were indistinguishable. Thus the high intrinsic 
anti-tumor and memory activity of  the T cells induced with the modified vectors is 
not affected as a result of  the enhanced expansion of  the E7-specific T cell pool. This 
suggests that, also within the context of  rSFV-based vaccines, the frequency of  HPV-
specific effector cells is a main determinant of  tumor inhibition in the permutations 
studied here. 
To conclude, the inclusion of  a series of  immunogenic Th epitopes and ER 
targeting signal further increases the immunogenicity of  rSFV vaccines, resulting in 
therapeutic and prophylactic anti-tumor effects with a very low-dose of  vaccine. For 
clinical applications these modifications in antigen design will likely also increase 
antitumor responses and/or allow the use of  lower doses of  vaccine resulting in 
similar immune responses compared to the unmodified vectors. We anticipate that 
this strategy can readily be applied to enhance immunogenicity of  other viral vector 
platforms and/or target antigens with low immunogenicity.
MATERIALS AND METHODS 
Construction of rSFV replicon vectors. pSFVeE7SH was constructed by cloning the 
NotI-E7SH-XmaI fragment synthesized by PCR using the plasmid DNA TTFC-E7SH20 as 
a template into the PspOMI and XmaI sites of  pSFVeE6,7 (ref. 13) and the E6,7 fragment 
from pSFVeE6,7 was removed by SmaI and PspOMI digestion. pSFVe-TTFC-E6,7 was 
constructed by cloning the PspOMI-TTFC-PspOMI fragment synthesized by PCR using 
TTFC-E7SH as a template into the PspOMI sites of  pSFVeE6,7. pSFVe-TTFC-E7SH was 
constructed by cloning the NotI-TTFC-E7SH-PmeI synthesized by PCR using TTFC-E7SH 
as a template into the SmaI and PspOMI sites of  pSFVeE6,7 and the E6,7 fragment from 
pSFVeE6,7 was removed by SmaI and PspOMI digestion. To construct pSFVe-sigHELP-
E6,7-KDEL, three sequential clones were constructed. First, the plasmid DNA sigHELP-
E7SH-KDEL23 was point-mutated to remove two SpeI sites flanking the sig region to produce 
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msigm-HELP-E7SH-KDEL using the QuikChange II XL site-directed mutagenesis kit (Agilent 
Technologies, Amstelveen, The Netherlands). Second, the XhoI-E6,7-KDEL-XbaI fragment, 
synthesized by PCR using pSFVeE6,7 as a template, was ligated to the XhoI and XbaI sites 
of  msigm-HELP-E7SH-KDEL to produce msigm-HELP-E6,7-KDEL. The fragment KDEL was 
synthesized by PCR. Third, the E6,7 fragment from pSFVeE6,7 was removed by SmaI and 
PspOMI digestions and replaced by the NotI- msigm-HELP-E6,7-KDEL-SmaI fragment which 
was synthesized by PCR to produce pSFVe- msigm-HELP-E6,7-KDEL (pSFVe-sigHELP-E6,7-
KDEL). To construct pSFVe-sigHELP-E7SH-KDEL, pSFVeE6,7 was digested with SmaI and 
PspOMI to remove the E6,7 fragment and ligated to the NotI-msigm-HELP-E7SH-KDEL-SmaI 
fragment synthesized as previously described. All restriction enzymes were purchased from 
Thermo Scientific (Landsmeer, The Netherlands). Sequences of  all constructs were confirmed 
by sequencing.
Production, purification and titer determination of rSFV. rSFV particle production was 
performed as previously described13. In brief, the in vitro transcribed RNA of  the pSFV and 
pSFV-Helper 2 vectors were co-transfected into BHK-21 cells at a molar ratio of  1:1. Transfected 
BHK-21 cells were cultured at 30°C with 5% CO
2
 for 48 hours to produce rSFV particles. The 
supernatant containing rSFV particles was collected and purified on a discontinuous sucrose 
density gradient. Purified rSFV particles were serially diluted and titrated with BHK-21 cells. 
rSFV particles were stored at -80°C.
Cell culture. Baby hamster kidney cells (BHK-21) were obtained from the American Type 
Culture Collection (No. CCL-10) and cultured in RPMI1640 (Life technologies, Bleiswijk, The 
Netherlands) with 10% FBS (Lonza, Basel, Switzerland). C3 cells and TC-1 cells were cultured 
in IMDM (Life technologies) with 10% FBS, which for TC-1 cultures was supplemented with 
1 mM MEM sodium pyruvate, and 1Í MEM non-essential amino acids (both from Life 
technologies) and 30 μM β-mercaptoethanol. All cells were cultured in the presence of  100 U/
ml penicillin and 100 μg/ml streptomycin (Life technologies) at 37°C with 5% CO
2
.
Western blot analysis. BHK-21 cells (5 Í 105 cells) were incubated with rSFV (5 Í 106 
particles) for 24 hours. Cells were lysed on ice in TENT-SDS lysis buffer (1% SDS, 50 mM 
Tris-HCl, 5 mM EDTA, 150 mM NaCl, and 0.5% Triton-X-100, pH7.5) supplemented with 
0.2 mM phenyl-methane-sulphonyl-fluoride. Cell lysates were spun down and the supernatants 
were harvest and analyzed by SDS/PAGE and western blotting. HPV E7 protein was detected 
with a monoclonal mouse anti-HPV E7 antibody (Ab) (1/5000, Zymed Lab, South San 
Franciscom, CA, USA). Alkaline phosphatase-conjugated goat anti-mouse IgG Ab (Southern 
Biotech, Alabama, USA) was used as a secondary antibody. The E7 proteins were visualized by 
colorimetric detection using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate 
substrates solution (Roche applied science, Almere, The Netherlands). Densitometry analysis 
was performed using ImageJ software (NIH software).
Protein expression by pulse labeling. BHK-21 cells (5 Í 105 cells) were incubated with 
5 Í 106 rSFV replicons. Six hours after incubation, supernatant was removed and the cells 
were washed with phosphate buffered saline (PBS) 3 times. The cells were further cultured 
in L-methionine and L-cysteine-free DMEM for 30 min following addition of  [35S]-protein 
labeling mix (0.37 Mbq/well) (PerkinElmer, Groningen, The Netherlands). After 1 hour of  
[35S]-methionine labeling, cells were washed three times with PBS and cultured in medium 
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supplemented with 5 mM of  methionine and cysteine. After 1, 6, 18, 24 or 42 hours of  [35S]-
methionine labeling, cells were washed with cold PBS and lysed with TENT-SDS lysis buffer 
(1% SDS, 50 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, and 0.5% Triton-X-100, pH7.5) 
containing 0.2 mM phenyl-methane-sulphonyl-fluoride. Cell lysates were analyzed by SDS/
PAGE and autoradiography.
Mice. C57BL/6JOlaHsd female inbred mice of  8 to 10 weeks old were obtained from Harlan 
CPB (Zeist, The Netherlands). Housing and animal experiments (DEC: 6405) were approved 
by the local Animal Experimentation Ethical Committee (the Institutional Animal Care and 
Use Committee of  the University Medical Center of  Groningen).
rSFV immunizations. Mice were prime- and booster immunized intramuscularly (i.m.) with 
50 μl of  5 Í 106 rSFV particles (25 μl/thigh muscle). For negative controls, the same volume of  
PBS was injected i.m.. To determine the effect of  immunizations against tumor growth, mice 
were immunized with a suboptimal dose of  rSFV particles (1 Í 105 particle/mouse).
Detection of HPV E7-specific CD8+ cells. Mouse peripheral blood was collected by orbital 
puncture and erythrocytes were lysed. Cells were stained with PE-conjugated H-2Db E7
49-
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 tetramers for 10 min at room temperature. Followed by staining with PE-Cy7-anti-CD8a 
Ab (clone: 53-6.7), PerCP-Cyanine5.5-anti-CD44 Ab (clone: IM7), APC-anti-CD62L Ab 
(clone: MEL-14) and eFluor 450-anti-CD127 Ab (clone: A7R34) antibodies for 20 min at 
4°C. Antibodies were purchased from eBioscience (Vienna, Austria). Cells were stained 
with 4’-6’-diamidino-2-phenylindole to exclude dead cells before analyzing with LSR-II 
flow cytometer (BD Bioscience, Breda, The Netherlands). Data were analyzed using Flowjo 
software (Tree Star).
Detection of IFN-g and degranulation of HPV E7-specific CD8+ cells. Splenocytes isolated 
from immunized mice were stimulated with 10 μg/ml of  E7 synthetic peptides (RAHYNIVTF, 
H-2Db) in the presence of  1 μg/ml anti-CD28 Ab (clone: PV-1, Bioceros B.V., Utrecht, The 
Netherlands), eFluor 660-anti-CD107a Ab (clone: eBio1D4B) and eFluor 660-anti-CD107b 
Ab (clone: eBioABL-93) in a 96-well plate at 37°C with 5% CO
2
. Brefeldin A (1 mg/ml) was 
added 1 hour after culture. Cells were further incubated for 4 hours. Cells were then harvested, 
washed and stained with LIVE/DEAD fixable violet dead cell stain kit (Life technologies). 
Followed with PE-Cy7-anti-CD8a (clone: 53-6.7) staining at 4°C for 20 min. Cells were then 
fixed in 4% paraformaldehyde, permeabilized with Perm/wash buffer (BD Bioscience) and 
stained with PerCP-Cyanine5.5-anti-IFN-g Ab (clone: XMG1.2) at 4°C for 30 min. Antibodies 
were purchased from eBioscience; FACS analysis was conducted with LSR-II flow cytometer, 
and data were analyzed using Flowjo software (Tree Star).
Bulk CTL assay. Stimulator TC-1 cells were cultured in the presence of  50 U/ml recombinant 
murine IFN-g (Peprotech, London, UK) for 48 hours. The TC-1 cells were then irradiated (100 
Gy) and co-cultured with effector cells, splenocytes, at a ratio of  1:25 in a T25 flask at 37°C with 
5% CO
2
. Recombinant human IL-2 (4 U/ml) (Peprotech, London, UK) was added on day 5 of  
the culture. After 7 days culture, splenocytes were harvested and co-cultured with 51Chromium 
(51Cr)-labeled C3 target cells. C3 cells were cultured in the presence of  recombinant murine 
IFN-g (50 U/ml) 48 hours before co-culture with effector cells. C3 cells were labeled with 
51Cr (100 μCi/2 Í 106 cells) (PerkinElmer, Groningen, The Netherlands) for 1 hour at 37°C. 
97
4
Antigen design and immunogenicity of a cancer vaccine
Co-culture of  effector cells and target cells were performed in 96 well plate at 4 E:T ratios in 
triplicates at 37°C with 5% CO
2
 for 4 hours. 51Cr in the cells supernatants was measured with a 
RiaStar manual gamma counter (Packard, Meriden, CT). The percentage of  cytotoxicity was 
calculated with the formula % specific release = ((experimental release – spontaneous release) 
/ (maximal release – spontaneous release)) count per minute (c.p.m).
Tumor inoculation. Mice were inoculated subcutaneously (s.c.) with 2 Í 104 TC-1 cells 
suspended in 0.2 ml PBS. Tumor volume was measured by caliper. The volumes of  cylinder-
shaped tumors were calculated with the formula 0.7854 Í width2 Í length (cm3). Volumes 
of  round tumors were calculated with the formula 0.5236 Í diameter3 (cm3). Mice were 
euthanized when the tumor volume reached 1 cm3.
Statistical analysis. Data were analyzed with GraphPad Prism software (La Jolla, CA). 
Differences between two groups were calculated with the Mann-Whitney U test. Differences 
between two survival curves were calculated using the log-rank (Mantel-Cox) test. P < 0.05 
was considered as statistically significant.
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Supplementary Figure S1. Phenotypes and function of E7-specific CD8+ cells post recombinant Semliki 
Forest virus (rSFV) prime-boost immunizations. Mice were primed and boosted intramuscularly with 5 
Í106 rSFV particles with a 2-week interval. Ten days after the last immunization, mice were sacrificed and 









 (CD62L-CD127+) and T
eff
 (CD62L-
CD127-) and in total E7-specific CD8+CD44+ spleen cells. (c) Splenocytes were stimulated with E7
49-57
 
peptides (RAHYNIVTF, H-2Db) in the presence of  BFA at 37°C. After 4 hours of  stimulation, cells were 
harvested, subjected to intracellular cytokine staining and analyzed by flow cytometry. (d) Fold increase 
of  the frequency of  E7-specific cells in CD8+ spleen cells after 7-day re-stimulation with irradiated TC-1 
cells. The fold increase of  E7-specific CD8+ cells was calculated by dividing the frequency of  E7-specific 
CD8+ cells on day 7 after re-stimulation over the frequency of  E7-specific CD8+ cells on day 0 after re-
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Supplementary Figure S2. Effect of prophylactic recombinant Semliki Forest virus (rSFV) immuniza-
tions on tumor growth. Mice (n=7) were immunized intramuscularly with 1 Í 105 rSFV particles on days 
0 and 7. Three week after the last immunization, mice were inoculated subcutaneously with 2 Í 104 TC-1 
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Effect of an Immunogenic Carrier Protein on the Efficacy 
of an Alphavirus-based Hepatitis C Virus Vaccine
ABSTRACT 
We previously developed therapeutic vaccines against hepatitis C virus (HCV) 
infections. These vaccines are based on recombinant Semliki Forest virus (rSFV) 
replicon particles and encode all nonstructural proteins of  HCV or parts of  them. 
We also demonstrated that a highly immunogenic carrier protein that consists of  a 
series of  helper T cell (Th) epitope and endoplasmic reticulum (ER) targeting signals 
(sigHELP-KDEL) increases the efficacy of  an rSFV-based vaccine against human 
papillomavirus (HPV). To investigate whether the inclusion of  sigHELP-KDEL can 
augment HCV-specific immune responses, we applied this antigen design also for one 
of  our candidate HCV vaccines. 
An rSFV vector expressing a fusion protein of  sigHELP-KDEL and the 
nonstructural proteins NS3/4A of  HCV (rSFVe-sHELP-NS3/4A) was generated 
and its immunogenicity was compared to the parental vaccine, rSFVeNS3/4A. 
Similar to the effect observed with the HPV vaccines, insertion of  sigHELP-KDEL 
resulted in higher protein synthesis. Yet, whereas the immune response elicited by 
the modified HPV vaccine was enhanced by insertion of  sigHELP-KDEL, rSFVe-
sHELP-NS3/4A and rSFVeNS3/4A immunizations were as efficacious. Both 
vaccines induced similar frequencies and activities of  functional HCV-specific CD8+ 
T cells. Also the frequencies of  effector and memory population were identical. 
To conclude, inclusion of  the Th epitopes and ER targeting signals into rSFV 
expressing HCV NS3/4A does not alter the CD8+ T-cell response compared to 
that induced by the parental rSFVeNS3/4A vaccine. This implies that insertion of  
sigHELP-KDEL cannot be considered a universal strategy to augment rSFV vaccine 
efficacy. Effects of  carrier proteins on vaccine efficacy thus also depend on the target 
antigen expressed by the vaccine.
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INTRODUCTION 
Antigen-specific T-cell responses are essential to resolve acute and chronic hepatitis 
C virus (HCV) infections1-3. Recently developed novel HCV-specific direct acting 
antiviral (DAA) offer the prospect of  interferon-free treatments with an increased 
curative rate in patients infected with HCV genotype 1. However, treatment with 
DAA is sometimes associated with multiple side effects, drug-drug interaction, 
development of  resistance-associated variants, and importantly DAAs do not induce 
protective immunity in patients4. Aiming to induce HCV-specific immunity we 
developed therapeutic HCV vaccines based on a recombinant Semliki Forest virus 
(rSFV) vector. These vaccines aim to induce cellular immune responses against HCV 
infected cells expressing the nonstructural (NS) proteins of  HCV. The NS proteins 
are genetically conserved and immunogenic. We showed that these rSFV-based 
vaccines result in the induction of  functional CD8+ T cells containing both effector 
and memory population and delayed growth of  HCV NS protein-expressing tumor 
in vivo5. 
Helper T (Th) cells are indispensable for the induction and maintenance of  
memory CD8+ T-cell responses6. Oosterhuis et al demonstrated that the expression 
of  a series of  Th epitopes in a DNA-based vaccine stimulated both Th cells and 
cytotoxic T lymphocytes (CTLs). They furthermore demonstrated that inclusion of  
endoplasmic reticulum (ER) targeting signals within these DNA vaccines increased 
antigen stability7. The combined modifications strongly enhanced the immunogenicity 
of  their DNA vaccine. 
We previously demonstrated that the inclusion of  Th and ER targeting signals 
also strongly enhanced vaccine immunogenicity of  an rSFV vaccine expressing 
human papillomavirus (HPV) early proteins (Ip PP et al., submitted, Chapter 
4). Immunizations with these novel vaccines resulted in the induction of  a higher 
frequency of  functional antigen-specific T cells and anti-tumor activity already at a 
very low vaccine dosage. Thus these modifications may be applied universally to up-
regulate the immunogenicity of  rSFV-based vaccine. 
In the present study, aiming to enhance the immunogenicity of  the rSFV-
based HCV vaccine, we constructed a novel rSFV-based HCV vaccine expressing 
Th epitopes, ER targeting signals and HCV NS3/4A proteins. The new vaccine was 
characterized in vitro and the in vivo efficacy was compared to the parental rSFV 
vaccine expressing HCV NS3/4A. 
RESULTS AND DISCUSSION 
We modified our previously developed SFV replicon-based HCV vaccine by inserting 
a series of  Th epitopes, including the TTFC P30 pan DP epitope, PADRE pan DR 
epitope and HIV NEF pan DQ epitope (HELP)7. In addition, a human growth 
hormone signal peptide (sig)8 and a KDEL sequence9,10 were inserted to enable 
5106
Chapter 5
localization and retention of  the antigen within the ER. pSFVe-sigHELP-NS3/4A-
KDEL was thus constructed (Figure 1a) and the corresponding rSFV particles 
were produced as described in the materials and methods section. To characterize 
the rSFVe-sigHELP-NS3/4A-KDEL (rSFVe-sHELP-NS3/4A) and rSFVeNS3/4A 
vaccine, BHK-21 cells were infected with rSFV replicon particles and cell lysates 
were harvested 24 hours after incubation. Infection with rSFVe-sHELP-NS3/4A 
or rSFVeNS3/4A resulted in expression of  the sigHELP-NS3/4A-KDEL fusion 
protein (95 kDa, lane 2, upper band) and NS3/4A protein (81 kDa, lane 3, upper 
band), respectively (Figure 1b). A protein of  a smaller size (sigHELP-NS3: 86 kDa, 
NS3: 75 kDa), which is generated upon cleavage between NS3 and NS4A by the 
HCV NS3 protease, was observed in cell lysate infected with either rSFV particles. 
We previously demonstrated that inclusion of  sigHELP-KDEL in HPV-
expressing rSFV enhanced production and stability of  HPV proteins (Ip PP et 
al., submitted, Chapter 4). BHK-21 cells infected with rSFVe-sHELP-NS3/4A 
similarly produced a higher amount of  transgene compared to cells infected with 
rSFVeNS3/4A as demonstrated by a one-hour pulse labeling of  protein using [35S]-
methionine/cysteine. However in contrast to the HPV proteins, sigHELP-KDEL did 
Figure 1. Expression and stability of HCV NS3/4A protein in BHK-21 cell upon rSFVeNS3/4A or 
rSFVe-sHELP-NS3/4A infection. (a) Schematic representation of  the plasmid SFV DNA, the number 
indicates the nucleotide position in the plasmid DNA containing the full genome of  HCV genotype 1a (H/
FL). (b) BHK-21 cells were infected with rSFV particles at a multiplicity of  infection of  10 for 24 hours 
and cell lysates were collected for western blot analysis. HCV NS3 protein was detected using goat anti-
NS3 antibodies. Lane 1: no rSFV; lane 2: rSFVe-sHELP-NS3/4A; lane 3: rSFVeNS3/4A. (c) Stability of  
protein was analyzed by [35S]-methionine/cysteine pulse-chase labeling. BHK-21 cells were incubated with 
rSFVe-sHELP-NS3/4A, rSFVeNS3/4A or medium (no rSFV). Cells were pulsed with [35S]-methionine/
cysteine for 1 hour at 6 hours after addition of  rSFV particles. Cell lysates were collected at 1, 6, 18, 24 or 
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not increase stability of  the NS3/4A protein but rather decreased its stability. The 
sHELP-NS3/4A-KDEL protein was only detectable till 6 hours after [35S]-labeling 
while NS3/4A protein was detectable up to 24 hours (Figure 1c).
Next, we determined the immunogenicity of  both vaccines in vivo. Mice were 
immunized intramuscularly on day 0 and day 14 with 5 Í 106 purified rSFV particles 
and the frequency of  NS3-specific CD8+ T cells in peripheral blood was determined 
on days 7, 11, 18, 21 and 24 after immunization (Figure 2a). The frequency of  NS3-
specific CD8+ T cells in mice immunized with rSFVe-sHELPNS3/4A (sHELP-
NS3/4A) at all time points tested was as high as the frequency observed after 
rSFVeNS3/4A (NS3/4A) immunizations. On day 24, all mice were sacrificed, 
splenocytes were isolated and the cells characterized. Both rSFV vaccines induced 
equal numbers of  NS3-specific CD8+ T cells composed of  equal frequencies of  
effector T cells, effector memory T cells and central memory T cells (Figure 2b, 2c). 
a b
c
Figure 2. Frequency and phenotypes of NS3-
specific CD8+ T cells induced by rSFV-sHELP-
NS3/4A immunizations. Mice were immunized 
intramuscularly twice with a two-week interval with 
5 Í 106 rSFVeNS3/4A or rSFVe-sHELP-NS3/4A 
particles. (a) Kinetics of  the percentage of  NS3-
specific cells in the total CD8+ blood cells. (b) Mice 
were sacrificed on day 10 after the last immunization and the percentage of  NS3-specific cells in the total 
CD8+ splenocytes was determined. (c) Surface markers for the NS3-specific CD8+ T cell subsets: effector T 
cells (T
eff
), CD44+CD62L-CD127-, effector memory T cells (T
EM
), CD44+CD62L-CD127+, central memory 
T cells (T
CM
): CD44+CD62L+CD127+. Percentages of  each subset in the total NS3-specific CD44+CD8+ 
spleen cells are shown. Data represent mean ± or + S.E.M (n=3-4).
Next, the activity of  HCV-specific T cells upon antigen re-stimulation was measured 
using a CFSE dilution assay. Splenocytes from control or immunized mice were 
labeled with CFSE and cultured in the presence or absence of  Hepa1-6V-nsPs cells 
for 4 days to induce proliferation of  HCV-specific T cells. Hepa1-6V-nsPs cells are 
murine hepatoma cells expressing all NS proteins of  HCV5. Antigen-specific CD8+ T 
cells from rSFV-immunized mice but not from control mice had an increased level of  
proliferation upon HCV-specific re-stimulation (Figure 3, black bars). In the absence 
of  Hepa1-6V-nsPs cells, the proliferation of  CD8+ T cells isolated from immunized 
mice was higher compared to the background level observed in control splenocytes, 
suggestive of  strong in vivo activation of  T cells (Figure 3, white bars). Both rSFV 
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vaccines induced similar CD8+ T-cell response. A further analysis of  the activation of  
CD4+ T cells is needed to demonstrate if  immunization with rSFVe-sHELP-NS3/4A 
actually results in a stronger CD4+ T-cell response as a consequence of  the inclusion 
of  Th epitopes.
Figure 3. Proliferation of HCV-specific T cells 
upon in vitro re-stimulation. Splenocytes isolated 
from mice immunized twice with rSFV as described 
in figure 2 were labeled with CFSE and cultured in 
the presence or absence of  irradiated Hepa1-6V-nsPs 
cells at a 25:1 ratio. After 4 days of  culture, cells 
were harvested, stained with anti-CD8a antibodies 
and analyzed using flow cytometer. Percentages of  
proliferation represent the percentage of  proliferating 
daughter CFSE+CD8+ cells (sum of  generation 1 to 
7) in the total CFSE+CD8+ cell population (sum of  
generation 0 to 7). Data represent mean + S.E.M 
(n=3-4).
We previously demonstrated that the insertion of  sigHELP and KDEL 
resulted in a 2- to 4-fold increased expansion of  antigen-specific cells in rSFV-based 
HPV vaccines dependent of  the antigen expressed (HPV E6,7 or shuffled E7 protein 
(E7SH)) (Ip PP et al., submitted, Chapter 4). At high dose rSFV immunization (5 Í 
106 particle/mouse), mice immunized with rSFVe-sHELP-E7SH had an even higher 
number of  E7-specific cells compared to low dose immunization. This enhanced 
effect of  sigHELP-KDEL was not seen with the vaccine expressing the E6,7 fusion 
protein of  HPV. 
rSFVeNS3/4A immunizations resulted in a very high frequency of  NS3-
specific CD8 T cells (13% on day 7 after the booster immunization) (Figure 2a). 
Thus, the NS3-specific T-cell proliferative response may have reached already such a 
high level that insertion of  sigHELP-KDEL cannot further up-regulate the response. 
We also observed that insertion of  sigHELP-KDEL into the HCV vaccine did not 
increase the stability of  the NS3/4A protein. We previously demonstrated that the 
efficacy of  rSFV-based HPV vaccines is influenced by the stability of  the transgene 
expressed. This could be yet another explanation on why immunization with rSFVe-
sHELP-NS3/4A is just as efficacious as rSFVeNS3/4A immunization. To investigate 
the contribution of  sigHELP-KDEL in this rSFV vaccine, lower dose immunization 
may be needed.
In the present study, we focused on the T-cell response against one 
immunodominant NS3 epitope (NS3
603-611
) that is a known strong binder for MHC 
class I H-2Db molecule and is generally detected as a result of  other immunization 
approaches11. Induction of  robust T-cell response against the NS3
603-611
 peptide might 
be due to the presence of  Th epitopes located at the 5’ end of  the CTL epitopes, 
as predicted in the Immune Epitope Database and analysis resource (IEDB) (Table 
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MHC class II prediction
IEDB- H-2-IAb (<10 strong binding)
Protein/position Sequence 5’ of CTL epitope complete CTL epitope 3’ of CTL epitope
HCV NS3603-611 GAVQNEVTL 9,35 - 55,70 18,51 - 32,13 16,70 - 51,34
HPV E749-57 RAHYNIVTF 33,38 - 53,38 56,31 - 79,26 69,56 - 86,81
OVA257-264 SIINFEKL 51,45 - 69,97 51,88 - 81,68 9,57 - 82,66
a
Table 1. Prediction of Th epitopes at close proximity of the CTL epitope. Prediction of  H-2-IAb Th 
epitopes was performed using IEDB. Peptides were divided into 3 groups: peptides that contain part of  the 
CTL epitope either at the 5’ end or 3’ end and peptides that contain the complete CTL epitope. (a) The 
range of  percentile of  the analyzed peptides. (b) Individual percentile of  each analyzed peptide. Percentiles 
below 10 are considered as strong MHC class II binder. The highest and the lowest percentiles and are 
bolded and high-lined in grey. Peptides that contain the complete CTL epitope are also high-lined in grey. 
HCV NS3
603-611
 (HCV genotype 1 (H77), NCBI reference sequence: NC_004102.1), OVA
257-264
 (GenBank: 








, a known Th epitope located at the 3’ terminal of  the CTL epitope 
(OVA
257-264
) was also predicted by IEDB12. Moreover, several immunodominant 
tumor and viral antigens contain Th and CTL epitopes at close proximity. This co-
localization of  Th and CTL epitopes seems positively correlated to the dominancy 
of  the specific CTL epitope13,14. So far, based on knowledge and experimental proof, 
no unequivocal explanations exist for this positive correlation. Nonetheless, based on 
this observation, one could hypothesize that the close proximity of  a Th and CTL 
epitope in HCV NS3 supports such a potent Th response that external Th epitopes 
do not further augment the immune response. This hypothesis is supported by the 
observation that insertion of  external helper epitopes to a vector expressing the HPV 
E7
49-57
 CTL epitope, an epitope that according to IEDB is not in close proximity to a 
Th epitope(s), does enhance the vaccine immunogenicity. 
Is the vaccine-induced immune response protective? Despite the fact that 
rSFVeNS3/4A immunizations induced a very high frequency of  NS3-specific 
CD8+ T cells, the immunized mice were not completely protected against the tumor 
growth of  an HCV NS3/4A-expressing EL4 tumor5. Nevertheless, immunization 
with rSFVeNS3/4A resulted in enhanced immune pressure on the fast-growing EL4 
tumor cells leading to a significant reduction of  HCV nsPs expression. This resulted 
in delayed tumor growth and indicates that CD8+ T-cell response against NS3
603-611
 
is protective in C57BL/6 mice. Since responses against multiple epitopes in humans 
have been positively correlated to a better prognosis1,2,15,16, one may assume that 
responses against other protective subdominant epitopes may also play a role in tumor 
clearance. Further experiments are required to investigate whether the inclusion of  
sigHELP-KDEL could induce CTL response against subdominant epitopes. 
To summarize, at a high dose rSFVeNS3/4A and rSFVe-sHELP-NS3/4A 
immunizations induced equal levels of  NS3-specific CD8+ T cells with functional 
effector and memory phenotypes. This result contrasts with our previous finding 
showing that insertion of  sigHELP-KDEL in rSFV can enhance CTL responses (Ip 
PP et al., submitted, Chapter 4). This contrast may be attributed to the different 
antigenic nature of  the antigens expressed, for example by the presence of  internal 
Th epitopes and the stability of  the protein. Moreover, fusion of  sigHELP-KDEL 
with other antigens such as hepatitis B virus core protein in a DNA vaccine also 
does not enhance vaccine immunogenicity17. Further evaluations on the possible role 
of  sig-HELP-KDEL on rSFVeNS3/4A are required. This will include investigation 
of  the effect of  low dose rSFV immunization on the activation of  CD4+ T cells, the 
diversity and strength of  CD8+ T-cell responses, and their anti-tumoral effect.
MATERIALS AND METHODS 
Construction of SFV plasmid and production of recombinant SFV particles. Construction 
of  pSFVeNS3/4A (12839 bps) is previously described5. To generate the pSFVe-sigHELP-
NS3/4A-KDEL construct, a series of  Th epitopes (HELP), ER localization signal (sig), 
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HCV NS3/4A and ER retention signal (KDEL) were cloned into a SFV vector5. The BssHII-
sigHELP-NotI fragment was amplified by PCR using the pVAX1-SigHELP-E7SHKDEL 
vector7 (provided by K. Oosterhuis, J. B. Haanen and T. N. Schumacher, Netherlands Cancer 
Institute, Amsterdam, The Netherlands) as a template and ligated into pSFV4.2e to generate 
pSFVe-sigHELP. pSFVe-sigHELP was then linearized with NotI digestion and ligated with the 
NotI-NS3/4A-KDEL-NotI, which was amplified by PCR from the plasmid DNA containing 
the full-length cDNA of  HCV H77 genotype 1a consensus sequences (H/FL) (kindly provided 
by Rice, CM via Apath, LLC (AIDS Research and Reference Reagent Program, Division of  
AIDs, NIAID, NIAID, NIH: p90HCVconsensuslongpU)19, and the four amino acid KDEL 
sequence was synthesized by PCR, to produce pSFVe-sigHELP-NS3/4A-KDEL (13160 bps). 
Recombinant SFV particles, rSFVeNS3/4A and rSFVe-sigHELP-NS3/4A-KDEL (abbr. 
rSFVe-sHELP-NS3/4A) were produced in BHK-21 cells and purified with discontinuous 
sucrose gradient as previously described5,18.
Cell lines. Baby hamster kidney cells (BHK-21) obtained from ATCC (No. CCL-10), were 
cultured in RPMI medium (Life Technologies, Bleiswijk, The Netherlands), containing 10% 
FCS (Lonza, Basel, Switzerland) and 100 U/ml penicillin and 100 μg/ml streptomycin (Life 
Technologies). Hepa1-6V-nsPs cells5 were cultured in DMEM medium (GE Healthcare, 
Fairfield, CT, USA) containing 10% FCS and 100 U/ml penicillin and 100 μg/ml streptomycin. 
All cells were cultured at 37°C with 5% CO
2
.
Detection of HCV NS3 proteins by western blotting. BHK-21 cells were incubated with 
activated rSFV particles, rSFVeNS3/4A and rSFVe-sHELP-NS3/4A, with a multiplicity of  
infection of  10 for 24 hours at 37°C. The medium of  the BHK-21 cells was removed and the 
cells were washed twice with PBS. Cells were lysed with cold TENT-SDS lysis buffer (150 mM 
NaCl, 50 mM Tris, 5 mM EDTA, 0.5% Triton-X-100, 1% SDS, pH7.5) containing 0.2 mM 
phenylmethanesulfonylfluoride (PMSF). Cell lysates were analyzed by 12% mini-protean TGX 
stain-free polyacrylamide gel (Bio-Rad, Veenendaal, The Netherlands) and western blotting. 
The tryptophan content was analyzed using Gel Doc EZ imager (Bio-Rad). HCV NS3 proteins 
were detected with goat anti-NS3 Ab at 1/1000 dilution (Abcam, Cambridge, UK). Alkaline 
phosphatase-conjugated rabbit anti-goat IgG Ab at 1/2000 dilution (Southern Biotech, 
Alabama, USA) was used as secondary antibodies. The NS3 proteins were visualized by 
colorimetric detection using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate 
substrates solution (Roche applied science, Almere, The Netherlands). 
 
Mice and rSFV immunization. Female C57BL/6OLaHsd mice (8-10 weeks of  age) were 
obtained from Harlan CPB, Zeist. Mice received intramuscular injections of  rSFV (5 Í 
106 particles/mouse) on day 0 and day 14 of  the experiment. All animal experiments were 
approved by the local Animal Experimentation Ethical committee (the Institutional Animal 
Care and Use Committee of  the University Medical Center of  Groningen).
Protein stability detected by [35S]-methionine/cysteine pulse-chase labeling. BHK-
21 cells (5 Í 105 cells in a well of  a 6-well plate) were incubated with 5 Í 106 recombinant 
rSFVeNS3/4A or rSFVe-sHELP-NS3/4A particles. After 6 hours, supernatant was removed 
and the cells were washed with phosphate buffered saline (PBS). The cells were then further 
cultured in L-methionine and L-cysteine-free DMEM for 30 min following addition of  [35S]-
5112
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methionine/cysteine mix (0.37 Mbq/well) (PerkinElmer, Groningen, The Netherlands). After 
1 hour of  [35S]-methionine/cysteine labeling, cells were washed with PBS and further cultured 
in medium supplemented with 5 mM L-methionine and L-cysteine. Cells were then washed 
and lysed with TENT-SDS lysis buffer (50 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, and 
0.5% Triton-X-100, 1% SDS, pH7.5) containing 0.2 mM PMSF at 1, 6, 18, 24 and 42 hours 
after [35S]-methionine labeling. Cell lysate was analyzed by SDS/PAGE and autoradiography.
Detection of HCV NS3-specific CD8+ T cells. After removal of  erythrocytes, peripheral 
blood cells and splenocytes were stained with HCV-NS3
603-611
-PE dextramers (Immudex, 
Copenhagen, Denmark) for 10 minutes at room temperature. T cell phenotypes were 
characterized with the following antibodies: anti-CD8a-PE-Cy7 (53-6.7), anti-CD44-PerCp-
Cy5.5 (IM7), anti-CD62L-APC (MEL-14) and anti-CD127-eFluor450 (A7R34). Surface 
staining was performed at 4 °C for 20 min. Antibodies were obtained from eBioscience (Vienna, 
Austria). Propidium Iodide (eBioscience) or DAPI were used as live/death cells distinction. 
Samples were analyzed using a LSR-II cytometer (BD Biosciences, Breda, The Netherlands). 
FACS data were analyzed using Flowjo software (Tree Star).
Proliferation assay. Splenocytes were labeled with 5 μM carboxyfluorescein diacetate 
succinimidylester (CFSE, Life Technologies) in PBS at 37°C for 10 min in dark. Labeled cells 
were washed twice with PBS cultured with medium only or with irradiated (100 Gray) Hepa1-
6V-nsPs cells at a ratio of  25:1 for 4 days at 37°C. After four days of  incubation, the cells were 
harvested and stained with anti-CD8a-PE-Cy7 (53-6.7, ebioscience) at 4°C for 20 min. FACS 
analysis was performed using a LSR-II cytometer (BD Biosciences). Data were analyzed using 
Flowjo software (Tree Star).
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Chapter 6
Identification and Validation of Hepatitis C Virus 
Cytotoxic T Lymphocyte Epitopes
ABSTRACT 
Vaccine design requires prediction and validation of  immunogenic MHC class 
I epitopes expressed by target cells as well as MHC class II epitopes expressed by 
antigen presenting cells essential for the induction of  optimal immune responses. 
Epitope prediction methods are based on different algorithms and are instrumental 
for a first screen of  possible epitopes. Yet their results do not reflect a one-to-one 
correlation with experimental data. We combined several in silico prediction methods 
to unravel the most promising hepatitis C virus (HCV) vaccine epitopes and validated 
these epitopes in in vitro and in vivo studies. Resolution of  HCV infection involves 
induction of  a robust and broad-spectrum T-cell response. Cytotoxic T lymphocyte 
(CTL) epitopes within the HCV nonstructural proteins (nsP) were identified and 
proteasomal cleavage sites and helper T cell (Th) epitopes at close proximity to these 
CTL epitopes were analyzed using multiple prediction algorithms. Here we show 
that the combination of  the algorithms strongly increased the prediction accuracy 
as validated by in vitro and in vivo evaluation of  the affinity and functions of  the 
predicted CTL epitopes, respectively. This combined in silico analysis enhances the 
preciseness for identification of  functional HCV-specific CTL epitopes. The design 
of  vaccine based on the combined prediction of  CTL, Th epitopes and proteasomal 
cleavage sites do not only apply to HCV, but also to other viral and non-viral antigens 
in which T-cell responses play a crucial role.
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INTRODUCTION 
Hepatitis C virus (HCV) is a positive-stranded RNA virus that primarily infects and 
persists in human hepatocytes. Clearance of  HCV involves killing of  virus-infected 
cells by cellular immunity, particularly by cytotoxic T lymphocytes (CTLs). However, 
80% of  HCV-infected patients are not able to clear the virus and HCV infection 
persists. Development of  chronic HCV results in liver cirrhosis and 10 to 15% of  
chronically infected patients develop hepatocellular carcinoma in 10 to 15 years 
after the primary infection. During disease progression, viral mutants arise due to a 
combined result of  a high mutation rate of  the HCV genome and immune pressure1,2.
In 2011 two antiviral HCV protease inhibitors, telaprevir and boceprevir, were 
approved for treatment for chronic HCV infection next to/combined with the standard 
treatment with pegylated interferon alpha and ribavirin. Although the sustained 
antiviral response improved by the use of  these new drugs, two-thirds of  chronically 
HCV-infected patients are still non-responders to all available treatments3,4. Antiviral 
treatments aim to eliminate HCV by inhibiting HCV replication but do not induce 
HCV-specific CTLs which has been shown to be crucial for clearance of  HCV-infected 
cells5. Therefore, to effectively control HCV infection, immune-boosting intervention 
such as therapeutic vaccines, that aim to induce robust cellular immunity and to 
eliminate HCV-bearing cells, should be developed and used in combination with 
current HCV therapies.
Spontaneous resolution of  HCV infection has been positively correlated to 
the activation of  a wide T-cell repertoire recognizing multiple HCV epitopes6,7. 
CTL epitopes can be predicted by mathematics algorithms that compare the protein 
sequence of  interest to a large database of  known epitopes. However, data on the in 
vivo function of  predicted CTL epitopes is limited. Some protective CTL epitopes 
have been identified in HCV-infected patients8-10. Yet, selection of  epitopes to be 
included in a personalized vaccine is crucial and should take into account differences 
in virus genotypes and subtypes and the presence of  escape viral mutants. Thus, in 
order to define high potential candidates for a therapeutic HCV vaccine, it is crucial 
to identify circulating virus sequences and their corresponding antigenic epitopes by 
high throughput methods.
In this study, we aimed to set up a procedure to define and subsequently verify 
protective HCV CTL epitopes and Th epitopes. We selected immunogenic epitopes 
within conserved HCV proteins based on the results from several mathematic 
algorithms available. Next, we measured the binding affinity of  the predicted 
CTL peptides to MHC class I molecules in vitro. Furthermore, we determined the 




Selection and characteristics of HCV synthetic long peptides that may 
contain CTL epitopes 
The MHC class I epitope prediction algorithms SYFPEITHI11, NetMHCpan 2.8 (ref. 
12) and Immune Epitope Database and Analysis Resource (IEDB)13 were used to 
predict CTL epitopes within HCV nonstructural proteins (nsPs) that bind H-2Kb/
Db. The first round of  HCV CTL epitope selection was based on the predictions 
by the most commonly used online algorithm, SYFPEITHI (Table 1). Eighteen 





 (multiple human MHC alleles)15, which 
are know binders for other MHC alleles, were selected as negative controls. As a 
result, twenty CTL epitopes were further analyzed with the NetMHCpan 2.8 and 
IEDB prediction algorithms. The threshold for strong binder is < 0.5 (% rank) in 
both NetMHCpan 2.8 and IEDB. Seven out of  eighteen SYFPEITHI predicted CTL 
epitopes were predicted by either NetMHCpan 2.8 or IEDB (Table 1). Surprisingly, 




 were predicted as strong binders by both 
NetMHCpan 2.8 and IEDB. 
To test the performance of  these selected algorithms, the binding capacity 
of  the HCV synthetic long peptides (SLPs) containing the selected CTL epitopes 
based on the prediction of  the three algorithms (Table 1) were determined on 
MHC class I expressing cells, RMA-S cells (Figure 1). One concentration (10 μM) 
of  SLPs was used in this MHC stabilization assay as to screen the possible H-2Db 
and H-2Kb binders. HCV SLPs were classified as weak, intermediate and strong 
binders according to the ability to stabilize MHC class I molecules on the surface 
of  RMA-S cells (depicted by the level of  fluorescence index). Known CTL epitope 
peptides of  ovalbumin (OVA
257-264
) and human papillomavirus (HPV E7
49-57
) were 
included as positive controls for H-2Kb and H-2Db binding, respectively. Among 13 
predicted HCV H-2Db binders, predicted by at least one algorithm (solid and half-
open circles), there was one strong binder (NS3
507-524












Three predicted H-2Kb binders (open circles) stabilized H-2Db molecules and were 






) (Figure 1a). 
In ten SLPs that were predicted to be H-2Kb binders by at least one algorithm (open 
and half-open circles), one was classified as an intermediate binder (NS5B
152-169
) and 




). Two predicted H-2Db binders (solid 






Binding affinity of HCV short peptides to MHC class I molecules
In general, SLPs that contain a CTL epitope predicted by two or more algorithms 
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Protein/
position
Sequence (CTL epitopes are 
underlined)



















H-2Db H-2Kb H-2Db H-2Kb H-2Db H-2Kb H-2Db H-2Kb
NS372-87 IQMYTNVDQDLVGWPA 24 10 0,8 3 2,05 2,25 + -
NS3165-180 KAVDFIPVENLGTTMR 30 8 2 32 2,5 18,5 - +
NS3214-228 VPAAYAAQGYKVLVL 0 22 10 15 24 6,8 ++ +
NS3323-340 ATPPGSVTVSHPNIEEVA 23 9 0,08 8 0,3 9,45 + - v
NS3383-400 ALGINAVAYYRGLDVSVI 0 22 32 1,5 19,1 1,15 ++ -
NS3507-524 AETTVRLRAYMNTPGLPV 22 11 0,1 0,25 0,7 0,7 +++ - v
NS3525-542 CQDHLEFWEGVFTGLTHI 0 21 50 32 13,95 7,9 ++ -
NS3547-563 LSQTKQSGENFPYLVAY 28 22 0,3 1,5 0,4 1,15 ++ -
NS3601-618 RLGAVQNEVTLTHPITKY 29 12 0,08 32 0,2 12,95 + - v
NS5A58-75 HCGAEITGHVKNGTMRIV 24 8 5 32 2,65 36,5 - -
NS5A98-115 CTPLPAPNYKFALWRVSA 20 12 7 32 19 19 - -
NS5A140-157 CPCQIPSPEFFTELDGVR 21 22 8 1,5 6,3 0,5 - -
NS5A269-284 ITRVESENKVVILDSF 24 7 4 50 5,1 45,5 - -
NS5B1-16 SMSYSWTGALVTPCAA 13 11 2 0,03 5,3 0,2 + + v
NS5B46-63 CQRQKKVTFDRLQVLDSH 15 11 15 0,05 27 0,25 - - v
NS5B152-169 GGRKPARLIVFPDLGVRV 15 22 32 15 22 12,35 - ++ v
NS5B249-266 ARVAIKSLTERLYVGGPL 22 12 0,8 3 1,35 2,8 - -
NS5B329-346 VQEDAASLRAFTEAMTRY 20 12 0,4 1,5 9,7 13,95 ++ +
NS5B402-419 HTPVNSWLGNIIMFAPTL 21 8 7 8 12 2,7 - -
NS5B423-439 MILMTHFFSVLIARDQL 13 21 8 0,17 9,1 0,3 - - v
were able to bind and stabilize MHC class I molecules (Table 1). However, some 
SLPs that contain CTL epitopes predicted only by SYFPEITHI did not bind to MHC 
class I molecules. Since SLPs contain extra amino acid flanking the predicted CTL 
epitopes, binding affinity of  SLPs to MHC class I molecules may be reduced16,17. 
Thus, binding capacity of  the CTL epitopes was confirmed with short synthetic 
peptides that contain only the CTL epitope. Short synthetic peptides were selected 
based on one of  the following criteria: (i) CTL epitope has to be predicted by at 
least 2 algorithms and/or classified as a weak, intermediate or strong binder from 
1Fluorescence index of H-2Db: 0,2-0,5 +; 0,5-1,5 ++; > 1,5 +++
2Fluorescence index of H-2Kb: 0,2-2 +; 2-8: ++; > 8 +++
Table 1. Selection of synthetic long peptides containing CTL epitopes from HCV nsPs by prediction 
algorithms. Sequences of  the long synthetic peptides, for which MHC binding affinity was shown in figure 
1, are shown. Strong binders are depicted in bold and high-lined in grey. The cut off  score of  SYFPEITHI 
is set at 20, high score indicates strong binder. The cut off  score of  NetMHCpan 2.8 and IEDB is set at 0.5 





Figure 1. Stabilization of MHC class I molecules with binding of HCV SLPs. To induce MHC class I 
expression on cell surface, RMA-S cells were cultured at 26°C for 48 hours prior to the incubation with 
SLPs. Cells were then incubated with 10 μM of  SLPs at 26°C for 4 hours, followed by a 1 hour cultured 
at 37°C. The expression level of  surface MHC class I molecules, (a) H-2Db and (b) H-2Kb, were analyzed 




 short peptides were positive controls for binding to H-2Db 
and H-2Kb molecules, respectively. Dash lines indicate the cutoff  values for H-2Db (0.2-0.5: weak binders 
(+); 0.5-1.5: intermediate binders (++); > 1.5: strong binders (+++)) and H-2Kb (0.2-2: weak binders (+); 
2-8: intermediate binders (++); > 8: strong binders (+++)).













); (ii) CTL epitope has to be predicted by at 
least 1 algorithm and classified as intermediate or strong binder from the result of  
MHC I stabilization assay (NS5B
152-169
). Since the accuracy of  prediction greatly 
increased when peptides were analyzed with two or more algorithms, four extra CTL 









). And also for this analysis, 
121
6
Validation of HCV CTL epitopes
the known CTL epitopes of  ovalbumin (OVA
257-264
) and human papillomavirus (HPV 
E7
49-57
), which are strong H-2Kb and H-2Db binders, respectively, were selected as 
positive controls. 
Binding affinity of  selected short synthetic peptides on MHC class I molecules 
was determined by MHC class I stabilization assay with various concentrations of  
peptide (Figure 2). As expected, stabilization of  both H-2Db and H-2Kb molecules 
increased with increasing concentration of  peptide. The kinetic of  the stabilization 
of  H-2Db molecules was similar for all selected short peptides. The plateau of  
stabilization was reached at approximately 30 μM of  peptides (Figure 2a). Two 
kinetic patterns of  stabilizations of  H-2Kb molecules were observed. For strong 













), there was a dose dependent increase of  FI and the plateau of  stabilization 







), stabilization of  H-2Kb molecules was 
modest at low peptide concentration (0.3–10 μM). However, the stabilization effect 
increased exponentially once the concentration was above 30 μM. This observation 
may explain the reason why we did not see strong H-2Kb binders when SLPs at 10 
μM were used in the MHC I stabilization assay (Figure 1). Results of  stabilization 
of  MHC class I molecules with short peptides matched with the result from all of  
the MHC class I prediction algorithms used (H-2Db: > 90% matched; H-2Kb: 100% 
matched) (Table 2).
a b
Figure 2. Binding affinity of HCV short peptides to MHC class I molecules. Short synthetic HCV 
peptides were serial diluted and incubated with RMA-S cells as described in figure 1. Dash lines indicate 
the cutoff  values for H-2Db (0.2-0.5: weak binders (+); 0.5-1.5: intermediate binders (++); > 1.5: strong 










The presence of proteasomal degradation sites at the carboxyterminal site 
of the predicted CTL epitopes
Under physiological conditions, proteins have to be cleaved by proteasomes into 
short peptides in order to be loaded on MHC class I molecules. Proteasomal cleavage 
sites were predicted with MAPPP, PAProC I and Netchop. MAPPP and Netchop 
predict the cleavage site of  constitutive proteasomes and PAProC I predicts cleavage 
site of  both constitutive proteasomes and immunoproteasomes. From the result of  at 
least two prediction algorithms, proteasomal cleavage sites were present at all strong 
MHC class I binders (+++) (Table 2). 
The presence of MHC class II epitopes flanking the predicted CTL epitopes
It has been observed that immunodominant CTL epitopes such as Influenza B 
nucleoprotein are flanked and/or overlap with Th epitopes18-20. Association of  CTL 
and Th epitope may indeed enhance the immunogenicity of  the CTL epitopes in 
vivo21. To investigate the presence of  MHC class II epitope flanking the strong MHC 
class I binders, we next performed prediction of  MHC class II epitopes with IEDB. 
Notably, most of  the identified strong MHC class I strong binders were flanked with 
at least one MHC class II epitope. And three MHC class I strong binders (both H-2Db 







). Flanking of  MHC class I epitope with MHC class II epitope 
was also observed in our positive control, OVA
257-264
 (Table 2). 
Induction of peptide-specific effector CD8+ T cells in vivo
Induction of  in vivo T-cell response depends on both the presentation of  peptides 
and the availability, avidity and affinity of  precursor CD8+ T cells22,23. Here, we 
investigated the induction of  T-cell response against the predicted CTL epitopes in 
mice immunized three times with the rSFV particles expressing all HCV nsPs, NS3/4A 
or NS5A/B’ (rSFVeNS2’-5B’, rSFVeNS3/4A or rSFVeNS5A/B’). Splenocytes were 
isolated 1 to 3 weeks after the last immunization and re-stimulated with selected short 
peptides in order to induce degranulation (surface expression of  CD107a/b) and 
secretion of  IFN-γ by peptide-specific CD8+ T cells (Figure 3). rSFV immunizations 









. When no peptides were added to the splenocytes, 
we already observed the presence of  endogenous CD107a/b+IFN-γ+CD8+ cells 
from mice immunized with any rSFV particles but not from mice immunized with 
PBS. This indicates that rSFV immunizations in general induced functional CD8+ 
T-cell responses. In order to check the specific response against peptide, background 
(without peptide re-stimulation) subtraction was applied. Frequencies above zero 
indicate specific response against the re-stimulating peptide. CD8+ T-cell response 
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Table 2. Detail analysis of selected short synthetic HCV peptides. Prediction of  proteasomal cleavage 
sites and MHC class II epitopes flanking the selected CTL epitopes (a) H-2Db, (b) H-2Kb. CTL epitope and 
its flanking amino acids (11 amino acid at 5’ end and 11 amino acid at 3’ end of  the CTL epitope) were 
analyzed with MHC class II prediction algorithm (IEDB). Rankings below 10 were considered as strong 
binder. The values represent the range of  ranking of  the analyzed amino acids. Data were sorted according 
to the binding affinity of  short peptides to RMA-S cells (Figure 2), strong binders at the top of  the row (a: 





 was the highest among all selected peptides and was detected in 





 were low and induced in mice immunized with rSFVeNS5A/B’ 
or rSFVeNS2’-5B’. A very low response against NS2
139-147
 was observed only in 
mice immunized with rSFVeNS2’-5B’ but not in mice with other immunizations. 
Of  note, all responding peptides were predicted by at least one algorithm for MHC 
class I prediction. Proteasomal cleavages site was presented in the carboxyterminal 







) contain MHC class II epitopes at close proximity of  their CTL epitopes with 
relatively high ranking (Table 2). 
DISCUSSION
Identification of  protective HCV CTL epitopes is essential in the development of  
an efficient vaccine for patients with chronic HCV infection. Treatment can be 
personalized based on the circulating HCV genotype(s). Ideally one should identify 
HCV epitopes expressed by the patients’ infected cells and induce T-cell responses 
against the identified epitopes with vaccine immunizations. Identification of  HCV 
epitopes from cell lines expressing HLA-A2 and HCV proteins has been performed 
with electro-spray ionization quadrupole time of  flight mass spectrometry/tandem 
mass spectrometry (ESI Q-TOF-MS/MS) and the data were consistent with the 
Figure 3. Induction of peptide-specific effector CD8+ T cells in vivo. Mice were intramuscularly 
immunized thrice with rSFV expressing HCV nsPs (rSFVeNS2’-5B’, rSFVeNS3/4A or rSFVeNS5A/B’) 
or PBS control with a one-week interval. Mice were sacrificed 1 to 3 weeks after the boost immunization. 
Splenocytes were isolated and cultured with 10 μg/ml of  peptides for 5 hours before surface and 
intracellular staining. Background (splenocytes incubated with an equivalent concentration of  DMSO) 
subtraction was applied and values above background are shown. Data represent combined results from 
three independent experiments, showing the mean +SEM (2-5 mice per group), PBS control (2 mice). u 
one mouse per group.
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results predicted from mathematic algorithms24. This method could also be used 
to identify naturally processed and presented HCV peptides from HCV-infected 
hepatocytes. However a widespread use of  this analysis is limited as liver biopsies of  
individual patients are required for the analysis and taking biopsies is not standard 
procedure in these patients. Moreover, the percentage of  HCV-infected hepatocytes 
in biopsies may be too low for MS analysis25,26. An alternative method is to identify 
CTL epitopes in silico based on the HLA phenotype and the viral sequence identified 
from blood of  HCV-infected patients. 
Here we show that the prediction accuracy for the identification of  potential 
CTL epitopes is improved by combing several mathematic algorithms for MHC 
class I epitopes, MHC class II epitopes and proteasomal cleavage sites prediction. 
From all the HCV nsPs we narrowed down to 22 CTL epitopes by online prediction 
algorithms, of  which 10 were proven to bind to H-2b molecules on RMA-S cells. 
We next showed that immunization with rSFV expressing all nsPs induced a strong 
epitope-specific T-cell response against 1 out of  10 H-2b binders and a weak response 
against 3 other epitopes. 
Although the use of  SLPs for the validation of  the MHC class I binding 
capacity of  CTL epitopes would allow a rapid screening of  multiple epitopes within 
a protein, not all epitopes within such an SLP can bind to MHC molecules likely due 
to flanking amino acids. Thus only short peptides with the exact CTL epitopes can 
be used for this analysis. 
Computational analyses used in this study are machine-learning algorithms, 
i.e., the programs are trained with large database for reliable result. Therefore, most 
algorithms favor the detection of  immunodominant epitopes. Predictions are made 
with allele-specific motif  methods that are based on amino acid sequence27,28. For 
example, peptide position 2 and 9 are classical anchor residues most important for 
binding to the HLA-A*0201 allele and are typically occupied by leucine, valine and 
isoleucine29. With allele-specific motif  methods, peptides containing appropriate 
amino acid at anchoring positions are predicted as MHC class I binders but this type 
of  prediction does not necessarily correlate with the physiological function of  the 
epitopes. 
Antigen processing and presentation involve a complex regulation of  antigen 
degradation, interaction with chaperones, binding to the peptide-loading complex, 
loading onto MHC class I molecules and transport to the cell surface30. For both, 
presentation of  intracellular antigens and cross-presentation of  extracellular 
antigens, antigen degradation by constitutive and/or immune proteasome is 
required. Upon exposure of  IFN-γ in lymphoid cells, the constitutive proteasomes 
are replaced by immunoproteasomes which have altered preference for cleavage 
site31. The immunoproteasomes favor the processing of  immunodominant peptides32. 
Normal human liver cells also express immunoproteasomes besides constitutive and 
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intermediate proteasomes that enable the broadening of  the repertoire of  antigenic 
peptide33. In order to define the physiological function of  predicted CTL epitopes, 
we analyzed the proteasomal cleavage site recognized by constitutive proteasomes 
(MAPPP, PAProC I and Netchop) or immunoproteasomes (PAProC I) present at the 
carboxyterminal of  the predicted CTL epitopes. Combining MHC I prediction with 
proteasomal cleavage prediction indeed increases the accuracy of  MHC I peptide 
prediction34. In this study, all predicted strong H-2Db and H-2Kb binders contained 
proteasomal cleavage sites predicted by at least two algorithms. 
Activation of  CD8+ T cells relies on both recognition of  MHC I-peptide 
complex on APCs and co-stimulatory activation signals provided by adjacent cells 
such as APCs and/or CD4+ helper T cells. Activated CD4+ helper T cells orchestrate 
the activation of  CD8+ T cells by secretion of  IL-2 and/or activation of  dendritic 
cells for up-regulation of  MHC I molecules and antigen presentation21. Interestingly, 
many known immunodominant CD8+ T cell epitopes such as OVA
257-264
 contain 
Th epitopes overlapping or at close proximity of  one another21,35. This may allow 
presentation of  both MHC I and MHC II peptides by the same dendritic cells 
resulting in activation of  both CD8+ and CD4+ T cells simultaneously36. Another 
explanation is that activated helper T cells acquire MHC II-peptide complex from 
APCs as well as co-stimulating molecules leading to activation of  Th1 responses 
and central memory CD8+ T-cells responses37-39. It is proposed that the uptake the 
MHC II peptides may be further processed into MHC I peptides which can be 
loaded onto recycled MHC I molecules and present to CD8+ T cells21,40,41. This will 
lead to higher activation of  CD8+ T cells as the helper T cells provide both antigen 





) overlapped with strong Th epitopes (Table 
2). The immunodominant epitope (NS3
603-611
), which induces a very strong CD8+ 
T-cell response in mice immunized with rSFVeNS2’-5B’ or rSFVeNS3/4A, contains 
intermediate Th epitopes at the 5’ ends of  the CTL epitope. Remarkably, MHC 
class II epitope prediction by IEDB may not identify all possible Th epitopes, as for 
example, it has been shown that E7
44-62
, binds to MHC class II molecules in vitro but it 
was not predicted as strong binders43. Beside from the results of  prediction algorithm, 
the presence of  Th epitope should be determined by in vitro experiments such as 
MHC class II binding assay.
In vivo, only 1 out of  22 predicted CTL epitopes induced strong CD8+ T-cell 
responses and 3 out of  22 induced minor CD8+ T-cell responses. Subdominant 
CTL epitopes could not be identified with rSFVeNS2’-5B’, rSFVeNS3/4A 
or rSFVeNS5A/B’ immunizations. Inclusion of  more epitopes may increase 
competition between T cells of  different specificity resulting in a reduced response 
to subdominant epitopes44. Furthermore, expression of  full protein may reduce the 
expression level of  one particular peptide compared to expression of  only 1 peptide. 
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This may lead to insufficient presentation of  antigen resulting in unstable contact 
between CD8+ T cells and APC, thereby unable to fully activate T cells45. Although 
the biological function of  responses against subdominant epitopes is unknown, an 
alternative approach to check the accuracy of  in silico predictions is to immunize with 
synthetic long peptides expressing only one particular CTL epitope and its flanking 
sequences. In this way, immune response will be directed to that specific epitope. A 
major drawback of  such an approach would be the number of  mice that is required 
for this analysis. 
In summary, we in vivo validated in silico approaches for epitope prediction. 
We showed that responses against predicted dominant CTL epitope were induced 
in mice immunized with HCV-nsPs expressing rSFV. Subdominant epitopes, which 
were predicted by the mathematic algorithms, may have to be confirmed with peptide 
immunizations. Furthermore, our studies confirm the observation that the presence of  
Th epitope in close proximity to CTL epitopes is a prediction for a dominant epitope. 
Combining with proteasomal cleavage sites and Th epitope algorithms increases 
the accuracy of  CTL epitope identification. This will enable researchers to identify 
and narrow down the potential CTL epitopes as candidates for therapeutic vaccine 
development. For clinical practice, the establishment of  an ex vivo stimulation assay 
with patients’ PBMCs is warranted to select from the rationally designed candidate 
vaccines the one that is most immunogenic for that specific patient.
MATERIALS AND METHODS 
Prediction algorithms and nucleotide sequences. HCV peptides associated with MHC 
class I molecules (H-2Db and H-2Kb) were predicted with SYFPEITHI, NetMHCpan 2.8 
and Immune epitope database and analysis resource (IEDB). HCV peptides associated with 
MHC class II molecules (H-2-IAb) were predicted with IEDB. Proteasomal cleavage sites of  
the selected HCV peptides were predicted with MAPPP, PAProC I and Netchop. Protein 
analyzed: all nsPs of  HCV genotype 1 (H77) (NCBI reference sequence: NC_004102.1), 
ovalbumin (GenBank: AAB59956.1) and E7 protein of  Human papillomavirus type 16 
(GenBank: AAL96657.1).
Synthetic peptides. Long synthetic peptides (13 to 18-mers) were kindly received from BEI 
Resources, NIAID, NIH: Peptide Array, Hepatitis C Virus, H77, NS2 protein, NR-3751; NS3 
protein, NR-3752; NS4A protein, NR-3753; NS4B protein, NR-3754; NS5A protein, NR-
3755; NS5B protein, NR-3756. Short synthetic peptides (8 to 9-mers) were manufactured by 
the department of  Immunohematology, Leiden University Medical Center, The Netherlands. 
The purities of  the synthetic peptide were analyzed with HPLC. All synthetic peptides have a 
purity of  > 90%.
MHC class I stabilization assay. RMA-S cells were provided by Cornelis JM Melief  
(Leiden University Medical Center, The Netherlands) and were maintained in IMDM (Life 
Technologies, Bleiswijk, The Netherlands) supplemented with 10% FBS and 100 U/ml 





cells were cultured with 5% CO
2
 for 48 hours to induce expression of  MHC class I. Cells were 
then incubated with various concentrations of  synthetic peptides at 26°C for 4 hours, followed 
by cultured at 37°C for 1 hour. Cells were harvested, washed once with 0.5%BSA/PBS and 
stained with APC-anti-H-2Kb Ab (clone: AF6-88.5.5.3) and FITC-anti-H-2Db Ab (clone: 28-
14-8) (eBioscience, Vienna, Austria) at 4°C for 20 min. The surface expression of  MHC class I 
molecules were analyzed by FACSCalibur cytometer (BD Bioscience) and data were analyzed 
with FlowJo software (Tree Star). Fluorescence index was calculated by dividing the median 
fluorescence intensity (MFI) value of  cells incubated with SLPs by the MFI value of  cells 
incubated with equivalent concentration of  DMSO.
Mice. Specific pathogen-free female inbred C57BL/6JOlaHsd (H-2b) mice were obtained from 
a commercial vendor (Harlan CPB, Zeist, The Netherlands) and were kept under the institute 
guidelines of  the University of  Groningen, The Netherlands. All mice were 8 to 10 weeks of  
age at the start of  all experiments. Animal experiments were approved by the local Animal 
Experimentation Ethical Committee (the Institutional Animal Care and Use Committee of  
the University Medical Center of  Groningen).
rSFV particles production and immunizations. rSFVeNS2’-5B’, rSFVeNS3/4A and 
rSFVeNS5A/B’ were produced as previously described46. Mice were primed and boosted 
immunized intramuscularly with a 2-week interval with 5 Í 106 rSFV in 50 μl (25 μl/thigh 
muscle) under anesthesia (isoflurane/O
2
). For negative controls, the same volume of  PBS was 
injected intramuscularly.
Degranulation and IFN-g	staining. Splenocytes isolated from immunized mice were cultured 
with 10 μg/ml of  synthetic peptides in the presence of  anti-CD28 Ab (clone: PV-1, Bioceros 
B.V., Utrecht, The Netherlands), eFluor 660-anti-CD107a Ab (clone: eBio1D4B) and eFluor 
660-anti-CD107b Ab (clone: eBioABL-93) in a 96-well plate at 37°C with 5% CO
2
. One hour 
after culture, brefeldin A (1 mg/ml) was added and the cultures were further incubated for 4 
hours. Cells were then harvested, washed and stained with LIVE/DEAD fixable violet dead 
cell stain kit (Life Technologies) according to manufacturer’s manuals. Followed by surface 
staining with PE-Cy7-anti-CD8a Ab (clone: 53-6.7) at 4°C for 20 min and intracellular staining 
with PerCP-Cyanine5.5-anti-IFN-g Ab (clone: XMG1.2) at 4°C for 30 min. All antibodies 
were purchased from eBioscience. FACS analysis was conducted with LSR-II flow cytometer, 
and data was analyzed with FlowJo software (Treestar).
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SUMMARIZING DISCUSSION 
Our immune system is equipped with a natural ability to combat diseases such as 
infections and tumors. However, microbes and tumors have evolved mechanisms to 
escape from recognition by the immune system. In this way, microbes may persist and 
tumors may develop. To circumvent this phenomenon the immune system should be 
boosted. This can be achieved through the use of  immunotherapy as a treatment 
regimen. 
Hepatitis C virus (HCV) is one of  the known human tumor-associated 
viruses that can evade the host immune system. More than 70% of  the HCV-infected 
patients cannot clear the virus naturally and become chronic carriers. Persistent HCV 
infection results in chronic inflammation and thereby may lead to carcinogenesis 
as the worst possible outcome. Current standard treatment for chronic infection 
focuses on directly targeting the virus by using a combination of  anti-viral drugs. 
Treatments targeting the immune system are warranted but still under development. 
In Chapter 2, we presented a summary of  the recent literature on the development 
of  immunotherapy against HCV infection. Most immunotherapeutic strategies have 
achieved potent anti-viral efficacy in preclinical studies. However, the translation of  
vaccine efficacy to HCV-infected patients has had limited success thus far. Despite the 
fact that most of  the candidate vaccines were able to induce HCV-specific immune 
responses, they were not potent enough to resolve HCV infection. This indicates that 
there is room for improvement regarding vaccine efficacy. 
The goal of  the work described in this thesis was to develop an 
immunotherapeutic regimen against HCV infection. For this, we generated a 
therapeutic vaccine based on an alphavirus, Semliki Forest virus (SFV), to induce 
robust and long-lasting cellular immune responses. 
Development of a therapeutic HCV vaccine based on SFV
Chronic HCV infection and HCV-induced hepatocellular carcinoma are often seen 
in combination with a poor and exhausted cellular immune response1-3. Thus, the 
capacity to induce a broad cellular immune response is an essential requirement for 
an effective therapeutic HCV vaccine. Others have shown that robust T-cell responses 
against the conserved nonstructural proteins (nsPs) of  HCV are positively associated 
with spontaneous recovery from acute HCV infection4-6. In Chapter 3, we described 
the production and characterization of  rSFV vectors encoding parts (NS3/4A or 
NS5A/B’) or all nsPs (NS2’-5B’) of  HCV. Inclusion of  all HCV nsPs (6.1 kb) increases 
the size of  the recombinant RNA approximately 25% beyond the original size of  the 
wild-type SFV RNA. And although this large genome reduces the production of  
rSFV 5-fold, the viral particles are functional. The particles express all HCV nsPs and 
in vivo induce protective nsPs-specific cellular immune responses. Inclusion of  this 
large foreign gene in rSFV thus does not reduce the efficacy of  the vaccine.
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Compared to mice immunized with rSFV expressing HCV NS3/4A, mice 
immunized with rSFV expressing all HCV nsPs had lower numbers of  NS3
603-611
-
specific CD8+ T cells. Yet, this did not affect the anti-tumor activity. A reduced 
magnitude of  the NS3
603-611
-specific T-cell response may be due to differences in 
immunodominance hierarchy of  the NS3
603-611
 epitope induced by different rSFV 
immunizations (rSFVeNS3/4A versus rSFVeNS2’-5B’). Immunodominance 
hierarchy, the observation that an antigen-specific T-cell response of  one specificity 
is stronger than the others with different specificities, is often associated with the 
frequency of  antigen-specific precursor T cells and the abundance of  antigen7. Reduced 
immunodominance hierarchy of  NS3
603-611
 after rSFVeNS2’-5B’ immunization may 





by this vaccine. A low magnitude of  the NS3
603-611
-specific T-cell response reduces the 
immune pressure on the virus and reduces the development of  escape mutants8-10. 
Furthermore, immunization with rSFVeNS2’-5B’ may allow induction of  cellular 
immune responses against other CTL epitopes that are desirable for viral clearance11,12. 
Enhancement of SFV-based vaccine immunogenicity
In the studies described in Chapter 4 and 5, we tried to enhance the immunogenicity 
of  the rSFV vaccine. This can be achieved with strategies such as an alternative 
immunization route13, combination with immune modulators14 or direct modification 
of  the viral vector itself15-17. We directly modified the rSFV vaccine by inclusion of  
immunogenic carrier proteins that are commonly used to enhance immunogenicity 
of  DNA vaccines18. Two carrier proteins, (i) tetanus toxin fragment C (TTFC) and 
(ii) a series of  helper T cell (Th) epitopes fused with endoplasmic reticulum (ER) 
targeting signals (sigHELP-KDEL), were selected based on their high potency in 
DNA vaccines19,20. We studied the effect of  these carrier proteins on rSFV expressing 
proteins of  Human papillomavirus (HPV) (Chapter 4) or HCV (Chapter 5).
Inclusion of  sigHELP-KDEL in an HPV rSFV-based vaccine led to enhanced 
immunogenicity, next to increased efficacy of  eradication of  TC-1 tumors in mice. 
Immunization with sigHELP-KDEL-expressing HPV rSFV vaccines resulted in 
doubling of  the number of  HPV E7-specific T cells from approximately 3% to 6% 
of  the total CD8+ T cell population compared to immunization with HPV rSFV 
vaccines without the inclusion of  sigHELP-KEDL. The enhanced immunogenicity 
is attributed to the increased antigen production and stability by re-locating the 
antigen into the ER as well as by stimulation of  CD4+ T cell activation (Chapter 4). 
Enhanced immunogenicity was not observed when TTFC was incorporated in rSFV. 
TTFC is a relatively large protein that may contain CTL epitopes that could alter the 
immunodominance hierarchy of  the antigen of  interest and may not enhance the 
CD8+ T-cell response against the E7
49-57
 peptides as expected21. 
Interestingly, we observed that inclusion of  sigHELP-KDEL into HCV-
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expressing rSFV (rSFVeNS3/4A) did not improve the stability of  the protein and the 
immunogenicity of  the vaccine (Chapter 5). As observed by Oosterhuis, inclusion of  
sigHELP-KDEL was also not effective in enhancing the immunogenicity of  DNA 
vaccines expressing hepatitis B virus core protein, human gp100 and plasmodium 
berghei circumsporozoite protein22. Immunization with rSFVeNS3/4A already 
induced as much as 12% of  NS3
603-611
-specific cells in the total CD8+ T-cell population. 
The NS3
603-611
 epitope is an immunodominant CTL epitope and flanked with Th 
epitopes. The localization of  Th and CTL epitopes at close proximity has been shown 
to be positively associated with the immunogenicity of  the CTL epitope23,24. Because 
of  the strong immunogenicity of  NS3
603-611
, the inclusion of  immunogenic carrier 
proteins may not be able to further enhance the immunogenicity of  this particular 
epitope. 
The vaccine immunogenicity in these two studies was purely based on the 
evaluation of  the CD8+ T-cell response against one immunodominant epitope, HPV 
E7
49-57
 or HCV NS3
603-611
. In order to further investigate the role of  sigHELP-KDEL 
on the overall vaccine immunogenicity, studies on the CD8+ T-cell response against 
other (subdominant) CTL epitopes will have to be performed.
Design of personalized therapeutic vaccines against HCV
Since chronic HCV infection is often associated with the development of  viral escape 
mutants, induction of  protective immunity against both wild-type virus and escape 
mutants is needed for development of  an effective therapeutic HCV vaccine25. Immune 
response against the wild-type virus can be induced by an off-the-shelf  vaccine that 
induces responses against conserved HCV proteins. Vaccines against escape mutants 
can only be designed when the sequences of  the escape mutants or the peptides 
presented on the human leukocyte antigen (HLA) molecules of  the infected cells are 
identified. Analysis of  the HLA ligandome (immunopeptidome), i.e., all the peptides 
presented on the HLA molecules of  the HCV-infected cells, by mass spectrometry 
is an ideal solution. However, complete analysis of  HLA ligandome often involves 
extensive use of  patient material, such as liver biopsies, that is generally not obtained 
from every patient with chronic HCV infection. Another way to identify protective 
epitopes presented by the circulating virions is to obtain the genome sequence of  
the virus and identify CTL epitope using mathematic predictions26,27. In Chapter 
6, we identified (non-mutated) HCV CTL epitopes in silico with combinations of  
mathematic algorithms (SYFPEITHI, NetMHCpan 2.8 and IEDB). CTL epitopes 
presented by H-2Kb and H-2Db were identified and validated in vitro and in vivo. 
In vivo evaluation demonstrated that immunization of  C57BL/6 mice with 









). All these four epitopes 









contain at least one Th epitope at close proximity to the CTL epitope. As described 
earlier, the presence of  a Th epitope enhances the immunogenicity of  the nearby CTL 
epitope23,24. It has been proposed that both CTL and Th peptides can be presented 
by the same dendritic cells resulting in activation of  both CD8+ CTL and CD4+ Th 
cells simultaneously28. Another hypothesis is that Th peptides could be degraded into 
shorter CTL peptide resulting in increased presentation of  CD8 peptides23. In both 
scenarios, there is increased presentation of  CTL epitopes and activation of  CD4+ Th 
cells which will eventually up-regulate the CD8+ T-cell response. 






 were mild, 
possibly due to competition between epitopes29, this result verified the accuracy of  
the mathematic predictions. To further confirm the in vivo functions of  the predicted 
CTL peptides, immunizations with rSFV or other vaccine formats encoding the 
predicted CTL epitopes and their flanking Th epitopes will be required. 
FUTURE PERSPECTIVES 
Therapeutic HCV vaccine design
Antigen selection
Induction of  a protective T-cell response against a broad-spectrum of  viral epitopes is 
the main aim of  a therapeutic HCV vaccine. A broad-spectrum of  T-cell responses can 
be achieved by enclosing all conserved HCV proteins in a vaccine regimen. However, 
HCV evades our immune system and develops escape mutants30. Responses against 
epitopes derived from the escape mutant are also essential for clearance of  virus-
infected cells. Analysis of  the HLA ligandome of  the infected cells, which enables 
identification of  all viral epitopes presented on the HLA molecules, would be the 
most precise way to select T-cell epitopes for a rational design of  candidate vaccines. 
Increasing antigen immunogenicity
When multiple antigens are incorporated in a vaccine, a broad immune response is 
induced. However, the magnitude of  each T-cell response varies. This creates a vertical 
immunodominance hierarchy that may be different among different patients. Since 
the immunodominance hierarchy is determined by factors such as the availability of  
the antigen and the presence of  a Th epitope31, it is of  crucial importance to maintain 
the “internal helps” in a vaccine especially in vaccine platforms that do not express 
the whole naïve antigen such as a peptide-based vaccine.
We propose that the immunodominancy hierarchy can be altered by inclusion 
of  a potent carrier protein that provides “external help”. As we have shown, the 
immunogenicity of  HPV E7 was greatly enhanced by the inclusion of  sigHELP-
KDEL. Therefore, when “internal help” is not available in an antigen with low 
immunogenicity, a potent carrier protein with “external help” can be included in a 
vaccine for enhancement of  immunogenicity.
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Safety of a therapeutic HCV vaccine in humans
HCV normally infects less than ~10% of  the total hepatocytes in humans32. The 
incidence of  fulminant hepatitis or severe acute liver disease induced by HCV 
infection is rare and is only associated with high viremia33,34 and a high percentage 
of  infected hepatocytes (approx. 20%)35. Spontaneous recovery from acute HCV 
infection, which is associated with the presence of  a strong and broad-spectrum T-cell 
response, does reduce viral titer without elevation of  serum alanine aminotransferase 
(ALT), a marker for liver damage36. Even spontaneous recovery from chronic HCV 
infection, which is associated with increase neutralizing antibodies and restoration 
of  T-cell function, does not lead to severe liver disease37. This implies that both the 
cytopathogenic damage by CD8+ T cell and non-cytopathogenic clearance of  virus 
by antiviral responses are responsible for the outcome of  the disease. 
Due to the limitation of  our subcutaneous tumor mouse model, we could not 
evaluate the immuno-pathogenic effects on the liver. Association of  HCV-specific 
CD8+ T-cell response with liver damage was observed in a HCV transgenic mouse 
model expressing HCV structural protein in all hepatocytes38. Induction of  cytotoxic 
effect by vaccinations is very unlikely due to the low infection rate of  liver cell in most 
patients; however, special precautions could be needed when immunizing patients 
that have a very high frequency of  infected liver cells or late stage liver disease. 
Foreseeing future treatment for HCV-infected patients 
The efficacy of  HCV therapy recently improved because of  the newly approved 
HCV-specific direct-acting antivirals (DAAs), telaprevir and boceprevir, in 2011 (ref. 
39, 40). New DAAs, e.g., simeprevir, sofosbuvir and faldaprevir will be approved 
in 2014-2015 (ref. 41). However, DAAs are costly and may induce side effects that 
result in early termination of  therapy42. Furthermore, (memory) immune responses 
are not induced by DAAs, as they do not target to the immune system. Therefore 
immunotherapy either given as a single treatment modality or in combination 
with DAAs could further improve treatment success of  patients with chronic HCV 
infections and may also prevent HCV reinfection when immune memory responses 
are induced. Curative treatment and prevention of  reinfections would contribute 
greatly to the global control of  HCV infection. 
As recommended by the European Association for the study of  liver, all 
patients with HCV-related liver disease should be treated no matter the stage of  liver 
fibrosis43. As a matter of  fact, the treatment effect of  currently available drugs is 
associated with the stage of  liver disease. The earlier the stage, the better the prognosis 
preventing progression of  liver fibrosis44. It is also expected that immunotherapy 
against HCV should be most effective at early stage of  the liver disease due to the 
low extent of  immune suppression and exhaustion1. Therefore, we propose that 
immunotherapy should be given to all HCV-infected patients at any stage of  the 
7140
Chapter 7
liver disease including those who are naïve to standard treatment, partial or non-
responder to standard treatment. Vaccination with rSFV expressing the conserved 
genome of  HCV will induce a broad immune response against the conserved HCV 
proteins. If  HCV infection persists with the emerging escape mutants, that are also 
resistant to the current DAAs45-48, a personalized vaccine will have to be designed 
based on the prediction with bioinformatics algorithms or actual identification of  T 
cell epitopes with HLA ligandome analysis. This personalized vaccine could come 
as peptide, a viral vector (e.g., rSFV) or other vaccine formats and used as a booster 
immunization in order to eradicate the escape mutants. Furthermore, based on the 
immunogenicity of  the antigen, “external help” could be included into rSFV for 
better vaccine immunogenicity. 
By combining rSFV immunizations with DAAs and other immunotherapies 
such as the immune modulators anti-CTLA-4 and anti-PD-L1 antibodies, treatment 
efficacy can possibly be further enhanced. DAAs can reduce viral load, while 
immune modulators can restore the exhausted HCV-specific cell49-51. Of  course, the 
most appropriate combination and its toxicity will have to be evaluated.
CONCLUSIONS
Taken together, preclinical studies presented in this thesis provide more insight in the 
development of  immunotherapy against HCV infection. By using a potent alphavirus 
vector, a broad and robust cellular immune response is induced. Furthermore, we 
showed that rSFV can be modified to enhance the vaccine’s immunogenicity. This 
modified rSFV thus enhances responses against antigens with low immunogenicity. 
These features make rSFV a widely applicable platform for future vaccines. Lastly, 
we demonstrated that the choice of  antigens to be included in a candidate vaccine 
could be predicted by mathematic algorithms combined with ex vivo validation. A 
precise design of  HCV vaccines will be crucial for effective eradication of  HCV.
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Achtergrond en doel van het onderzoek
Ons afweersysteem voorkomt en bestrijdt infecties veroorzaakt door micro-
organismen zoals virussen, bacteriën en parasieten. Daarnaast kunnen cellen van 
het afweersysteem, immuuncellen, ook ontspoorde lichaamseigen cellen of  cellen 
die dreigen te ontsporen herkennen en doden. Deze ontsporende cellen kunnen zich 
ontwikkelen tot kankercellen. 
Anderzijds hebben micro-organismen en tumoren mechanismen ontwikkeld 
om de afweer te omzeilen of  te onderdrukken. Deze mechanismen worden ook wel 
immuunevasie en immuunsuppressie genoemd. De gevolgen hiervan zijn duidelijk, 
mensen lopen infecties op die soms chronisch worden en ongeveer een derde van de 
mensen krijgt kanker. 
Infecties kunnen soms behandeld worden met antivirale middelen (virale 
infecties) of  antibiotica (bacteriële infecties), afhankelijk van de veroorzaker van 
de infectie. Standaard behandelingen van kanker zijn gebaseerd op chirurgie, 
chemotherapie en/of  radiotherapie. Deze behandelingen zijn niet altijd toereikend 
waardoor patiënten chronische infecties of  een ongeneeslijke vorm van kanker 
ontwikkelen. 
Een benadering die op het gebied van de behandeling van infecties en kanker 
steeds veelbelovender wordt is ‘immuuntherapie’. Het doel van immuuntherapie is 
de afweer zo sterk te activeren dat geïnfecteerde cellen of  kankercellen herkend en 
gedood kunnen worden. In het toonaangevende wetenschappelijke tijdschrift Science 
werd immuuntherapie tot dé ‘wetenschappelijke doorbraak van het jaar 2013’ verkozen.   
In dit proefschrift is onderzoek beschreven naar de ontwikkeling van 
immuuntherapie gericht tegen hepatitis C virus infecties.  
Hepatitis C virussen (HCV) behoren tot de zogenaamde tumorvirussen. 
Infectie met een tumorvirus kan uiteindelijk leiden tot het ontstaan van kanker. 
HCV kan het immuunsysteem omzeilen waardoor 70 procent van de geïnfecteerde 
patiënten het virus niet kwijtraakt en de infectie chronisch wordt. Een chronische 
HCV infectie leidt tot leverontsteking, wat kan leiden tot levercirrose en in een deel 
van de patiënten tot leverkanker, hepatocellulair carcinoom.
Wereldwijd zijn ongeveer 150 miljoen mensen chronisch besmet met het 
virus en sterven er jaarlijks 350.000 mensen aan een HCV-gerelateerde leverziekte. 
In Nederland zijn ongeveer 60.000 mensen besmet met HCV, vaak nog zonder het 
te weten. De standaard behandeling van HCV infecties bestond in Nederland tot 
voor kort uit een combinatie van ribavirine (een antiviraal middel) en interferon. 
Deze behandeling is in een deel van de patiënten effectief  maar heeft ook veel 
bijwerkingen. Recent zijn er twee nieuwe antivirale middelen tegen HCV toegelaten 
die nu bij sommige patiënten toegevoegd worden aan de standaard behandeling. 
Er zijn echter nog geen vaccins beschikbaar die kunnen beschermen tegen 




nog niet beschikbaar. 
Het doel van het onderzoek zoals beschreven in dit proefschrift is de 
ontwikkeling van immuuntherapie tegen HCV infectie. Hiervoor zijn recombinante 
vaccins gemaakt en onderzocht die afgeleid zijn van een knaagdiervirus, het Semliki 
Forest virus (SFV). 
SFV kan zodanig veranderd worden dat het virus een cel maar één keer kan 
infecteren en geen nieuwe virusdeeltjes maakt. Daarnaast kan het virus zodanig 
veranderd worden dat het eiwitten naar keuze gaat produceren. Een cel die 
geïnfecteerd wordt met zo’n recombinant virus deeltje zal een grote hoeveelheid 
van dit eiwit aanmaken en vervolgens afsterven. Deze afstervende cel wordt daarna 
opgenomen door antigeen-presenterende cellen die het eiwit presenteren aan andere 
cellen van het immuunsysteem. Het immuunsysteem maakt daarop afweercellen die 
HCV geïnfecteerde cellen kunnen herkennen en doden, zogenaamde cytotoxische T 
cellen (CTL).
In het inleidende hoofdstuk 1 van dit proefschrift wordt het kader van 
het promotieonderzoek omschreven. Naast een inleiding in de immunologie en 
immuuntherapie worden HCV en humaan papillomavirus (HPV) geïntroduceerd. 
HPV is  ook een tumorvirus dat in hoofdstuk 4 als een doelwitvirus gebruikt is om te 
onderzoeken of  kankervaccins versterkt kunnen worden.  
In hoofdstuk 2 is recente literatuur samengevat die onderzoek beschrijft naar 
de ontwikkeling van immuuntherapie van HCV infecties. Veel van deze onderzoeken 
laten zien dat de ontwikkelde immuuntherapieën in proefdieren antivirale effecten 
bewerkstelligen. Helaas hebben deze behandelingen in patiënten lang niet zulke 
goede resultaten. Er worden wel immuunresponsen opgewekt maar die zijn niet 
voldoende effectief  om de infectie te klaren. 
Therapeutisch HCV vaccin gebaseerd op Semliki Forest virus
Patiënten met een chronische HCV infectie en HCV-geïnduceerd hepatocellulair 
carcinoom hebben vaak een zwakke, uitgeputte afweer tegen het virus. Patiënten 
die het virus snel kunnen klaren hebben daarentegen een sterke, brede afweer tegen 
het virus, met name tegen de meer geconserveerde eiwitten van het virus, de niet 
structurele eiwitten (nsPs). Idealiter induceert een therapeutisch HCV vaccin dus een 
brede afweer tegen de nsPs van HCV. 
In hoofdstuk 3 beschrijven we de ontwikkeling en karakterisering van drie 
recombinante SFV vaccins die een deel van de nsPs van HCV (NS3/4A of  NS5A/B’) 
of  alle nsPs van HCV (NS2’-5B) tot expressie brengen, respectievelijk rSFVeNS3/4A, 
rSFVeNS5A/B’ en rSFVeNS2’-5B’.
De inbouw van het RNA wat codeert voor alle nsPs (NS2’-5B’) in de SFV 
vector maakt het recombinante SFV RNA ongeveer 25 procent groter dan het 
oorspronkelijke SFV RNA.  En hoewel de productie van dit recombinante virus vijf  
keer lager is dan de virussen die een deel van de nsPs tot expressie brengen zijn de 
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virus deeltjes functioneel en leiden tot een nsP-specifieke afweercellen. 
rSFVeNS2’-5B’ immunisatie in muizen leidt tot lagere aantallen specifieke 
CTLs tegen een epitoop van het NS3 eiwit (NS3
603-611
) dan immunisatie met 
SFVeNS3/4A, toch is er geen verschil in antitumor activiteit tussen beide vaccins. 
De lagere frequentie aan afweer cellen met het ‘grotere’ vaccin kan te wijten zijn 
aan zogenaamde immuun dominantie hiërarchie. De verlaagde immuun dominante 
hiërarchie van NS3
603-611
 na rSFVeNS2’-5B’ immunisatie kan veroorzaakt worden door 
de expressie van andere immunogene epitopen met dit ‘grotere’ vaccin. Echter, een 
meer gespreide afweer tegen meerdere epitopen is belangrijk zoals boven beschreven 
en kan ook belangrijk zijn om ‘escape mutanten’ te voorkomen. Concluderend, de 
HCV vaccins die ontwikkeld zijn activeren afweercellen die op hun beurt kankercellen 
die deze HCV nsPs tot expressie brengen herkennen en doden. 
Verhoging van de immunogeniciteit van vaccins gebaseerd op SFV
In hoofdstuk 4 en 5 onderzoeken we methoden om de immunogeniciteit van rSFV 
vaccins verder te verhogen. Dit kan op verschillende manieren. Hier onderzochten 
we het effect van de inclusie van immunogene carriereiwitten in de virale vector. Deze 
carriereiwitten verhogen de immunogeniciteit van DNA vaccins. Of  dit mechanisme 
ook effectief  is in virale vector vaccins was niet bekend.  
Twee carriereiwit-cassettes i) tetanus toxine fragment C (TTFC) en ii) een 
serie helper T cel (Th) epitopen gefuseerd aan een endoplasmatisch reticulum (ER) 
targeting signaal (sigHELP-KDEL) werden ingebouwd in SFV vaccins. In hoofdstuk 
4 wordt het effect van deze eiwitten in een bestaand rSFV vaccin gericht tegen HPV 
en in hoofdstuk 5 in een van de rSFV vaccins gericht tegen HCV beschreven.  
Inclusie van sigHELP-KDEL in het HPV vaccin verhoogt het aantal HPV-
specifieke CTLs en de antitumor activiteit van het vaccin.  De sterkere immuunrespons 
kan te wijten zijn aan de verhoogde eiwit productie door de vaccins, door de verhoogde 
stabiliteit van het eiwit en door activering van Th cellen. Inclusie van TTFC verhoogt 
de immunogeniciteit van het rSFV-HPV vaccin niet. TTFC is een relatief  groot eiwit 
dat ook CTL epitopen kan bevatten waardoor de hiërarchie in immuundominantie 
van de eiwitten die tot expressie komen kan veranderen.
Interessant is dat, in tegenstelling tot het SFV-HPV vaccin, de inclusie van 
sigHELP-KDEL in het SFVeNS3/4A vaccin de stabiliteit van het eiwit en de 
immuunrespons niet verhoogt.  Anderen hebben laten zien dat inclusie van sigHELP 
ook niet in alle DNA vaccins leidt tot een verhoging van de immunogeniciteit. 
Wellicht is het ook niet mogelijk om de al hoge respons tegen het 
immuundominante CTL epitoop van NS3 te verhogen. Het NS3
603-611
 CTL epitoop 
wordt  geflankeerd door Th epitopen en er zijn aanwijzingen dat wanneer CTL en Th 
epitopen elkaar overlappen of  vlak bij elkaar liggen dit  gepaard gaat met een hoge 
immunogeniciteit van het CTL epitoop. Een immunogeniciteit die wellicht optimaal 




In beide studies is een enkel CTL epitoop onderzocht. Verder onderzoek zal 
moeten uitwijzen of  de inclusie van deze carriereiwitten wellicht andere responsen 
kan versterken. 
Ontwerpen van gepersonaliseerde therapeutische vaccins tegen HCV
Chronische HCV infectie gaat vaak gepaard met het ontstaan van virus ‘escape-
mutanten’, daarom moet een therapeutisch vaccin niet alleen immuniteit opwekken 
tegen het wild-type virus maar ook tegen de escape-mutanten. Immunisatie tegen 
het wild-type virus zou idealiter kunnen met een ‘off-the-shelf ’ vaccin. Afweer 
tegen de escape-mutanten kan alleen opgewekt worden door het vaccin zodanig te 
ontwerpen dat cellen geïnfecteerd met escape-mutanten ook herkend worden. Voor 
de ontwikkeling van zo’n gepersonaliseerd vaccin is de sequentie van de escape 
mutant nodig en moeten de epitopen die gepresenteerd worden door de patiënt-
specifieke HLA moleculen van HCV geïnfecteerde cellen geïdentificeerd worden, 
i.e. de HLA ligandome (immunopeptidome). Deze analyse kan gedaan worden met 
massaspectometrie ware het niet dat hiervoor veel HCV-geïnfecteerde cellen van de 
patiënt nodig zijn. Een andere benadering is een theoretische benadering waarbij 
gebruik gemaakt wordt van mathematische voorspellingen. In hoofdstuk 6 is deze 
theoretische methode toegepast op een aantal geïdentificeerde HCV CTL epitopen. 
Vervolgens zijn deze epitopen in vivo en in vitro geïdentificeerd en gevalideerd. 
Immunisatie met SFVeNS2’-5B leidt tot responsen tegen 4 voorspelde 
epitopen. Alle vier de epitopen kunnen ook op basis van theoretische voorspelling 
van de proteosomale klieving ontstaan en drie van de vier epitopen lijken geflankeerd 
te worden door, of  liggen dichtbij een Th epitoop. Hoewel de immuun responsen laag 
zijn lijkt het resultaat de mathematische voorspelling te bevestigen. Verder onderzoek 
zal moeten uitwijzen of  op basis van deze mathematische voorspellingen patiënt-
specifieke vaccins ontworpen kunnen worden.    
Concluderend
Het onderzoek in dit proefschrift vergroot ons inzicht in de ontwikkeling en de 
mogelijkheden van immuuntherapie gericht tegen HCV infectie. De SFV vaccins die 
ontworpen zijn induceren een robuuste cellulaire immuunrespons. Verder laten we 
zien dat rSFV vaccins  geoptimaliseerd kunnen worden waardoor responsen tegen 
antigenen met een lage intrinsieke activiteit verhogen. Deze eigenschappen maken 
dat rSFV een veelbelovend platform kan zijn voor nieuwe vaccins. Tot slot hebben we 
laten zien dat de keuze van het antigeen wat ingebouwd moet worden in een vaccin 
voorspeld kan worden door mathematische algoritmen. De ontwikkeling  van een 
HCV vaccin voor het behandelen van HCV patiënten is van groot belang, de kennis 
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